carbamazepine has been researched along with Absence Seizure in 786 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "To evaluate and compare the effects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate (ESL) for focal (partial-onset) seizures (FS)." | 9.27 | Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. ( Abou-Khalil, B; Blum, D; Cheng, H; Gama, H; Grinnell, T; Jung, J; Klein, P; Rocha, F; Ryvlin, P; Shah, A; Specchio, LM, 2018) |
| " One study compared clonazepam to carbamazepine as monotherapy for participants with newly diagnosed psychomotor epilepsy (a condition corresponding to what is now termed mesial temporal lobe epilepsy)." | 9.22 | Clonazepam monotherapy for treating people with newly diagnosed epilepsy. ( Bragazzi, NL; Brigo, F; Igwe, SC; Lattanzi, S, 2022) |
| "This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study (KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy." | 9.22 | Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. ( Marson, AG; Noack-Rink, M; Pohlmann-Eden, B; Ramirez, F; Tofighy, A; Trinka, E; Werhahn, KJ; Wild, I, 2016) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 9.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| "One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study." | 9.16 | Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). ( Bosco, D; Consoli, D; Galati, F; Neri, G; Ottonello, GA; Passarella, B; Perticoni, GF; Plastino, M; Postorino, P; Ricci, S; Toni, D, 2012) |
| "To evaluate the pharmacokinetics of eslicarbazepine acetate (ESL) at steady-state in adults with partial-onset seizures who have taken ESL for at least 1 year with one or two concomitant antiepileptic drugs (AEDs)." | 9.15 | Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ( Almeida, L; Elger, C; Falcão, A; Halász, P; Perucca, E; Soares-da-Silva, P, 2011) |
| "For a retrospective observational investigation based on real clinical practice of relative efficacy of valpoic acid (VPA), carbamazepine (CBZ) and topiramate (TPM) we have selected 106 patients with age of seizure onset before 17 years with a undoubted diagnosis of symptomatic or cryptogenic occipital lobe epilepsy (OLE), who had received treatment according to ILAE recommendations, and observation time since the last treatment change was from 2 to 10 years." | 9.14 | [Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children]. ( , 2010) |
| "To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial." | 9.13 | Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. ( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008) |
| "To compare topiramate (TPM) with investigator's choice of carbamazepine (CBZ) or valproate (VPA) for initial treatment in patients with newly diagnosed epilepsy." | 9.10 | Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. ( Brodie, MJ; Chadwick, DW; Mattson, RH; Neto, W; Privitera, MD; Wang, S, 2003) |
| "To determine the potential effectiveness of phenytoin (PHT) in preventing early postoperative seizures in patients undergoing craniotomy for supratentorial brain tumors." | 9.10 | Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. ( De Santis, A; Perucca, E; Sinisi, M; Stocchetti, N; Villani, R, 2002) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 9.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization." | 9.08 | A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. ( Alexander, J; Anhut, H; Chadwick, DW; Garofalo, EA; Greiner, MJ; Murray, GH; Pierce, MW, 1998) |
| "The results of a multicenter, double-blind, placebo-controlled clinical trial of the efficacy and safety of progabide (PGB) in the treatment of partial seizures are presented." | 9.06 | A controlled study of progabide in partial seizures: methodology and results. ( Bowman, T; Cloyd, J; Crosby, C; Dreifuss, FE; Graves, N; Jacobs, M; Leppik, IE; Porter, R; Santilli, N; Stackman, J, 1987) |
| " One study compared clonazepam to carbamazepine as monotherapy for participants with newly diagnosed psychomotor epilepsy (a condition corresponding to what is now termed mesial temporal lobe epilepsy)." | 9.01 | Clonazepam monotherapy for treating people with newly diagnosed epilepsy. ( Bragazzi, NL; Brigo, F; Igwe, SC; Lattanzi, S, 2019) |
| "To review the time to treatment failure, remission and first seizure with carbamazepine compared with phenytoin when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic-clonic seizures (with or without other generalised seizure types)." | 9.01 | Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. ( Marson, AG; Nevitt, SJ; Tudur Smith, C, 2019) |
| "To review the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, potential drug-drug interactions, and place in therapy of the intravenous (IV) formulation of carbamazepine (Carnexiv) for the treatment of seizures in adult patients." | 8.98 | Intravenous Carbamazepine for Adults With Seizures. ( DeFalco, AP; Tillery, EE; Vickery, PB, 2018) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset focal or generalized seizures." | 8.98 | Clobazam monotherapy for focal or generalized seizures. ( Anand, V; Arya, R; Garg, SK; Giridharan, N, 2018) |
| "The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting." | 8.90 | Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. ( Citraro, R; De Sarro, G; Franco, V; Grillo, E; Iudice, A; Russo, E, 2014) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset partial or generalized seizures." | 8.90 | Clobazam monotherapy for partial-onset or generalized-onset seizures. ( Anand, V; Arya, R; Garg, SK; Michael, BD, 2014) |
| "To review the best evidence comparing phenobarbitone and phenytoin when used as monotherapy in participants with partial onset seizures or generalised tonic-clonic seizures with or without other generalised seizure types." | 8.89 | Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. ( Marson, AG; Nolan, SJ; Pulman, J; Tudur Smith, C, 2013) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 8.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| " In this review, the safety of the newer AED oxcarbazepine during pregnancy is assessed based on published pregnancy outcome data." | 8.82 | Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. ( Montouris, G, 2005) |
| "More than two-thirds of patients with WHO grade 2 glioma related epilepsy treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first-choice agent." | 8.31 | Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure. ( Chumas, P; Fairclough, S; Goodden, J; Maguire, M; Mathew, R, 2023) |
| "This study aimed to investigate the factors affecting the plasma concentration of monohydroxylated derivative (MHD) of oxcarbazepine (OXC) in children with epilepsy." | 8.12 | Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy. ( Huang, A; Huang, S; Song, H; Yao, N, 2022) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 7.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "This study evaluated the effect of androsterone (AND), a metabolite of testosterone, on the ability of selected classical and novel antiepileptic drugs to prevent seizures caused by maximal electroshock (MES), which may serve as an experimental model of human generalized tonic-clonic seizures in mice." | 7.91 | Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Aebisher, D; Bartusik-Aebisher, D; Buszewicz, G; Kołodziejczyk, P; Mróz, K; Mróz, T; Tutka, P; Łuszczki, JJ, 2019) |
| "This study investigates the neuronal protective effect of SXC combined with carbamazepine (CBZ) on epilepsy and cognitive impairment in kainic acid-kindled SD rats." | 7.91 | Neuronal protective effect of Songling Xuemaikang capsules alone and in combination with carbamazepine on epilepsy in kainic acid-kindled rats. ( Chen, M; Jia, C; Jiao, H; Wei, L; Yang, H; Yin, W; Zhang, R, 2019) |
| "This study aimed to assess efficacy and safety of oxcarbazepine (OXC) oral suspension in pediatric patients aged 2-5 years with partial seizures (PS) and/or generalized tonic-clonic seizures (GTCS) in real-world clinical practice in China." | 7.88 | Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study. ( Chen, YB; Deng, YC; Fang, F; Hu, XS; Huang, XF; Jiang, L; Lin, ZD; Qin, J; Wang, Y; Wu, Y; Yin, F; Zhang, YQ, 2018) |
| "This cross-sectional study included 36 patients with focal seizures and impaired awareness treated for 12-32 months with carbamazepine monotherapy and 38 healthy volunteers." | 7.88 | Effects of Chronic Carbamazepine Treatment on the ECG in Patients with Focal Seizures. ( Adoor, M; Delhaas, T; Hermans, BHM; Koot, LAM; Kramer, BW; Raju, TR; Sathyaprabha, TN; Satishchandra, P; Sinha, S, 2018) |
| "The PPK model, using the power scaling of body weight, effectively elucidated the topiramate serum concentration profile ranging from pediatric to adult patients." | 7.85 | Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ( Ikeda, A; Ito, S; Matsubara, K; Sugimoto, M; Takeuchi, M; Yamamoto, S; Yano, I; Yonezawa, A, 2017) |
| " Here, we suggest that triggering limbic seizures with low doses of PTZ in pilocarpine-treated marmosets might provide a more effective basis for the development of AED." | 7.83 | Seizures triggered by pentylenetetrazol in marmosets made chronically epileptic with pilocarpine show greater refractoriness to treatment. ( Blanco, MM; Cinini, SM; Lima, TZ; Mello, LE; Pontes, JC; Queiroz, CM, 2016) |
| "Carbamazepine (CBZ) is the gold standard antiepileptic drug (AED) for focal onset seizures." | 7.80 | Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus. ( Beran, RG; Cordato, DJ; Malkan, A; Patel, V, 2014) |
| "Carbamazepine controlled multiple seizure types and did not induce or increase the frequency of myoclonic or absence seizures in these patients." | 7.80 | Carbamazepine treatment of generalized tonic-clonic seizures in idiopathic generalized epilepsy. ( Kenyon, K; Mintzer, S; Nei, M, 2014) |
| "Lacosamide (LCM), a new antiepileptic drug (AED) approved as adjunctive therapy for the treatment of patients with partial-onset seizures, has limited pharmacokinetic and drug interaction data." | 7.80 | Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. ( Duncan, JS; Markoula, S; Patsalos, PN; Ratnaraj, N; Sander, JW; Teotonio, R, 2014) |
| "To investigate whether single nucleotide polymorphisms (SNPs) of rs2298771 and rs3812718 of the sodium channel α-subunit type 1 (SCN1A) gene affect the efficacy of carbamazepine (CBZ) treatment for seizures in Chinese Han epileptic patients." | 7.80 | Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients. ( Liu, Z; Sheng, Y; Tang, B; Wang, P; Zhou, B; Zhou, Q, 2014) |
| "Carbamazepine is used to control seizures." | 7.78 | Carbamazepine-induced hypogammaglobulinemia. ( Canbakan, B; Eroglu, S; Goksugur, N; Ozaras, N; Ozaras, R; Tabak, O, 2012) |
| "The aim of the present study was to investigate whether single nucleotide polymorphisms (SNPs) in the sodium channel a subunit type 1 (SCN1A) gene affect the retention rate of carbamazepine (CBZ) used to treat seizures in Chinese Han patients with epilepsy." | 7.78 | Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. ( Li, GL; Liu, D; Liu, ZQ; Qu, J; Xu, XJ; Yin, JY; Zhou, BT; Zhou, HH; Zhou, QH, 2012) |
| "In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal." | 7.78 | Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin. ( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012) |
| "), its effects on seizures, EEG epileptiform activity and EEG amplitude increases induced by two convulsive agents were evaluated and compared with the effects of carbamazepine." | 7.78 | The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures. ( Aldana, BI; Gómez, CD; Nekrassov, V; Sitges, M, 2012) |
| "The effects of ALAC administered per os were evaluated by standard protocols against audiogenic seizures in Genetic Epilepsy Prone Rats (GEPR-9 rats), maximal electroshock (MES)-induced seizures in rats, pilocarpine-induced seizures in mice, spontaneous chronic seizures in mice exposed to pilocarpine-induced status epilepticus (SE), and absence seizures in WAG/Rij rats." | 7.77 | Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. ( Citraro, R; De Fazio, S; De Sarro, G; Mainardi, P; Perucca, E; Raggio, R; Russo, E; Scicchitano, F, 2011) |
| "Thirteen pregnancies in ten women on oxcarbazepine (OXC) monotherapy and one pregnancy in a woman on OXC and topiramate therapy were retrospectively analyzed." | 7.75 | Seizure deterioration in women treated with oxcarbazepine during pregnancy. ( Hansen-Schwartz, J; Petrenaite, V; Sabers, A, 2009) |
| " The aim of the present work was to assess the involvement of P-glycoprotein in carbamazepine and phenobarbital hippocampal pharmacokinetics in an experimental model of epilepsy, induced by repetitive MP administration." | 7.75 | Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ( Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Mayer, MA; Opezzo, JA; Taira, CA, 2009) |
| "The purpose of the present study was to evaluate the effect of kainic acid (KA)-induced acute seizures on the pharmacokinetic profiles of antiepileptic drug, carbamazepine (CBZ) in mice." | 7.74 | Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures. ( Honda, N; Nishimura, A; Shibata, N; Sugioka, N; Takada, K, 2008) |
| " We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated." | 7.74 | Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. ( Bomprezzi, C; Formica, F; Iacoangeli, M; Mauro, AM; Morresi, S; Provinciali, L; Scerrati, M, 2007) |
| "The present study evaluated the effectiveness of intraperitoneal (IP) injections and oral administration of carbamazepine (CBZ) in food on the frequency of spontaneous motor seizures in rats with kainate-induced epilepsy." | 7.74 | Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. ( Clark, S; Dudek, FE; Grabenstatter, HL, 2007) |
| "To compare the temporal pattern of seizures after acute withdrawal of oxcarbazepine (OXC) and phenytoin (PHT) in the epilepsy monitoring unit (EMU)." | 7.74 | Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring. ( Abou-Khalil, BW; Azar, NJ; Song, Y; Wang, L, 2008) |
| "To investigate whether histidine can enhance the anticonvulsant efficacy of carbamazepine (CBZ) and simultaneously improve the spatial memory impairment induced by transauricular kindled seizures in Sprague-Dawley rats." | 7.73 | Histidine enhances carbamazepine action against seizures and improves spatial memory deficits induced by chronic transauricular kindling in rats. ( Chen, Z; Jin, CL; Li, Q; Liu, LY; Xu, LS; Yang, LX; Zhu-Ge, ZB, 2005) |
| "We investigated the effect of carbamazepine on convulsions associated with mild gastroenteritis." | 7.73 | [Low-dose therapy with carbamazepine for convulsions associated with mild gastroenteritis]. ( Furukawa, S; Hayashi, T; Ichiyama, T; Matsufuji, H; Nishikawa, M; Suenaga, N, 2005) |
| "Serious complications after carbamazepine poisoning, such as coma, seizures, respiratory failure, cardiac conduction abnormalities, and death are more likely with serum levels greater than 170 micromol L(-1)." | 7.73 | Multidose activated charcoal in the treatment of carbamazepine overdose with seizures: a case report. ( Jukić, I; Mise, S; Titlić, M; Tonkić, A, 2005) |
| "We report on a 4-year 8-month-old boy with Panayiotopoulos syndrome who showed atypical evolution with newly developed absence seizures and EEG exacerbation induced by carbamazepine." | 7.73 | EEG and seizure exacerbation induced by carbamazepine in Panayiotopoulos syndrome. ( Akiyama, T; Endoh, F; Ito, M; Kikumoto, K; Ohtsuka, Y; Oka, M; Yoshinaga, H, 2006) |
| "To report a case of pseudo mycosis fungoides due to carbamazepine." | 7.72 | Carbamazepine-induced pseudo mycosis fungoides. ( Dursun, A; Gül, U; Kiliç, A, 2003) |
| " The present study investigated the influence of L-histidine on the protective effects of carbamazepine and phenytoin against maximal electroshock-induced seizures in mice." | 7.72 | L-histidine is a beneficial adjuvant for antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Kamiński, RM; Kleinrok, Z; Kozicka, M; Zółkowska, D, 2004) |
| "We investigated the anticonvulsant and adverse behavioral effects of lamotrigine (LTG), a novel antiepileptic drug (AED), as well as other conventional AEDs on kindled seizures in rats." | 7.70 | Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats. ( Kuroda, S; Morimoto, K; Otsuki, K; Sato, K; Yamada, N, 1998) |
| "The efficacy of Flunarizine (FLU), a calcium channel blocker, in combination with conventional antiepileptic drugs, phenytoin (PHT), carbamazepine (CBZ), sodium valproate (VPA), and ethosuximide (ESM), at ED50 doses, were examined for protective effects against maximal electroshock seizures (MES) and pentylenetetrazol (PTZ) induced seizures in mice." | 7.70 | Additive anticonvulsant effect of flunarizine and sodium valproate on electroshock and chemoshock induced seizures in mice. ( David, J; Joseph, S; Joseph, T, 1998) |
| " However, this calcium channel antagonist (10 mg kg(-1)) enhanced the anticonvulsive activity of carbamazepine, valproate and phenobarbital against maximal electroshock-induced seizures in mice." | 7.70 | Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Jagiello-Wojtowicz, E; Jasinski, M; Kaminski, R; Kleinrok, Z, 1999) |
| "Systemic injections of 4-aminopyridine precipitate epileptiform generalized seizures characterized mainly by shivering of the body, tail movements and tonic-clonic convulsions in rats and mice." | 7.70 | Acute 4-aminopyridine seizures increase the regional cerebral blood flow in the thalamus and neocortex, but not in the entire allocortex of the mouse brain. ( Ayesha, A; Gopinath, S; Mathew, M; Mihály, A; Owunwanne, A; Shihab-Eldeen, A, 2000) |
| "One of the most dangerous aspects of theophylline toxicity is seizures." | 7.69 | Adenosine receptors are not involved in theophylline-induced seizures. ( Hornfeldt, CS; Larson, AA, 1994) |
| "Limbic seizures were provoked in freely moving rats by intrahippocampal administration of the muscarinic receptor agonist pilocarpine via a microdialysis probe (10 mM for 40 min at 2 microliters/min)." | 7.69 | Hippocampal and cerebellar extracellular amino acids during pilocarpine-induced seizures in freely moving rats. ( Ebinger, G; Michotte, Y; Smolders, I; Van Belle, K, 1997) |
| "We examined the anticonvulsant effects of BW1003C87 (5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine ethane sulphonic acid), which is structurally related to the new antiepileptic drug, lamotrigine, and compared its effects to those of the conventional antiepileptic drugs, phenytoin and carbamazopine, using the rat amygdala-kindling model of epilepsy." | 7.69 | BW1003C87, phenytoin and carbamazepine elevate seizure threshold in the rat amygdala-kindling model of epilepsy. ( Morimoto, K; Sato, H; Sato, K; Sato, S; Yamada, N, 1997) |
| "Initial studies of the effect of chronic carbamazepine (CBZ) against cocaine-induced seizures indicated that there were genetic differences in both the time course for the development of the anticonvulsant effects of CBZ against cocaine-induced seizures and the persistence of these effects." | 7.68 | Genetic differences in the time course for the development and persistence of the anticonvulsant effects of carbamazepine against cocaine seizures. ( Frieman, M; Goldberg, SR; Marley, RJ; Shimosato, K, 1993) |
| "Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats." | 7.68 | Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. ( Cavalheiro, EA; Dziki, M; Kleinrok, Z; Parada, J; Turski, W, 1992) |
| "The effects of chronic carbamazepine (CBZ) on the development and expression of cocaine-kindled seizures and seizures produced by an acute injection of cocaine were evaluated in BALB/cByJ, C57Bl/6J and SJL/J mice." | 7.68 | Pharmacogenetic assessment of the effects of carbamazepine on cocaine-kindled and cocaine-induced seizures. ( Goldberg, SR; Marley, RJ, 1992) |
| "This study evaluated a possible mechanism by which glycine potentiates the activity of anticonvulsant drugs against maximal electroshock seizures in rats." | 7.68 | Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by D-serine and antagonized by 7-chlorokynurenic acid. ( Peterson, SL, 1991) |
| "Diabetes Mellitus was observed in a patient given carbamazepine." | 7.68 | Carbamazepine-induced Diabetes mellitus. ( Obembe, A, 1991) |
| "This study evaluated the potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats." | 7.68 | Potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats. ( Adams, HR; Frye, GD; Peterson, SL; Trzeciakowski, JP, 1990) |
| "The effects of chronic carbamazepine on cocaine-kindled seizures and behavioral sensitization were examined in this study." | 7.68 | Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine-induced hyperactivity. ( Costello, M; Nutt, DJ; Post, RM; Tandeciarz, S; Weiss, SR, 1990) |
| "Fourteen animals with stable generalized kindled seizures received three doses of carbamazepine and its epoxide (12." | 7.67 | Effects of carbamazepine and its epoxide metabolite on amygdala-kindled seizures in rats. ( Albright, PS; Bruni, J, 1984) |
| "Four adult men with resistant partial seizures underwent an intensive open-label protocol designed to evaluate long-term add-on lamotrigine (LTG) therapy." | 7.67 | Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ( Ashworth, M; Keally, M; Kupferberg, H; Mikati, MA; Osborne-Shafer, P; Schachter, SC; Schomer, DL; Seaman, CA; Sheridan, PH; Valakas, A, 1989) |
| "Glutamic acid diethyl ester (GDEE) is a glutamate antagonist which acts preferentially at the quisqualate-sensitive receptor and has been shown to be an effective anticonvulsant in alcohol withdrawal and homocysteine-induced seizures but ineffective in other seizure models." | 7.67 | Inhibition of quisqualate-induced seizures by glutamic acid diethyl ester and anti-epileptic drugs. ( Freed, WJ; Schwarz, SS, 1986) |
| "The effect of carbamazepine and its -10,11-epoxide on the development of amygdala-kindled seizures and on completed kindled seizures in the rat was evaluated." | 7.67 | Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development. ( Post, RM; Weiss, SR, 1987) |
| "We studied 15 children with complex partial seizures in whom one or more seizure type was exacerbated during treatment with carbamazepine." | 7.67 | Exacerbation of seizures in children by carbamazepine. ( Hosey, LC; Snead, OC, 1985) |
| "This study investigates the ability of adenosine antagonists to reverse the anticonvulsant effects of carbamazepine on amygdala-kindled seizures in order to elucidate the possible physiological relevance of the potent effects of carbamazepine on adenosine receptors." | 7.67 | Adenosine antagonists. Lack of effect on the inhibition of kindled seizures in rats by carbamazepine. ( Marangos, PJ; Patel, J; Post, RM; Weiss, SR, 1985) |
| "An apparent case of carbamazepine-induced leukocytosis in a 26-year-old woman is presented." | 7.66 | Carbamazepine-induced leukocytosis. ( Murphy, JE; Springer, PK; Stewart, RB, 1980) |
| "Carbamazepine is an anticonvulsant most effective in treating complex partial and generalized tonic-clonic seizures." | 7.66 | Dystonia associated with carbamazepine administration: experience in brain-damaged children. ( Crosley, CJ; Swender, PT, 1979) |
| "Effects of carbamazepine on alcohol withdrawal seizures and symptoms were studied in rats." | 7.66 | Carbamazepine: prevention of alcohol withdrawal seizures. ( Chu, NS, 1979) |
| "Serum levels and seizure control were investigated in a prospective study when carbamazepine was given as a single drug to 32 patients with a variety of seizures." | 7.66 | Carbamazepine as a single drug in the treatment of epilepsy. A prospective study of serum levels and seizure control. ( Callaghan, N; Duggan, B; Feely, M; O'Callaghan, M, 1978) |
| "Relapse of seizures can have major adverse psychosocial consequences and also may carry a risk of morbidity and mortality." | 7.01 | Should antiseizure medications be withdrawn after an extended period of seizure freedom in individuals with adult-onset epilepsy? ( Asadi-Pooya, AA; Mesraoua, B; Perucca, E; Tomson, T, 2023) |
| " Patients were converted during an carbamazepine, phenytoin, or valproate) to lamotrigine via a protocol-specified dosing algorithm or to conventional therapy via standard dosing guidelines." | 6.71 | Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. ( Hammer, AE; Kaminow, L; Schimschock, JR; Vuong, A, 2003) |
| "The duration and frequency of seizure activities and electrographic seizure onset of 41 patients totally withdrawing from CBZ monotherapy (n = 20), LTG monotherapy (n = 10) and CBZ + LTG combined therapy (n = 11) were intensively studied by therapeutic intensive seizure analysis (TISA) method." | 6.71 | Changes of seizures activity during rapid withdrawal of lamotrigine. ( Koebnick, C; Pauli, E; Stefan, H; Tilz, C; Wang, B; Wang-Tilz, Y, 2005) |
| "Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients)." | 6.69 | Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. ( Cardinali, C; Zamponi, N, 1999) |
| "Carbamazepine has been used in adults and children for over 30 years." | 6.68 | Treatment of neonatal seizures with carbamazepine. ( al Hifzi, I; Khan, M; Majeed-Saidan, M; Singh, B; Singh, P, 1996) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 6.47 | Spotlight on levetiracetam in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Disulfiram has been widely used for over six decades in the treatment of alcohol dependence, as an aversive therapeutic agent." | 5.62 | Disulfiram-induced epileptic seizures. ( Mendes, MA; Nogueira, V; Pereira, I; Teixeira, J, 2021) |
| "Carbamazepine was ineffective, and seizures were exacerbated with levetiracetam (LEV)." | 5.56 | Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. ( Goji, A; Kagami, S; Mori, T; Tayama, T; Toda, Y, 2020) |
| "Almost all seizure durations were >20 seconds." | 5.51 | Effect of carbamazepine on spontaneous recurrent seizures recorded from the dentate gyrus in rats with kainate-induced epilepsy. ( Dudek, FE; Grabenstatter, HL, 2019) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Recurrent seizures requiring either emergency room (ER) visits or hospitalization were used to measure the efficacy of seizure control." | 5.42 | Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. ( Chan, L; Chi, NF; Chien, LN; Chiou, HY; Hu, CJ; Huang, YH; Kuan, YC, 2015) |
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "DRESS syndrome is an idiosyncratic reaction to drugs, which can occur in both adults and children." | 5.39 | Carbamazepine-induced DRESS syndrome in a child: rapid response to pulsed corticosteroids. ( Tan, B; Teng, P, 2013) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 5.39 | Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Florek-Luszczki, M; Karwan, S; Luszczki, JJ; Wlaz, A, 2013) |
| "Seizures were prevented in 50% and 75% of the animals by chronic CBZ and VPC, respectively." | 5.35 | Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. ( Nekrassov, V; Sitges, M, 2008) |
| "Simultaneously, the impact of acute seizures and efflux transport mechanisms on brain distribution was quantified." | 5.35 | Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. ( Clinckers, R; Danhof, M; Della Pasqua, O; Ebinger, G; Michotte, Y; Smolders, I; Voskuyl, RA, 2008) |
| " Chronic administration of ETA (12." | 5.35 | Effect of ethacrynic acid on the anticonvulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Swiderska, G; Łukawski, K, 2009) |
| "The antiseizure effect of tested combinations was not sex-dependent and not reversed by hydrocortisone pretreatment." | 5.33 | Influence of aminoglutethimide and spironolactone on the efficacy of carbamazepine and diphenylhydantoin against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ, 2005) |
| " Adjusting the maintenance dosage of H(2)-histamine antagonists has been recommended in elderly patients since age-related reduction in renal plasma flow, glomerular filtration rate and renal tubular function may be present, which can in turn elevate histamine levels in plasma and cerebrospinal fluid." | 5.31 | H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. ( Bergemann, N; Diebold, K; Mundt, C; Roesch-Ely, D; Sartor, K; von Einsiedel, RW, 2002) |
| "Using an amygdala-kindled seizure paradigm, we evaluated the acute and chronic anticonvulsant effects of lamotrigine (LTG)." | 5.31 | Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam. ( Heynen, T; Krupp, E; Li, XL; Post, RM; Weiss, SR, 2000) |
| "ADD and seizure severity were also measured in response to both threshold and suprathreshold kindling stimulation." | 5.31 | Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of acute carbamazepine. ( Gilbert, TH; Teskey, GC, 2001) |
| "In adults with focal seizures, adjunctive BRV treatment does not affect plasma concentrations of the evaluated AEDs but increases carbamazepine epoxide metabolite." | 5.30 | Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. ( Moseley, BD; Otoul, C; Staelens, L; Stockis, A, 2019) |
| "In the maximal electroshock seizure threshold test, clobenpropit dose-dependently raised the electroconvulsive threshold for tonic (hindlimb extension) seizures, but a significant increase of about 15% was determined only at the high dose of 40 mg/kg i." | 5.30 | Effect of clobenpropit, a centrally acting histamine H3-receptor antagonist, on electroshock- and pentylenetetrazol-induced seizures in mice. ( Fischer, W; van der Goot, H, 1998) |
| "Carbamazepine (CBZ) is an effective anticonvulsant agent." | 5.30 | Exacerbation of epileptic seizures by carbamazepine: report of 10 cases. ( Fraticelli, E; Parmeggiani, A; Rossi, PG, 1998) |
| "Nifedipine was found to have anticonvulsant activity in both models but flunarizine only had an anticonvulsant effect in the PTZ seizure incidence/latency test." | 5.29 | Protective effect of flunarizine and nifedipine alone and in combination with anticonvulsant drugs against PTZ-induced seizures in mice. ( Pleuvry, BJ; Rodger, C, 1993) |
| "Seizures were repetitive and death occurred in 10." | 5.28 | Antiepileptic drugs delay the onset of seizures induced by aminophylline in conscious rats. ( David, J; Joseph, T; Kulkarni, C, 1992) |
| "Pregnant women with epilepsy on one or more of the following AEDs: lamotrigine, carbamazepine, phenytoin or levetiracetam." | 5.27 | AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. ( Bagary, M; Coleman, J; D'Amico, M; Denny, E; Dodds, J; Eldridge, S; Greenhill, L; Hard, K; Kelso, A; Khan, KS; Marlin, N; McCorry, D; Middleton, L; Moss, N; Newton, S; Pirie, A; Pullen, A; Rikunenko, R; Roberts, T; Rogozińska, E; Thangaratinam, S; Weckesser, A, 2018) |
| "To evaluate and compare the effects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate (ESL) for focal (partial-onset) seizures (FS)." | 5.27 | Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. ( Abou-Khalil, B; Blum, D; Cheng, H; Gama, H; Grinnell, T; Jung, J; Klein, P; Rocha, F; Ryvlin, P; Shah, A; Specchio, LM, 2018) |
| "QUIN seizures showed particular sensitivity to carbamazepine (5 mg/kg) but were resistant to diphenylhydantoin unless a relatively high dose was used (100 mg/kg)." | 5.27 | Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. ( Samanin, R; Tullii, M; Vezzani, A; Wu, HQ, 1986) |
| "Her seizures are now treated successfully with phenytoin." | 5.27 | A possible case of carbamazepine-induced pancreatitis. ( Soman, M; Swenson, C, 1985) |
| "The time to seizures was increased nearly five times by clonazepam and over three times by very small amounts of propylene glycol." | 5.26 | Protection from oxygen-induced seizures by clonazepam and propylene glycol. ( Beckman, DL; Crittenden, DJ, 1981) |
| "Carbamazepine is a suitable substitute for phenobarbital, primidone, and phenytoin, alone or in combination, when used in the treatment of generalized tonic-clonic or partial epilepsy." | 5.26 | Carbamazepine as a substitute treatment of single and compound seizures. ( McFarland, HR, 1978) |
| "Cannabidiol was effective in blocking convulsions when given concurrently with, but not prior to delta9THC." | 5.26 | Anticonvulsant drug antagonism of delta9tetrahydrocannabinol-induced seizures in rabbits. ( Consroe, P; Eisenstein, D; Martin, P, 1977) |
| "Oxcarbazepine is indicated for the treatment of partial or generalised tonic-clonic seizures." | 5.24 | Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ( Alexandre Junior, V; Antunes, NJ; Coelho, EB; Della Pasqua, O; Lanchote, VL; Takayanagui, OM; Tozatto, E; van Dijkman, SC; van Hasselt, JGC; Wichert-Ana, L, 2017) |
| " One study compared clonazepam to carbamazepine as monotherapy for participants with newly diagnosed psychomotor epilepsy (a condition corresponding to what is now termed mesial temporal lobe epilepsy)." | 5.22 | Clonazepam monotherapy for treating people with newly diagnosed epilepsy. ( Bragazzi, NL; Brigo, F; Igwe, SC; Lattanzi, S, 2022) |
| "This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study (KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy." | 5.22 | Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. ( Marson, AG; Noack-Rink, M; Pohlmann-Eden, B; Ramirez, F; Tofighy, A; Trinka, E; Werhahn, KJ; Wild, I, 2016) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 5.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| "One hundred and twenty-eight patients with poststroke seizures were randomly allocated to treatment with either levetiracetam (LEV) or sustained-release carbamazepine (CBZ) in a multicenter randomized open-label study." | 5.16 | Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). ( Bosco, D; Consoli, D; Galati, F; Neri, G; Ottonello, GA; Passarella, B; Perticoni, GF; Plastino, M; Postorino, P; Ricci, S; Toni, D, 2012) |
| "One to seven seizures were recognized before starting CBZ or Lidocaine therapy, followed by complete cessation in 57 episodes and one or two recurrent seizures in five." | 5.15 | Clinical trial of minimal treatment for clustering seizures in cases of convulsions with mild gastroenteritis. ( Komatsu, M; Kubota, T; Nakajima, M; Okumura, A; Shimakawa, S; Tanabe, T, 2011) |
| "To evaluate the pharmacokinetics of eslicarbazepine acetate (ESL) at steady-state in adults with partial-onset seizures who have taken ESL for at least 1 year with one or two concomitant antiepileptic drugs (AEDs)." | 5.15 | Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ( Almeida, L; Elger, C; Falcão, A; Halász, P; Perucca, E; Soares-da-Silva, P, 2011) |
| "5 years), with predominantly focal forms of epilepsy treated with trileptal (oxcarbazepine)." | 5.14 | [Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents]. ( , 2010) |
| "For a retrospective observational investigation based on real clinical practice of relative efficacy of valpoic acid (VPA), carbamazepine (CBZ) and topiramate (TPM) we have selected 106 patients with age of seizure onset before 17 years with a undoubted diagnosis of symptomatic or cryptogenic occipital lobe epilepsy (OLE), who had received treatment according to ILAE recommendations, and observation time since the last treatment change was from 2 to 10 years." | 5.14 | [Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children]. ( , 2010) |
| "To evaluate the response to albendazole treatment in patients who had SSECTL and new onset seizures treated with antiepileptic drugs (AED) in a prospective clinical trial." | 5.13 | Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. ( Chattopadhyay, A; Khandelwal, N; Sawhney, IM; Thussu, A, 2008) |
| "To compare topiramate (TPM) with investigator's choice of carbamazepine (CBZ) or valproate (VPA) for initial treatment in patients with newly diagnosed epilepsy." | 5.10 | Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. ( Brodie, MJ; Chadwick, DW; Mattson, RH; Neto, W; Privitera, MD; Wang, S, 2003) |
| "An earlier 6-month, multicenter, open-label study in patients with complex partial seizures found that a switch from multiple daily doses of conventional carbamazepine (CBZ) to twice-daily CBZ extended-release capsules(CBZ-ERC) was well tolerated, with maintenance of seizure control over the study period and significant improvements in quality of life (P < 0." | 5.10 | Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study. ( Garnett, WR; Hogan, RE; Thadani, VM, 2003) |
| "To determine the potential effectiveness of phenytoin (PHT) in preventing early postoperative seizures in patients undergoing craniotomy for supratentorial brain tumors." | 5.10 | Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. ( De Santis, A; Perucca, E; Sinisi, M; Stocchetti, N; Villani, R, 2002) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 5.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "Gabapentin is widely approved as add-on therapy for epilepsy treatment for partial seizures with and without secondary generalization." | 5.08 | A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. ( Alexander, J; Anhut, H; Chadwick, DW; Garofalo, EA; Greiner, MJ; Murray, GH; Pierce, MW, 1998) |
| "The results of a multicenter, double-blind, placebo-controlled clinical trial of the efficacy and safety of progabide (PGB) in the treatment of partial seizures are presented." | 5.06 | A controlled study of progabide in partial seizures: methodology and results. ( Bowman, T; Cloyd, J; Crosby, C; Dreifuss, FE; Graves, N; Jacobs, M; Leppik, IE; Porter, R; Santilli, N; Stackman, J, 1987) |
| " Drug interactions were studied during a randomized, double-blind, crossover trial of the efficacy and toxicity of PGB in patients with partial seizures taking phenytoin (PHT) and carbamazepine (CBZ)." | 5.06 | Effect of progabide on serum phenytoin and carbamazepine concentrations. ( Brundage, RC; Cloyd, JC; Graves, NM; Leppik, IE; Welty, TE, 1987) |
| "We illustrate several key methods in a real IPD-MA, where IPD of 1225 participants from 5 randomized clinical trials were combined to compare the effects of Carbamazepine and Valproate on the incidence of epileptic seizures." | 5.05 | Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example. ( de Jong, VMT; Debray, TPA; Eijkemans, MJC; Marson, AG; Moons, KGM; Riley, RD; Tudur Smith, C, 2020) |
| " One study compared clonazepam to carbamazepine as monotherapy for participants with newly diagnosed psychomotor epilepsy (a condition corresponding to what is now termed mesial temporal lobe epilepsy)." | 5.01 | Clonazepam monotherapy for treating people with newly diagnosed epilepsy. ( Bragazzi, NL; Brigo, F; Igwe, SC; Lattanzi, S, 2019) |
| "Under the medicine treatment of magnesium valproate with carbamazepine, the patient experienced partial seizures approximately once per month that lasted 30 to 60 seconds each without any complications observed during a follow-up period of 24 months." | 5.01 | A potential cause of adolescent onset Dyke-Davidoff-Masson syndrome: A case report. ( Jiang, Z; Li, B; Li, J; Li, Y; Wang, L; Zhang, T, 2019) |
| "The aim of the current study was to systematically review the literature to compare the efficacy of levetiracetam (LEV) with that of carbamazepine (CBZ) to control seizures and reduce the burden of interictal epileptiform discharges in children with rolandic epilepsy (RE) and also to compare their tolerability." | 5.01 | Levetiracetam versus carbamazepine in treatment of rolandic epilepsy. ( Asadi-Pooya, AA; Eidi, H; Forouzesh, M; Mirzaghafour, SE, 2019) |
| "To review the time to treatment failure, remission and first seizure with carbamazepine compared with phenytoin when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic-clonic seizures (with or without other generalised seizure types)." | 5.01 | Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. ( Marson, AG; Nevitt, SJ; Tudur Smith, C, 2019) |
| "To review the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, potential drug-drug interactions, and place in therapy of the intravenous (IV) formulation of carbamazepine (Carnexiv) for the treatment of seizures in adult patients." | 4.98 | Intravenous Carbamazepine for Adults With Seizures. ( DeFalco, AP; Tillery, EE; Vickery, PB, 2018) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset focal or generalized seizures." | 4.98 | Clobazam monotherapy for focal or generalized seizures. ( Anand, V; Arya, R; Garg, SK; Giridharan, N, 2018) |
| "To review the time to treatment failure, remission and first seizure with carbamazepine compared with phenobarbitone when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic-clonic seizures (with or without other generalised seizure types)." | 4.98 | Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. ( Marson, AG; Nevitt, SJ; Tudur Smith, C, 2018) |
| "To review the time to withdrawal, remission, and first seizure of carbamazepine compared with phenobarbitone when used as monotherapy in people with partial onset seizures (simple or complex partial and secondarily generalised) or generalised onset tonic-clonic seizures (with or without other generalised seizure types)." | 4.93 | Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. ( Marson, AG; Nolan, SJ; Tudur Smith, C; Weston, J, 2016) |
| "The authors analyze the published evidence on the efficacy of perampanel against secondarily generalized seizures (SGS) and report the currently available development of intravenous (IV) formulations of carbamazepine (CBZ), commenting on their potential in the clinical setting." | 4.90 | Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. ( Citraro, R; De Sarro, G; Franco, V; Grillo, E; Iudice, A; Russo, E, 2014) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset partial or generalized seizures." | 4.90 | Clobazam monotherapy for partial-onset or generalized-onset seizures. ( Anand, V; Arya, R; Garg, SK; Michael, BD, 2014) |
| "To review the best evidence comparing phenobarbitone and phenytoin when used as monotherapy in participants with partial onset seizures or generalised tonic-clonic seizures with or without other generalised seizure types." | 4.89 | Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. ( Marson, AG; Nolan, SJ; Pulman, J; Tudur Smith, C, 2013) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 4.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "Clinically significant side effects of the new anticonvulsants, such as metabolic acidosis from topiramate, autoimmune reactions from lamotrigine, hyponatremia from oxcarbazepine, or psychosis from levitiracetam can cause serious morbidity and mortality if unrecognized." | 4.86 | Emergent complications of the newer anticonvulsants. ( Dang, CV; Nelson, L; Wade, JF; Wasserberger, J, 2010) |
| "Oxcarbazepine, the 10-keto analogue of carbamazepine, is approved for the treatment of partial seizures or generalized tonic-clonic seizures." | 4.84 | Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. ( Bring, P; Ensom, MH, 2008) |
| "03 mmol/kg for the induction of seizures), produced a significant reduction in the anticonvulsant effects of carbamazepine, phenobarbital, phenytoin, and valproate against maximal electroshock-induced seizures in mice." | 4.84 | [Caffeine and antiepileptic drugs: experimental and clinical data]. ( Błaszczyk, B; Chrościńska-Krawczyk, M; Czuczwar, SJ; Jankiewicz, K, 2007) |
| "To compare the effects of carbamazepine and lamotrigine monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures." | 4.83 | A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. ( Chadwick, DW; Gamble, C; Marson, AG; Williamson, PR, 2006) |
| " In this review, the safety of the newer AED oxcarbazepine during pregnancy is assessed based on published pregnancy outcome data." | 4.82 | Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. ( Montouris, G, 2005) |
| "Oxcarbazepine as monotherapy is a viable alternative to established AEDs in the treatment of partial and generalised tonic-clonic seizures in adults and children." | 4.81 | Oxcarbazepine: an update of its efficacy in the management of epilepsy. ( Goa, KL; Wellington, K, 2001) |
| " As with carbamazepine (CBZ), these findings suggest clinical efficacy against generalized tonic-clonic and, to some extent, partial seizures." | 4.79 | Oxcarbazepine: mechanisms of action. ( Feldmann, KF; McLean, MJ; Olpe, HR; Portet, C; Schmutz, M; Wamil, AW, 1994) |
| " We describe the phenomenon of amygdala-kindled seizures episodically breaking through effective daily pharmacotherapy with carbamazepine and valproate, suggesting that these observations could reflect the balance of pathological vs compensatory illness-induced changes in gene expression." | 4.79 | A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. ( Post, RM; Weiss, SR, 1996) |
| " Preclinical data are presented that another primary pathological process--the occurrence of kindled seizures--can evoke endogenous compensatory processes that are either anticonvulsant in their own right, or enable the anticonvulsant effects of a drug such as carbamazepine." | 4.78 | Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic. ( Post, RM; Weiss, SR, 1992) |
| "More than two-thirds of patients with WHO grade 2 glioma related epilepsy treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first-choice agent." | 4.31 | Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure. ( Chumas, P; Fairclough, S; Goodden, J; Maguire, M; Mathew, R, 2023) |
| " This study was aimed at determining the influence of isopimpinellin (ISOP-a coumarin) when administered either separately or in combination with borneol (BOR-a monoterpenoid), on the antiseizure potencies of four classic ASMs (carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), and valproate (VPA)) in the mouse model of maximal electroshock-induced (MES) tonic-clonic seizures." | 4.31 | Anticonvulsant effects of isopimpinellin and its interactions with classic antiseizure medications and borneol in the mouse tonic-clonic seizure model: an isobolographic transformation. ( Bojar, H; Chmielewski, J; Florek-Łuszczki, M; Jankiewicz, K; Skalicka-Woźniak, K; Łuszczki, JJ, 2023) |
| "Carbamazepine (CBZ) is a common antiepileptic drug that may cause overdoses with seizures as a common neurological manifestation." | 4.12 | Stimulus-induced focal motor seizure in a pediatric patient with carbamazepine overdose. ( Fujimoto, A; Kanai, S; Maegaki, Y; Nakamura, Y; Ohta, K; Okanishi, T, 2022) |
| " The patient was treated with Carbamazepine and Clonazepam achieving the disappearance of seizures." | 4.12 | Expanding the genetic and clinical characteristics of Protocadherin 19 gene mutations. ( Dell'Isola, GB; Di Cara, G; Fattorusso, A; Imperatore, V; Mencaroni, E; Prontera, P; Striano, P; Tascini, G; Verrotti, A, 2022) |
| "This study aimed to investigate the factors affecting the plasma concentration of monohydroxylated derivative (MHD) of oxcarbazepine (OXC) in children with epilepsy." | 4.12 | Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy. ( Huang, A; Huang, S; Song, H; Yao, N, 2022) |
| "Dyke-Davidoff-Masson Syndrome (DDMS) is a rare clinical condition in which atrophy or hypoplasia of one cerebral hemisphere occurs secondary to brain insult during fetal or early childhood, which results in variable clinical manifestations like hemiparesis, seizures, expressive aphasia, and mental retardation." | 4.12 | Dyke-davidoff-masson syndrome: A case report of an adolescent boy at a tertiary hospital in Adamawa, North-Eastern Nigeria. ( C Dahiru, AM; Emmanuel, P; Hirayama, K; Manchan, DB; Namuya, NP; Raheem, N; Usman, AB; Usman, AU, 2022) |
| " In this study, we examined the effect of both acute and chronic treatment with moclobemide on seizures and the action of first-generation antiepileptic drugs: valproate, carbamazepine, phenobarbital and phenytoin." | 4.02 | Acute and chronic treatment with moclobemide, a reversible MAO-inhibitor, potentiates the antielectroshock activity of conventional antiepileptic drugs in mice. ( Banach, M; Borowicz-Reutt, KK, 2021) |
| " Exanthema as especially clinically relevant adverse drug event was rightly chosen for carbamazepine by 18 (8%) and for lamotrigine by 12 (5%) participants." | 4.02 | Knowledge of epilepsy among German pharmacists. ( Bertsche, A; Bertsche, T; Herziger, B; Jeschke, S; Müller, RM; Neininger, MP, 2021) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 3.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "Carbamazepine and topiramate both have established potentials for causing teratogenesis, and it is possible that replacement of carbamazepine with a less teratogenic AED, for example levetiracetam, might result in any subsequent depression that occurs in pregnancy being inappropriately attributed to the newly introduced agent." | 3.96 | Antiepileptic drugs and depression during pregnancy in women with epilepsy. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Horgan, D; Lander, CM; Mitchell, J; O'Brien, TJ; Vajda, FJE, 2020) |
| "This study evaluated the effect of androsterone (AND), a metabolite of testosterone, on the ability of selected classical and novel antiepileptic drugs to prevent seizures caused by maximal electroshock (MES), which may serve as an experimental model of human generalized tonic-clonic seizures in mice." | 3.91 | Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Aebisher, D; Bartusik-Aebisher, D; Buszewicz, G; Kołodziejczyk, P; Mróz, K; Mróz, T; Tutka, P; Łuszczki, JJ, 2019) |
| " None of the clinical factors appeared to affect seizure outcomes significantly except that treatment with carbamazepine was a protective factor against uncontrolled seizures (OR = 0." | 3.91 | Factors predicting uncontrolled seizures in epilepsy with auditory features. ( Chen, L; Zhang, L; Zhu, X; Zou, X, 2019) |
| "Newly diagnosed rats with epilepsy were treated with carbamazepine (CBZ) during a 4-week baseline period to establish their baseline seizure rate in the presence of 50% adherence." | 3.91 | Correction of medication nonadherence results in better seizure outcomes than dose escalation in a novel preclinical epilepsy model of adherence. ( Hill, AC; Newell, TG; Thomson, KE; White, HS, 2019) |
| "This study investigates the neuronal protective effect of SXC combined with carbamazepine (CBZ) on epilepsy and cognitive impairment in kainic acid-kindled SD rats." | 3.91 | Neuronal protective effect of Songling Xuemaikang capsules alone and in combination with carbamazepine on epilepsy in kainic acid-kindled rats. ( Chen, M; Jia, C; Jiao, H; Wei, L; Yang, H; Yin, W; Zhang, R, 2019) |
| " Acute amiodarone at the dose of 75 mg/kg significantly potentiated the anticonvulsive effect of carbamazepine, but not that of valproate, phenytoin or phenobarbital in the maximal electroshock-induced seizures in mice." | 3.88 | Amiodarone, a multi-channel blocker, enhances anticonvulsive effect of carbamazepine in the mouse maximal electroshock model. ( Banach, M; Borowicz-Reutt, KK; Popławska, M, 2018) |
| "This study aimed to assess efficacy and safety of oxcarbazepine (OXC) oral suspension in pediatric patients aged 2-5 years with partial seizures (PS) and/or generalized tonic-clonic seizures (GTCS) in real-world clinical practice in China." | 3.88 | Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study. ( Chen, YB; Deng, YC; Fang, F; Hu, XS; Huang, XF; Jiang, L; Lin, ZD; Qin, J; Wang, Y; Wu, Y; Yin, F; Zhang, YQ, 2018) |
| " The frequency of number of seizures/week was higher in the carbamazepine cohort compared to valproic acid cohort." | 3.88 | Carbamazepine Verses Valproic Acid as Monotherapy in Epileptic Patients. ( Ali, N; Nazish, H; Shakir, S, 2018) |
| "This cross-sectional study included 36 patients with focal seizures and impaired awareness treated for 12-32 months with carbamazepine monotherapy and 38 healthy volunteers." | 3.88 | Effects of Chronic Carbamazepine Treatment on the ECG in Patients with Focal Seizures. ( Adoor, M; Delhaas, T; Hermans, BHM; Koot, LAM; Kramer, BW; Raju, TR; Sathyaprabha, TN; Satishchandra, P; Sinha, S, 2018) |
| "The PPK model, using the power scaling of body weight, effectively elucidated the topiramate serum concentration profile ranging from pediatric to adult patients." | 3.85 | Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ( Ikeda, A; Ito, S; Matsubara, K; Sugimoto, M; Takeuchi, M; Yamamoto, S; Yano, I; Yonezawa, A, 2017) |
| " The initial anticonvulsant screening was performed in mice (ip) using the 'classical' maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) tests as well as in the six-Hertz (6Hz) model of pharmacoresistant limbic seizures." | 3.83 | New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones. ( Abram, M; Andres-Mach, M; Kamiński, K; Obniska, J; Rapacz, A; Zagaja, M; Łuszczki, JJ, 2016) |
| "The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)pyridine (MPEP - a selective antagonist for the glutamate metabotropic receptor subtype mGluR5) on the protective action of some novel antiepileptic drugs (lamotrigine, oxcarbazepine, pregabalin and topiramate) against maximal electroshock-induced seizures in mice." | 3.83 | Influence of MPEP (a selective mGluR5 antagonist) on the anticonvulsant action of novel antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Florek-Luszczki, M; Kondrat-Wrobel, MW; Luszczki, JJ; Zolkowska, D, 2016) |
| "Using the mouse maximal electroshock test, the reference model of tonic-clonic seizures, the aim of the present study was to determine the type of interaction between mexiletine (a class IB antiarrhythmic drug) and classical antiepileptics: valproate, carbamazepine, phenytoin, and phenobarbital." | 3.83 | Mexiletine and its Interactions with Classical Antiepileptic Drugs: An Isobolographic Analysis. ( Banach, M; Borowicz-Reutt, KK; Piskorska, B, 2016) |
| " Here, we suggest that triggering limbic seizures with low doses of PTZ in pilocarpine-treated marmosets might provide a more effective basis for the development of AED." | 3.83 | Seizures triggered by pentylenetetrazol in marmosets made chronically epileptic with pilocarpine show greater refractoriness to treatment. ( Blanco, MM; Cinini, SM; Lima, TZ; Mello, LE; Pontes, JC; Queiroz, CM, 2016) |
| " This compound was effective in delaying onset of PTZ-evoked seizures at the dose of 5mg/kg in kindled animals and significantly reduced oxidative stress better than standard drug phenobarbital (PB)." | 3.81 | Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents. ( Kumari, S; Mishra, CB; Tiwari, M, 2015) |
| " Therapy with carbamazepine considerably reduced the frequency and entent of seizures." | 3.81 | Nocturnal paroxysmal dystonia - case report. ( Kania, K; Kozubski, W; Niśkiewicz, I; Tokarz-Kupczyk, E; Wierzbicka-Wichniak, A, 2015) |
| " Diazepam produced a dose-dependent protection against 6-Hz seizures in control and pilocarpine mice, both at 2 weeks and 8 weeks after SE, but with a more pronounced increase in potency in post-SE animals at 2 weeks." | 3.81 | Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. ( Kaminski, RM; Leclercq, K, 2015) |
| "The natural compounds carvacrol and thymol completely prevented seizures in the 6 Hz, 32 mA partial seizure model." | 3.80 | Seizure prevention by the naturally occurring phenols, carvacrol and thymol in a partial seizure-psychomotor model. ( Baker, MT; Mishra, RK, 2014) |
| " In addition, the potency of compound 4n against seizures induced by Pentylenetetrazole, 3-Mercaptopropionic acid, and Bicuculline suggested its broad spectrum activity, and the mechanisms of action including inhibition of voltage-gated ion channels and modulation of GABAergic activity might involve in its anticonvulsant activity." | 3.80 | Design, synthesis and anticonvulsant activity evaluation of novel 4-(4-substitutedphenyl)-3-methyl-1H-1,2,4-triazol-5(4H)-ones. ( Cao, X; Liu, DC; Quan, ZS; Shu, B; Wang, SB; Zheng, Y, 2014) |
| "Carbamazepine (CBZ) is the gold standard antiepileptic drug (AED) for focal onset seizures." | 3.80 | Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus. ( Beran, RG; Cordato, DJ; Malkan, A; Patel, V, 2014) |
| "Carbamazepine controlled multiple seizure types and did not induce or increase the frequency of myoclonic or absence seizures in these patients." | 3.80 | Carbamazepine treatment of generalized tonic-clonic seizures in idiopathic generalized epilepsy. ( Kenyon, K; Mintzer, S; Nei, M, 2014) |
| "Lacosamide (LCM), a new antiepileptic drug (AED) approved as adjunctive therapy for the treatment of patients with partial-onset seizures, has limited pharmacokinetic and drug interaction data." | 3.80 | Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. ( Duncan, JS; Markoula, S; Patsalos, PN; Ratnaraj, N; Sander, JW; Teotonio, R, 2014) |
| "To investigate whether single nucleotide polymorphisms (SNPs) of rs2298771 and rs3812718 of the sodium channel α-subunit type 1 (SCN1A) gene affect the efficacy of carbamazepine (CBZ) treatment for seizures in Chinese Han epileptic patients." | 3.80 | Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients. ( Liu, Z; Sheng, Y; Tang, B; Wang, P; Zhou, B; Zhou, Q, 2014) |
| "A 54-year-old woman with known epilepsy developed convulsions after using rifampicin and flucloxacillin, despite the use of maintenance treatment in the form of carbamazepine, valproic acid and clonazepam." | 3.80 | [Convulsions due to an interaction between anti-epileptic drugs and rifampicin]. ( Hanrath, MA; Swart, EL, 2014) |
| "A case of a female patient with juvenile absence epilepsy who developed generalized seizures after the treatment with valproic acid preparations is described." | 3.79 | [A paradoxical reaction on valproates in a female patient with juvenile absence epilepsy]. ( Geĭbatova, LG; Karlov, VA, 2013) |
| "To analyze seizure control, dose adjustments, and other changes of antiepileptic drug (AED) treatment during pregnancy in a large cohort of women with epilepsy entering pregnancy on monotherapy with carbamazepine, lamotrigine, phenobarbital, or valproate." | 3.79 | Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Tomson, T; Vajda, F, 2013) |
| "We report two female infants with early myoclonic encephalopathy (EME) whose intractable focal seizures were suppressed with lidocaine and carbamazepine (CBZ)." | 3.79 | Successful treatment of early myoclonic encephalopathy using lidocaine and carbamazepine. ( Kobayashi, K; Kodani, N; Maniwa, S; Nakano, K; Ohtsuka, Y, 2013) |
| "A novel class of 19 carbamates was synthesized, and their anticonvulsant activity was comparatively evaluated in the rat maximal electroshock (MES) and subcutaneous metrazol (scMet) seizure tests and pilocarpine-induced status epilepticus (SE) model." | 3.78 | Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. ( Bialer, M; Hen, N; Yagen, B, 2012) |
| "Carbamazepine is used to control seizures." | 3.78 | Carbamazepine-induced hypogammaglobulinemia. ( Canbakan, B; Eroglu, S; Goksugur, N; Ozaras, N; Ozaras, R; Tabak, O, 2012) |
| " calamus (HAEAC) on conventional antiepileptic drugs (AEDs), sodium valproate and carbamazepine was determined using pentylenetetrazole-induced seizures model in rats." | 3.78 | Interaction of hydroalcoholic extract of Acorus calamus Linn. with sodium valproate and carbamazepine. ( Gupta, YK; Katyal, J; Sarangal, V, 2012) |
| "The aim of the present study was to investigate whether single nucleotide polymorphisms (SNPs) in the sodium channel a subunit type 1 (SCN1A) gene affect the retention rate of carbamazepine (CBZ) used to treat seizures in Chinese Han patients with epilepsy." | 3.78 | Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. ( Li, GL; Liu, D; Liu, ZQ; Qu, J; Xu, XJ; Yin, JY; Zhou, BT; Zhou, HH; Zhou, QH, 2012) |
| "In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal." | 3.78 | Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin. ( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012) |
| "), its effects on seizures, EEG epileptiform activity and EEG amplitude increases induced by two convulsive agents were evaluated and compared with the effects of carbamazepine." | 3.78 | The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures. ( Aldana, BI; Gómez, CD; Nekrassov, V; Sitges, M, 2012) |
| " In addition, the potence of compound 1i against seizures induced by Pentylenetetrazole, Isoniazid, Thiosemicarbazide, 3-Mercaptopropionic acid, and Bicuculline in the chemical-induced seizure tests suggested that compound 1i displayed broad spectrum activity in several models, and it is likely to have several mechanisms of action including inhibiting voltage-gated ion channels and modulating GABAergic activity." | 3.77 | Synthesis and anticonvulsant activity of 7-phenyl-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-ones and their derivatives. ( Deng, XQ; Quan, LN; Quan, ZS; Song, MX; Wei, CX, 2011) |
| "Epileptic seizures associated with intrathecal baclofen (ITB) application have been observed in patients with traumatic brain injury." | 3.77 | Seizure after intrathecal baclofen bolus in a multiple sclerosis patient treated with oxcarbazepine. ( Bramanti, P; D'Aleo, G; Kofler, M; Rifici, C; Saltuari, L; Sessa, E, 2011) |
| "Many investigators agree that appropriate rational utilization of therapeutic drug monitoring (TDM) with Bayesian feedback dosage adjustment facilitates epilepsy treatment with carbamazepine (CBZ) and/or valproate (VPA) by increasing the seizure control and safety, as well as by reducing treatment costs." | 3.77 | Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy. ( Andreeva, OV; Bondareva, IB; Bondareva, KI; Jelliffe, RW, 2011) |
| "The effects of ALAC administered per os were evaluated by standard protocols against audiogenic seizures in Genetic Epilepsy Prone Rats (GEPR-9 rats), maximal electroshock (MES)-induced seizures in rats, pilocarpine-induced seizures in mice, spontaneous chronic seizures in mice exposed to pilocarpine-induced status epilepticus (SE), and absence seizures in WAG/Rij rats." | 3.77 | Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. ( Citraro, R; De Fazio, S; De Sarro, G; Mainardi, P; Perucca, E; Raggio, R; Russo, E; Scicchitano, F, 2011) |
| " However, zonisamide- and carbamazepine-treated animals had IT values similar to those of controls, but only zonisamide significantly decreased absence seizure development." | 3.77 | Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. ( Citraro, R; Constanti, A; De Fazio, S; De Sarro, G; Di Paola, ED; Perrota, I; Perrotta, I; Russo, E; Scicchitano, F, 2011) |
| "The aim of this work was to analyze the effect of oxcarbazepine (OXC) on sleep patterns, "head and body shakes" and monoamine neurotransmitters level in a model of kainic-induced seizures." | 3.77 | Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats. ( Alfaro-Rodríguez, A; Arch-Tirado, E; Ávila-Luna, A; Bueno-Nava, A; González-Piña, R; Uribe-Escamilla, R; Vargas-Sánchez, J, 2011) |
| "This prospective study was designed to investigate whether or not monotherapy with sodium valproate (VPA) or oxcarbazepine (OXC) affects plasma levels of fatty acylcarnitine esters in children with epilepsy." | 3.77 | Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine. ( Biberoglu, G; Cansu, A; Ezgu, FS; Hasanoglu, A; Hirfanoglu, TL; Serdaroglu, A; Tumer, L, 2011) |
| " Antiepileptics (carbamazepine, sodium valproate, zonisamide, clobazam, and topiramate), which are used for complex partial epilepsy or secondary generalized epilepsy in clinical practice, were orally administrated to kindled rats." | 3.76 | The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics. ( Akagi, M; Fujiwara, A; Ishikawa, T; Kaida, Y; Kamei, C; Takechi, K; Watanabe, Y, 2010) |
| " injection to mice at doses of 30, 100, and 300 mg/kg body weight synthesized compounds were examined in the maximal electroshock induced seizures (MES) and subcutaneous pentylenetetrazole (scPTZ) induced seizure models in mice." | 3.75 | Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea. ( Jain, NK; Kashaw, SK; Kashaw, V; Mishra, P; Stables, JP, 2009) |
| "Thirteen pregnancies in ten women on oxcarbazepine (OXC) monotherapy and one pregnancy in a woman on OXC and topiramate therapy were retrospectively analyzed." | 3.75 | Seizure deterioration in women treated with oxcarbazepine during pregnancy. ( Hansen-Schwartz, J; Petrenaite, V; Sabers, A, 2009) |
| "The aim of this work was to analyze the effect of carbamazepine (CBZ) on sleep patterns and on "head and body shakes" and to determine the role of serotonin (5-HT) in a model of kainic-induced seizures." | 3.75 | Neuro-protective effects of carbamazepine on sleep patterns and head and body shakes in kainic acid-treated rats. ( Alfaro-Rodríguez, A; Arch-Tirado, E; Carrasco-Portugal, M; González-Piña, R; Labra-Ruiz, N; Padilla-Martin, K; Pérez-Guillé, B; Soriano-Rosales, RE; Uribe-Escamilla, R, 2009) |
| " The aim of the present work was to assess the involvement of P-glycoprotein in carbamazepine and phenobarbital hippocampal pharmacokinetics in an experimental model of epilepsy, induced by repetitive MP administration." | 3.75 | Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ( Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Mayer, MA; Opezzo, JA; Taira, CA, 2009) |
| " The anticonvulsant activity of all the synthesized compounds was evaluated against maximal electroshock induced seizures (MES) and subcutaneous pentylenetetrazole (ScPTZ) induced seizure models in mice." | 3.74 | Synthesis and anticonvulsant activity of some novel 3-aryl amino/amino-4-aryl-5-imino-Delta2-1,2,4-thiadiazoline. ( Gupta, A; Jatav, V; Kashaw, SK; Mishra, P; Stables, JP, 2008) |
| "A series of appropriate alkanolamine and amide derivatives of xanthone were prepared and evaluated for anticonvulsant activity using maximal electroshock (MES) and subcutaneous pentylenetetrazole (scMet) induced seizures, and for neurotoxicity (TOX) using the rotorod test on mice and rats." | 3.74 | Anticonvulsant activity of some xanthone derivatives. ( Antkiewicz-Michaluk, L; Marona, H; Pekala, E; Szneler, E; Walczak, M, 2008) |
| "The purpose of the present study was to evaluate the effect of kainic acid (KA)-induced acute seizures on the pharmacokinetic profiles of antiepileptic drug, carbamazepine (CBZ) in mice." | 3.74 | Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures. ( Honda, N; Nishimura, A; Shibata, N; Sugioka, N; Takada, K, 2008) |
| " We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated." | 3.74 | Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. ( Bomprezzi, C; Formica, F; Iacoangeli, M; Mauro, AM; Morresi, S; Provinciali, L; Scerrati, M, 2007) |
| " Furthermore, we tested nefopam for protection against both, maximal electroshock-induced seizures (MES), and isoniazid-induced seizures in mice." | 3.74 | Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. ( Desogus, CM; Fernández-Sánchez, MT; Ferrero-Gutiérrez, A; Groppetti, A; Manfredi, B; Novelli, A; Pérez-Gómez, A; Rossoni, G, 2007) |
| " By contrast, offspring of rats exposed to carbamazepine (which at the dose used produced low plasma concentrations) or to generalized convulsive seizures showed no clear-cut evidence of dysplasias." | 3.74 | Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. ( Ben-Ari, Y; Depaulis, A; Jorquera, I; Manent, JB; Mazzucchelli, I; Perucca, E; Represa, A, 2007) |
| "Using the mouse maximal electroshock-induced seizure model, indicative of tonic-clonic seizures in humans, the present study was aimed at characterizing the interaction between remacemide and valproate, carbamazepine, phenytoin, and phenobarbital." | 3.74 | Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock. ( Borowicz, KK; Czuczwar, SJ; Luszczki, JJ; Malek, R; Patsalos, PN; Ratnaraj, N, 2007) |
| " But seizures occurred and the treatment by carbamazepine induced decreased blood level of itraconazole." | 3.74 | [Miliary cerebral Histoplasma capsulatum in an HIV-negative patient]. ( Bellard, S; Blanchard, C; Granier, H; Nicolas, X; Talarmin, F; Zagnoli, F, 2007) |
| "Carbamazepine hypersensitivity syndrome is a rare, life-threatening condition." | 3.74 | Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. ( Avner, M; Finkelstein, Y; Hackam, D; Koren, G, 2007) |
| "The present study evaluated the effectiveness of intraperitoneal (IP) injections and oral administration of carbamazepine (CBZ) in food on the frequency of spontaneous motor seizures in rats with kainate-induced epilepsy." | 3.74 | Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. ( Clark, S; Dudek, FE; Grabenstatter, HL, 2007) |
| "To compare the temporal pattern of seizures after acute withdrawal of oxcarbazepine (OXC) and phenytoin (PHT) in the epilepsy monitoring unit (EMU)." | 3.74 | Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring. ( Abou-Khalil, BW; Azar, NJ; Song, Y; Wang, L, 2008) |
| "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures." | 3.74 | Hyponatraemia during low-dose carbamazepine therapy. ( Danburam, A; Salawu, F, 2007) |
| " Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole." | 3.73 | Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. ( Arban, R; Brackenborough, K; Gerrard, P; Large, C; Maraia, G; Wilson, A; Winyard, L, 2005) |
| " More precisely, the influence of intrahippocampal perfusion of verapamil, a P-glycoprotein inhibitor, and probenecid, a multidrug resistance protein inhibitor, on the blood-brain barrier passage and anticonvulsant properties of oxcarbazepine were investigated in the focal pilocarpine model for limbic seizures." | 3.73 | Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. ( Clinckers, R; Ebinger, G; Meurs, A; Michotte, Y; Smolders, I, 2005) |
| " Anticonvulsant and acute neurotoxic adverse effect profiles of combinations of GBP and TGB with other AEDs at fixed ratios of 1:3, 1:1 and 3:1 were investigated in pentylenetetrazole (PTZ)-induced seizures and the chimney test (as a measure of motor impairment) in mice so as to identify optimal combinations." | 3.73 | Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. ( Czuczwar, SJ; Luszczki, JJ, 2005) |
| "To investigate whether histidine can enhance the anticonvulsant efficacy of carbamazepine (CBZ) and simultaneously improve the spatial memory impairment induced by transauricular kindled seizures in Sprague-Dawley rats." | 3.73 | Histidine enhances carbamazepine action against seizures and improves spatial memory deficits induced by chronic transauricular kindling in rats. ( Chen, Z; Jin, CL; Li, Q; Liu, LY; Xu, LS; Yang, LX; Zhu-Ge, ZB, 2005) |
| "We investigated the effect of carbamazepine on convulsions associated with mild gastroenteritis." | 3.73 | [Low-dose therapy with carbamazepine for convulsions associated with mild gastroenteritis]. ( Furukawa, S; Hayashi, T; Ichiyama, T; Matsufuji, H; Nishikawa, M; Suenaga, N, 2005) |
| "Serious complications after carbamazepine poisoning, such as coma, seizures, respiratory failure, cardiac conduction abnormalities, and death are more likely with serum levels greater than 170 micromol L(-1)." | 3.73 | Multidose activated charcoal in the treatment of carbamazepine overdose with seizures: a case report. ( Jukić, I; Mise, S; Titlić, M; Tonkić, A, 2005) |
| "We report on a 4-year 8-month-old boy with Panayiotopoulos syndrome who showed atypical evolution with newly developed absence seizures and EEG exacerbation induced by carbamazepine." | 3.73 | EEG and seizure exacerbation induced by carbamazepine in Panayiotopoulos syndrome. ( Akiyama, T; Endoh, F; Ito, M; Kikumoto, K; Ohtsuka, Y; Oka, M; Yoshinaga, H, 2006) |
| "The anticonvulsant effects produced by stiripentol (STP), carbamazepine (CBZ), and their combination in the maximal electroshock (MES)-induced seizures in mice were investigated using three-dimensional (3D) isobolographic analysis." | 3.73 | Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. ( Czuczwar, SJ; Luszczki, JJ, 2006) |
| "A 75-year-old white man with Alzheimer disease was observed to have seizures while receiving quetiapine 500 mg/d and carbamazepine 200 mg/d." | 3.72 | Seizures associated with quetiapine treatment. ( Dogu, O; Kaleagasi, HS; Sevim, S, 2003) |
| "To report a case of pseudo mycosis fungoides due to carbamazepine." | 3.72 | Carbamazepine-induced pseudo mycosis fungoides. ( Dursun, A; Gül, U; Kiliç, A, 2003) |
| " The present study investigated the influence of L-histidine on the protective effects of carbamazepine and phenytoin against maximal electroshock-induced seizures in mice." | 3.72 | L-histidine is a beneficial adjuvant for antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Kamiński, RM; Kleinrok, Z; Kozicka, M; Zółkowska, D, 2004) |
| "125 mg/kg) significantly potentiated the protective activity of carbamazepine against maximal electroshock-induced seizures in mice." | 3.71 | 2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anticonvulsant activity of carbamazepine and clonazepam in mice. ( Borowicz, KK; Czuczwar, SJ; Łuszczki, J, 2002) |
| "1-10 nmol; direct GABA(A) agonist); (3) YM90K (3-10 mg/kg; AMPA receptor antagonist); and (4) diazepam (2 and 5 mg/kg) and carbamazepine (5 and 20 mg/kg), two standard anticonvulsants, using the partially-kindled hippocampal model for epileptic seizures in freely moving rats." | 3.70 | Acute effects of various GABA receptor agonists and glutamate antagonists on focal hippocampal seizures in freely moving rats elicited by low-frequency stimulation. ( Ashby, CR; Katsumori, H; Minabe, Y; Osawa, M, 1998) |
| "We investigated the anticonvulsant and adverse behavioral effects of lamotrigine (LTG), a novel antiepileptic drug (AED), as well as other conventional AEDs on kindled seizures in rats." | 3.70 | Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats. ( Kuroda, S; Morimoto, K; Otsuki, K; Sato, K; Yamada, N, 1998) |
| "The efficacy of Flunarizine (FLU), a calcium channel blocker, in combination with conventional antiepileptic drugs, phenytoin (PHT), carbamazepine (CBZ), sodium valproate (VPA), and ethosuximide (ESM), at ED50 doses, were examined for protective effects against maximal electroshock seizures (MES) and pentylenetetrazol (PTZ) induced seizures in mice." | 3.70 | Additive anticonvulsant effect of flunarizine and sodium valproate on electroshock and chemoshock induced seizures in mice. ( David, J; Joseph, S; Joseph, T, 1998) |
| "Carbamazepine is a potent anticonvulsant agent with proven efficacy in the treatment of partial and tonic-clonic seizures." | 3.70 | Suspected carbamazepine-induced hepatotoxicity. ( Morales-Diaz, M; Pinilla-Roa, E; Ruiz, I, 1999) |
| "We have observed a 26-year-old diabetic male who had been treated with carbamazepine because of seizures." | 3.70 | A man with a mysterious hypogammaglobulinaemia and skin rash. ( Netten, PM; van der Meer, JW; van Ginneken, EE, 1999) |
| " The present study was conducted to determine if the adenosinergic system and adenosine A1 receptors are involved in the anticonvulsant action of the antiepileptic drugs phenobarbitone and carbamazepine, in pentylenetetrazole (PTZ)-induced seizures in rats." | 3.70 | Effect of adenosinergic modulation on the anticonvulsant effect of phenobarbitone and carbamazepine. ( Gupta, YK; Malhotra, J, 1999) |
| " However, this calcium channel antagonist (10 mg kg(-1)) enhanced the anticonvulsive activity of carbamazepine, valproate and phenobarbital against maximal electroshock-induced seizures in mice." | 3.70 | Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Jagiello-Wojtowicz, E; Jasinski, M; Kaminski, R; Kleinrok, Z, 1999) |
| "Video monitoring studies were undertaken to determine if the anticonvulsant, carbamazepine (CBZ), could prevent seizures in infant rats that had been intrahippocampally injected with tetanus toxin (TNTX)." | 3.70 | Insights into the tetanus toxin model of early-onset epilepsy from long-term video monitoring during anticonvulsant therapy. ( Anderson, AE; Hrachovy, RA; Lee, I; Rashid, S; Swann, JW, 1999) |
| " In the present study, it was evaluated whether circannual rhythms affect the anticonvulsant activity of phenobarbital, carbamazepine, or valproate in two mouse models of generalized seizures, i." | 3.70 | The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures. ( Fiedler, M; Löscher, W, 2000) |
| "Physicians may prescribe carbamazepine for HIV-infected patients to treat seizures or postherpetic neuralgia, which are complications of opportunistic infections such as herpes zoster or toxoplasmosis." | 3.70 | Carbamazepine--indinavir interaction causes antiretroviral therapy failure. ( Brinkman, K; Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Schuurman, R; ter Hofstede, HJ, 2000) |
| "To investigate the relationships between carbamazepine (CBZ) concentrations in serum and the brain, and the anticonvulsive efficacy in kainic acid (KA) induced seizures in rats, adult Wistar rats (n=25) were intraperitoneally given 40 mg/kg CBZ, followed by 15 mg/kg KA (n=20) or saline (control, n=5)." | 3.70 | Brain distribution and efficacy of carbamazepine in kainic acid induced seizure in rats. ( Wang, L; Wu, XR; Zhao, DY; Zuo, CH, 2000) |
| "Carbamazepine intoxication is associated with seizures, coma, arrhythmias, and death." | 3.70 | High-efficiency dialysis for carbamazepine overdose. ( Brophy, PD; Bunchman, TE; Kudelka, T; Maxvold, NJ; Schuerer, DJ, 2000) |
| "Systemic injections of 4-aminopyridine precipitate epileptiform generalized seizures characterized mainly by shivering of the body, tail movements and tonic-clonic convulsions in rats and mice." | 3.70 | Acute 4-aminopyridine seizures increase the regional cerebral blood flow in the thalamus and neocortex, but not in the entire allocortex of the mouse brain. ( Ayesha, A; Gopinath, S; Mathew, M; Mihály, A; Owunwanne, A; Shihab-Eldeen, A, 2000) |
| " This compound blocked bicuculline induced seizures, did not elevate seizure threshold following iv infusion of metrazole, and blocked influx of Ca2+ ions into cerebellar granule cells induced by K+ or veratridine." | 3.69 | Aroyl(aminoacyl)pyrroles, a new class of anticonvulsant agents. ( Almond, HR; Carmosin, RJ; Carson, JR; Pitis, PM; Stables, JP; Swinyard, EA; Vaught, JL; White, HS; Wolf, HH, 1997) |
| "Tolerance to carbamazepine's anticonvulsant effects on amygdala kindled seizures occurs contingently, that is, only when carbamazepine is given prior to, but not after the seizure occurs." | 3.69 | Contingent tolerance to carbamazepine: alterations in TRH mRNA and TRH receptor binding in limbic structures. ( Post, RM; Rosen, JB; Weiss, SR, 1994) |
| "One of the most dangerous aspects of theophylline toxicity is seizures." | 3.69 | Adenosine receptors are not involved in theophylline-induced seizures. ( Hornfeldt, CS; Larson, AA, 1994) |
| "Oxcarbazepine (OCBZ, Trileptal) and its main human monohydroxy metabolite (MHD) protected mice and rats against generalized tonic-clonic seizures induced by electroshock with ED50 values between 13." | 3.69 | Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. ( Brugger, F; Gentsch, C; McLean, MJ; Olpe, HR; Schmutz, M, 1994) |
| " Carbamazepine was reported to be moderately to markedly effective in the following percentage of patients: partial complex seizures, 85." | 3.69 | Efficacy of carbamazepine compared with other agents: a clinical practice survey. ( Denicoff, KD; Meglathery, SB; Post, RM; Tandeciarz, SI, 1994) |
| "The anticonvulsant activities of intraperitoneally (IP) given carbamazepine (CBZ) or diphenylhydantoin (DPH), expressed as their respective ED50 values in mg/kg, were assessed after caffeine (CAFF) treatment against maximal electroshock-induced seizures in mice." | 3.69 | Chronic caffeine and the anticonvulsant potency of antiepileptic drugs against maximal electroshock. ( Borowicz, K; Czuczwar, SJ; Gasior, M; Kleinrok, Z, 1996) |
| "Limbic seizures were provoked in freely moving rats by intrahippocampal administration of the muscarinic receptor agonist pilocarpine via a microdialysis probe (10 mM for 40 min at 2 microliters/min)." | 3.69 | Hippocampal and cerebellar extracellular amino acids during pilocarpine-induced seizures in freely moving rats. ( Ebinger, G; Michotte, Y; Smolders, I; Van Belle, K, 1997) |
| "We report the effects of two new dihydropyridine derivatives, isradipine (4-(4'-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedic arboxylic acid methylisopropylester) and niguldipine (1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride), and of dantrolene (1-[(5-[p-nitrophenyl]furfurylidene)-amino]hydantoin sodium, an inhibitor of Ca2+ release from intracellular stores) on the protective efficacy of antiepileptic drugs against maximal electroshock-induced seizures." | 3.69 | Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. ( Borowicz, KK; Czuczwar, SJ; Gasior, M; Kleinrok, Z, 1997) |
| "We examined the anticonvulsant effects of BW1003C87 (5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine ethane sulphonic acid), which is structurally related to the new antiepileptic drug, lamotrigine, and compared its effects to those of the conventional antiepileptic drugs, phenytoin and carbamazopine, using the rat amygdala-kindling model of epilepsy." | 3.69 | BW1003C87, phenytoin and carbamazepine elevate seizure threshold in the rat amygdala-kindling model of epilepsy. ( Morimoto, K; Sato, H; Sato, K; Sato, S; Yamada, N, 1997) |
| "Initial studies of the effect of chronic carbamazepine (CBZ) against cocaine-induced seizures indicated that there were genetic differences in both the time course for the development of the anticonvulsant effects of CBZ against cocaine-induced seizures and the persistence of these effects." | 3.68 | Genetic differences in the time course for the development and persistence of the anticonvulsant effects of carbamazepine against cocaine seizures. ( Frieman, M; Goldberg, SR; Marley, RJ; Shimosato, K, 1993) |
| "Immature rats are more susceptible to clonic seizures induced by aminooxyacetic acid (AOAA) than mature and senile rats." | 3.68 | Age dependency of the susceptibility of rats to aminooxyacetic acid seizures. ( Cavalheiro, EA; Dziki, M; Kleinrok, Z; Parada, J; Turski, W, 1992) |
| "The ability of [(+-)-5-aminocarbonyl-10,11-dihydro-5H-di-benzo [a,d]cyclohepten-5,10-imine (ADCI) and its structural analogs dizocilipine (MK-801) and carbamazepine to block ethanol withdrawal seizures was tested in mice made physically dependent upon ethanol." | 3.68 | Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizur ( Grant, KA; Rogawski, MA; Snell, LD; Tabakoff, B; Thurkauf, A, 1992) |
| "The first case describes a 15-year-old boy who received valproic acid and carbamazepine for partial seizures." | 3.68 | Loss of seizure control associated with generic substitution of carbamazepine. ( Arazi, R; Hale, BC; Pickering, PR; Welty, TE, 1992) |
| "The effects of chronic carbamazepine (CBZ) on the development and expression of cocaine-kindled seizures and seizures produced by an acute injection of cocaine were evaluated in BALB/cByJ, C57Bl/6J and SJL/J mice." | 3.68 | Pharmacogenetic assessment of the effects of carbamazepine on cocaine-kindled and cocaine-induced seizures. ( Goldberg, SR; Marley, RJ, 1992) |
| "Rats were tested for anticonvulsant responsivity to agents active at central and peripheral-type benzodiazepine receptors before and after they were made tolerant to the anticonvulsant effects of carbamazepine on amygdala-kindled seizures." | 3.68 | Contingent tolerance to carbamazepine: a peripheral-type benzodiazepine mechanism. ( Post, RM; Weiss, SR, 1991) |
| "This study evaluated a possible mechanism by which glycine potentiates the activity of anticonvulsant drugs against maximal electroshock seizures in rats." | 3.68 | Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by D-serine and antagonized by 7-chlorokynurenic acid. ( Peterson, SL, 1991) |
| "Diabetes Mellitus was observed in a patient given carbamazepine." | 3.68 | Carbamazepine-induced Diabetes mellitus. ( Obembe, A, 1991) |
| " Seizures were uninfluenced by treatment with carbamazepine." | 3.68 | Myoclonic epilepsy--pitfalls in diagnosis and management. ( Brodie, MJ; Larkin, JG; McGinn, G; McKee, PJ, 1991) |
| "This study evaluated the potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats." | 3.68 | Potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats. ( Adams, HR; Frye, GD; Peterson, SL; Trzeciakowski, JP, 1990) |
| "To determine the rate and factors that affect carbamazepine absorption, six patients being treated in the pediatric intensive care unit for frequent seizures received loading doses (7." | 3.68 | Rapid loading of critically ill patients with carbamazepine suspension. ( Greenwood, RS; Lawless, ST; Miles, MV; Tennison, MB; Zaritsky, AL, 1990) |
| "The effects of chronic carbamazepine on cocaine-kindled seizures and behavioral sensitization were examined in this study." | 3.68 | Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine-induced hyperactivity. ( Costello, M; Nutt, DJ; Post, RM; Tandeciarz, S; Weiss, SR, 1990) |
| " The compounds were screened in mice for their ability to antagonize maximal electroshock- and bicuculline-induced seizures; neurotoxicity was evaluated in the rotorod test." | 3.67 | Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy. ( Biziere, K; Brochard, J; Brodin, R; Chambon, JP; Hallot, A; Merlier, J, 1986) |
| "We evaluated the therapeutic efficacy and toxicity of high-dose monotherapy, using carbamazepine or phenytoin, in patients with previously uncontrolled seizures." | 3.67 | High-dose monotherapy in treatment of intractable seizures. ( Dinner, DS; Lesser, RP; Lüders, H; Pippenger, CE, 1984) |
| "Fourteen animals with stable generalized kindled seizures received three doses of carbamazepine and its epoxide (12." | 3.67 | Effects of carbamazepine and its epoxide metabolite on amygdala-kindled seizures in rats. ( Albright, PS; Bruni, J, 1984) |
| "Carbamazepine is a commonly used anticonvulsant agent, particularly in the management of partial seizures." | 3.67 | Leucopenia as an adverse reaction to carbamazepine therapy. ( Beran, RG; Rush, JA, 1984) |
| "Four adult men with resistant partial seizures underwent an intensive open-label protocol designed to evaluate long-term add-on lamotrigine (LTG) therapy." | 3.67 | Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ( Ashworth, M; Keally, M; Kupferberg, H; Mikati, MA; Osborne-Shafer, P; Schachter, SC; Schomer, DL; Seaman, CA; Sheridan, PH; Valakas, A, 1989) |
| "The anticonvulsive action of diazepam, carbamazepine, sodium valproate and their combinations with pyridoxal-5-phosphate, nicotinamide, and alpha-tocopherol were investigated in acute experiments on mice with corazole-induced seizures." | 3.67 | [Effect of diazepam, carbamazepine, sodium valproate and their combinations with vitamin preparations on epileptic activity]. ( Kryzhanovskiĭ, GN; Shandra, AA, 1985) |
| "Glutamic acid diethyl ester (GDEE) is a glutamate antagonist which acts preferentially at the quisqualate-sensitive receptor and has been shown to be an effective anticonvulsant in alcohol withdrawal and homocysteine-induced seizures but ineffective in other seizure models." | 3.67 | Inhibition of quisqualate-induced seizures by glutamic acid diethyl ester and anti-epileptic drugs. ( Freed, WJ; Schwarz, SS, 1986) |
| "The effect of carbamazepine and its -10,11-epoxide on the development of amygdala-kindled seizures and on completed kindled seizures in the rat was evaluated." | 3.67 | Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development. ( Post, RM; Weiss, SR, 1987) |
| "We studied 15 children with complex partial seizures in whom one or more seizure type was exacerbated during treatment with carbamazepine." | 3.67 | Exacerbation of seizures in children by carbamazepine. ( Hosey, LC; Snead, OC, 1985) |
| " In this model, tonic-clonic seizures are easily elicited by handling and the effects of administration of carbamazepine (CBZ), phenytoin (DPH), phenobarbital (PB), diazepam, valproic acid (VPA) and ethosuximide were quantitatively evaluated." | 3.67 | Seizure control following administration of anticonvulsant drugs in the quaking mouse. ( Abbott, LC; Bennett, GD; Finnell, RH; Taylor, SM, 1985) |
| "A 37-year-old female developed erythema multiforme 17 days after beginning carbamazepine for complex partial seizures." | 3.67 | Drug-induced erythema multiforme: a possible immunologic pathogenesis. ( Delafuente, JC, 1985) |
| "This study investigates the ability of adenosine antagonists to reverse the anticonvulsant effects of carbamazepine on amygdala-kindled seizures in order to elucidate the possible physiological relevance of the potent effects of carbamazepine on adenosine receptors." | 3.67 | Adenosine antagonists. Lack of effect on the inhibition of kindled seizures in rats by carbamazepine. ( Marangos, PJ; Patel, J; Post, RM; Weiss, SR, 1985) |
| "Carbamazepine and valproate each afforded protection against seizures induced by electroshock or by inhalation of hexafluorodiethyl ether (HFDE)." | 3.66 | Interactions between folates and carbamazepine or valproate in the rat. ( Carl, GF; Smith, DB, 1982) |
| "An apparent case of carbamazepine-induced leukocytosis in a 26-year-old woman is presented." | 3.66 | Carbamazepine-induced leukocytosis. ( Murphy, JE; Springer, PK; Stewart, RB, 1980) |
| "Carbamazepine is an anticonvulsant most effective in treating complex partial and generalized tonic-clonic seizures." | 3.66 | Dystonia associated with carbamazepine administration: experience in brain-damaged children. ( Crosley, CJ; Swender, PT, 1979) |
| "Effects of carbamazepine on alcohol withdrawal seizures and symptoms were studied in rats." | 3.66 | Carbamazepine: prevention of alcohol withdrawal seizures. ( Chu, NS, 1979) |
| "Serum levels and seizure control were investigated in a prospective study when carbamazepine was given as a single drug to 32 patients with a variety of seizures." | 3.66 | Carbamazepine as a single drug in the treatment of epilepsy. A prospective study of serum levels and seizure control. ( Callaghan, N; Duggan, B; Feely, M; O'Callaghan, M, 1978) |
| "Senegalese baboons (Papio papio), with a natural syndrome of photosensitive epilepsy, consistently show generalized myoclonic jerks if stimulated stroboscopically at hourly intervals, two to eight hours after the intravenous administration of allylglycine, 200 mg/kg." | 3.65 | A primate model for testing anticonvulsant drugs. ( Horton, RW; Meldrum, BS; Toseland, PA, 1975) |
| "A new syndrome, paradoxical intoxication, has been defined in which high levels of hydantoins, and in one instance carbamazepine, produced an increase in seizures with little or no evidence of intoxication; a decrease in these levels produced an improvement in seizure control." | 3.65 | Paradoxical intoxication--a complication of anticonvulsant administration. ( Ojemann, LM; Troupin, AS, 1975) |
| "Lacosamide was efficacious and generally well tolerated as monotherapy in patients with TLE with efficacy outcomes comparable with CBZ-CR, and fewer patients on LCM reported any TEAEs, drug-related TEAEs, or discontinued due to TEAEs." | 3.30 | Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial. ( Chellun, D; Dimova, S; Elmoufti, S; Floricel, F; Kubota, Y; O'Brien, TJ; Terada, K, 2023) |
| "Epilepsy is a chronic disease of the central nervous system characterized by recurrent epileptic seizures." | 3.01 | Second Generation of Antiepileptic Drugs and Oxidative Stress. ( Czuczwar, SJ; Kamieniak, M; Kośmider, K; Miziak, B, 2023) |
| "Relapse of seizures can have major adverse psychosocial consequences and also may carry a risk of morbidity and mortality." | 3.01 | Should antiseizure medications be withdrawn after an extended period of seizure freedom in individuals with adult-onset epilepsy? ( Asadi-Pooya, AA; Mesraoua, B; Perucca, E; Tomson, T, 2023) |
| "Seizures are among the most common clinical signs in people with glioblastoma." | 3.01 | The complexities underlying epilepsy in people with glioblastoma. ( Cole, AJ; Dietrich, J; Sokolov, E, 2023) |
| " Outcomes included incident seizures, delirium tremens, AW severity scores, adverse events, dropouts, dropouts from adverse events, length of hospital stay, use of additional medications, total benzodiazepine requirements, and death." | 2.82 | Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. ( Bach, P; Bahji, A; Crockford, D; Danilewitz, M; Devoe, DJ; El-Guebaly, N; Saitz, R, 2022) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "Epilepsy is one of the most common neurological disorders worldwide." | 2.82 | Characteristics of people with epilepsy in three Eastern African countries - a pooled analysis. ( Amos, A; Escheu, G; Harrison, W; Hauke, P; Kaducu, J; Keller, L; Matuja, W; Ngowi, BJ; Ovuga, E; Pfausler, B; Richter, V; Schmidt, V; Schmutzhard, E; Stelzle, D; Welte, TM; Winkler, AS, 2022) |
| "Seizure freedom (SF) was defined as no seizure recurrence during the 40-week maintenance period of medication." | 2.80 | The effect of recurrent seizures on cognitive, behavioral, and quality-of-life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. ( Heo, K; Kim, MJ; Kim, OJ; Kim, SO; Lee, BI; Lee, HW; Lee, SA; Shin, DJ; Song, HK, 2015) |
| "Patients, aged 8-58 years, with partial epilepsy who did not become seizure free on CBZ were randomized to either VPA add-on or PRM add-on." | 2.74 | Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy. ( Deckers, CL; Liu, YX; Sun, MZ; Wang, W, 2009) |
| "57] or adverse effects (RR 4." | 2.72 | Efficacy and Safety of Phenobarbitone as First-Line Treatment for Neonatal Seizure: A Systematic Review and Meta-Analysis. ( Kumar, J; Meena, J; Saini, L; Yadav, J, 2021) |
| "First seizures are always challenging for physicians." | 2.72 | Update on first unprovoked seizure in children and adults: A narrative review. ( Carrizosa-Moog, J; Jiménez-Villegas, MJ; Lozano-García, L, 2021) |
| " Patients were converted during an carbamazepine, phenytoin, or valproate) to lamotrigine via a protocol-specified dosing algorithm or to conventional therapy via standard dosing guidelines." | 2.71 | Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. ( Hammer, AE; Kaminow, L; Schimschock, JR; Vuong, A, 2003) |
| "had a 50% or greater decrease in seizure frequency compared with baseline (P<0." | 2.71 | Tiagabine as add-on therapy may be more effective with valproic acid--open label, multicentre study of patients with focal epilepsy. ( Jedrzejczak, J, 2005) |
| "The duration and frequency of seizure activities and electrographic seizure onset of 41 patients totally withdrawing from CBZ monotherapy (n = 20), LTG monotherapy (n = 10) and CBZ + LTG combined therapy (n = 11) were intensively studied by therapeutic intensive seizure analysis (TISA) method." | 2.71 | Changes of seizures activity during rapid withdrawal of lamotrigine. ( Koebnick, C; Pauli, E; Stefan, H; Tilz, C; Wang, B; Wang-Tilz, Y, 2005) |
| "Seventy three patients presenting with seizures and showing SSECTL on cranial CT scans (plain and contrast) were randomized into group A (6 months therapy) and group B (2 years therapy)." | 2.70 | Acute symptomatic seizures due to single CT lesions: how long to treat with antiepileptic drugs? ( Arora, A; Lal, V; Prabhakar, S; Sawhney, IM; Thussu, A, 2002) |
| "The most important factor determining seizure recurrence was continued therapy, which was the case for barbiturates, phenytoin and valproate." | 2.69 | Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. ( Chadwick, D, 1999) |
| " The pharmacokinetic assessment was repeated on day 18." | 2.69 | Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. ( Boellner, SW; Cao, GX; Cato, A; Guenther, HJ; Gustavson, LE; Qian, JX; Sommerville, KW, 1998) |
| "Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients)." | 2.69 | Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. ( Cardinali, C; Zamponi, N, 1999) |
| "Carbamazepine has been used in adults and children for over 30 years." | 2.68 | Treatment of neonatal seizures with carbamazepine. ( al Hifzi, I; Khan, M; Majeed-Saidan, M; Singh, B; Singh, P, 1996) |
| "Pharmacokinetic parameters, seizure control, effects on the behavioral state, and tolerability were considered." | 2.67 | A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients. ( Doorschot, CH; Loonen, AJ; Nijdam, JR; van Bavel, LP, 1992) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period." | 2.66 | Antiepileptic drugs as prophylaxis for postcraniotomy seizures. ( Dundar, Y; Greenhalgh, J; Marson, AG; Nevitt, SJ; Weston, J, 2020) |
| " Brivaracetam does not interact with most metabolizing enzymes and drug transporters, and therefore does not interfere with drugs that use these metabolic routes." | 2.66 | A review of the drug-drug interactions of the antiepileptic drug brivaracetam. ( Chanteux, H; Gidal, B; Laloyaux, C; Moseley, BD; Nicolas, JM; Stockis, A, 2020) |
| "Side effects and febrile recurrences may limit the value of CBZ for some children, although CBZ appears to reduce significantly recurrences after a 1st afebrile seizure." | 2.66 | A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood. ( Camfield, C; Camfield, P; Dooley, J; Garner, B; Smith, E, 1989) |
| " Two patients with mild symptoms were rechallenged with a lower verapamil dosage (120 mg twice a day) and showed similar rises in CBZ concentration and recurrent neurotoxic symptoms." | 2.66 | Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. ( Brodie, MJ; Macphee, GJ; McInnes, GT; Thompson, GG, 1986) |
| "Carbamazepine was compared with phenytoin in a double-blind study." | 2.65 | A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. ( Berger, JR; Bruni, J; Ramsay, RE; Wilder, BJ, 1983) |
| "It is also effective in generalized epilepsy and in several other conditions of the CNS." | 2.61 | An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. ( Ljung, H; Reimers, A, 2019) |
| "Carbamazepine (CBZ) was found to be effective in most cases." | 2.61 | Epilepsy in patients with EAST syndrome caused by mutation in the KCNJ10. ( Albaradie, R; Alhazmi, R; Alkhaldi, H; Chaudhary, M; Housawi, Y; Mir, A, 2019) |
| "Very little has been written on seizure management in palliative care (PC)." | 2.61 | Guidelines for seizure management in palliative care: Proposal for an updated clinical practice model based on a systematic literature review. ( Arce Arce, S; Benito-León, J; García-Albea Ristol, E; Ibáñez Estéllez, F; León Ruiz, M; Pérez Nieves, MT; Rodríguez Sarasa, ML; Sanjuán Rodríguez, L, 2019) |
| "A generalized tonic-clonic seizure (GTCS) is the most severe form of common epileptic seizure and carries the greatest risk of harm." | 2.58 | Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection. ( Bermejo, PE; Gibbs, AA; Huberfeld, G; Kälviäinen, R; Shorvon, SD, 2018) |
| "Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within the first month of cranial surgery." | 2.58 | Antiepileptic drugs as prophylaxis for postcraniotomy seizures. ( Dundar, Y; Greenhalgh, J; Marson, AG; Nevitt, SJ; Weston, J, 2018) |
| " The purpose of this review is to provide an up-to-date evidence summary of the incidence and outcomes of seizures following an SAH as well as the use of different AEDs post-SAH in order to evaluate the need for seizure prophylaxis, the choice of AEDs, and their dosing considerations in SAH patients." | 2.55 | Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review. ( Buxton, J; Mahmoud, SH, 2017) |
| "The use of AEDs for purposes other than seizure prophylaxis and their selection based on non-PK properties present a potential paradigm shift in the field of neuro-oncology." | 2.53 | Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. ( Gefroh-Grimes, HA; Gidal, BE, 2016) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure may vary from 3% to 92% over a five-year period." | 2.52 | Antiepileptic drugs as prophylaxis for post-craniotomy seizures. ( Greenhalgh, J; Marson, AG; Weston, J, 2015) |
| "Epilepsy is the commonest clinical presentation, though it may also present with headache, symptoms of raised intracranial tension, hydrocephalus and ocular symptoms depending upon the localisation of the parasitic cysts." | 2.52 | Antiepileptic drugs for seizure control in people with neurocysticercosis. ( Mathew, A; Sharma, M; Singh, T, 2015) |
| "The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be 15% to 20%; however, the risk of experiencing a seizure may vary from 3% to 92% over a five-year period." | 2.49 | Antiepileptic drugs as prophylaxis for post-craniotomy seizures. ( Greenhalgh, J; Marson, AG; Pulman, J, 2013) |
| "Seizures and intracranial hemorrhage are possible medical diseases that any obstetrician may encounter." | 2.49 | Seizures and intracranial hemorrhage. ( Alexander, JM; Wilson, KL, 2013) |
| "A common first choice for BCECTS is CBZ in the USA and Japan, and VPA in the EU." | 2.47 | Treatment of benign focal epilepsies in children: when and how should be treated? ( Oguni, H, 2011) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 2.47 | Spotlight on levetiracetam in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Studies on mechanisms of seizure generation and propagation have identified new potential targets for AEDs." | 2.45 | New antiepileptic drugs: molecular targets. ( Mula, M, 2009) |
| "Both seizures and antiepileptic drugs may induce disturbances in hormonal system." | 2.44 | [Endocrine effects of antiepileptic drugs]. ( Budziszewska, B; Lasoń, W; Leśkiewicz, M, 2008) |
| "The seizures were controlled without any side effects with sodium valproate 200 mg three times a day and gabapentin 300 mg twice a day." | 2.42 | Phenytoin and carbamazepine cross reactivity: report of a case and review of literature. ( Kalita, J; Misra, UK; Rathore, C, 2003) |
| "The pathophysiology of pilomotor seizures is discussed and the literature on the subject reviewed." | 2.41 | Status-like recurrent pilomotor seizures: case report and review of the literature. ( Chédru, F; Oubary, P; Roze, E, 2000) |
| "Minimal requirements: seizure-prevention outcome given as fraction of cases; AED or control assigned by random or quasi-random mechanism." | 2.41 | Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. ( Temkin, NR, 2001) |
| "Opinions vary as to which 'neonatal seizures' should be treated and which should not be." | 2.40 | [Neonatal seizures: the beginning and interruption of the treatment]. ( Caballar-Gonzaga, FJ; Dierkes, T; Koenigsberger, MR, 1997) |
| " The first appears to involve a nonspecific manifestation of drug intoxication; seizure-worsening in this context is usually reversible by dosage reduction or elimination of unnecessary polypharmacy." | 2.40 | Antiepileptic drugs as a cause of worsening seizures. ( Avanzini, G; Dulac, O; Gram, L; Perucca, E, 1998) |
| "Carbamazepine (CBZ) has become a commonly used antiepileptic agent in the pediatric population." | 2.38 | Carbamazepine dosing for pediatric seizure disorders: the highs and lows. ( Gilman, JT, 1991) |
| " In order to use these effectively, the critical care nurse must be aware of the indications and controversies surrounding their use, the patho-physiologic conditions that impact on the disposition, and appropriate dosing and monitoring of these agents in the critical care setting." | 2.38 | Anticonvulsants: pharmacotherapeutic issues in the critically ill patient. ( Dupuis, RE; Miranda-Massari, J, 1991) |
| "Neocortical focal seizures are characterized by motor jerks in one limb (Jacksonian type), head turning (adversive attack), or localized sensory manifestations, and limbic or psychomotor attacks by brief impairment of consciousness and often by motor automatisms." | 2.37 | [Therapy of brain-related minor seizures]. ( Hess, CW, 1988) |
| "Praziquantel was not used." | 2.37 | Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. ( Crawford, TO; Mitchell, WG, 1988) |
| " To support the use of cenobamate monotherapy, this pharmacokinetic (PK)-based simulation analysis evaluated the predicted PK exposure of cenobamate when used as monotherapy versus adjunctive therapy." | 1.91 | Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy. ( Ferrari, L; Kamin, M; Rosenfeld, WE; Vashi, V, 2023) |
| "Seizure relapses are the leading cause of admission to emergency rooms (ER) in people with epilepsy." | 1.72 | Factors involved in time reduction between seizure relapses in patients with epilepsy attending emergency rooms in Medellín, Colombia. ( Bernal Cobo, R; Giraldo Castrillón, YM; Giraldo Tapias, LM; Gómez Escobar, T; Rojas-Gualdrón, DF; Rueda Cárdenas, LF; Vásquez Trespalacios, EM; Zapata Berruecos, JF, 2022) |
| "New-onset seizures affect up to 10% of people over their lifetime, however, their health economic impact has not been well-studied." | 1.72 | Prospective multisite cohort study of patient-reported outcomes in adults with new-onset seizures. ( Ademi, Z; Au Yong, HM; Carney, PW; Carrillo de Albornoz, S; Chen, Z; D'Souza, W; Foster, E; Kwan, P; Liew, D; Nicolo, JP; O'Brien, TJ; Pellinen, J; Tailby, C; Vaughan, DN, 2022) |
| "We hypothesized that poor seizure control is associated with new-onset MHC diagnoses and/or new prescription drugs for MHCs." | 1.72 | Incidence of mental health conditions by seizure control among adults with epilepsy in the United States. ( Ferrari, L; Hauser, WA; Schabert, VF; Stern, S; Wade, CT; Willke, RJ, 2022) |
| "Data on epilepsy syndrome, duration, seizure types, concomitant and previous antiseizure medication (ASM) use, BRV dosing, efficacy, and side effects were recorded." | 1.72 | Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center. ( Green, SF; Hare, N; Kassam, M; Koepp, MJ; Rajakulendran, S; Rugg-Gunn, F; Sander, JW, 2022) |
| " VPA showed a relatively short half-life in both mice and rats, which correlated with a sharp decline in efficacy." | 1.72 | Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. ( Johnson, K; Mensah, JA; Metcalf, CS; Reilly, CA; Rower, JE; Wilcox, KS, 2022) |
| "When selecting an antiseizure medication, consideration should be given to the individual patient's risks of adverse consequences on other organ systems." | 1.72 | Long-Term Effects of Antiseizure Medications. ( LoPinto-Khoury, C, 2022) |
| "Since arrhythmia often accompanies seizures, patients suffering from epilepsy are frequently co-treated with antiepileptic and antiarrhythmic drugs." | 1.72 | Ranolazine Interacts Antagonistically with Some Classical Antiepileptic Drugs-An Isobolographic Analysis. ( Banach, M; Borowicz-Reutt, K, 2022) |
| "Protective (antiseizure) effects of 4-butyl-5-[(4-chloro-2-methylphenoxy)-methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione (TPL-16) and acute neurotoxic effects were determined in the tonic-clonic seizure model and rotarod test in mice." | 1.62 | Anticonvulsant Effectiveness and Neurotoxicity Profile of 4-butyl-5-[(4-chloro-2-methylphenoxy)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione (TPL-16) in Mice. ( Drabik, M; Florek-Łuszczki, M; Głuszak, M; Jankiewicz, M; Kozińska, J; Plech, T; Plewa, Z; Wróblewska-Łuczka, P; Łuszczki, JJ, 2021) |
| "Causative drugs for new-onset seizures were further investigated." | 1.62 | Antihistamines as a common cause of new-onset seizures: a single-center observational study. ( Kim, H; Kim, JB; Kim, SH, 2021) |
| "Disulfiram has been widely used for over six decades in the treatment of alcohol dependence, as an aversive therapeutic agent." | 1.62 | Disulfiram-induced epileptic seizures. ( Mendes, MA; Nogueira, V; Pereira, I; Teixeira, J, 2021) |
| "The antiseizure drug, carbamazepine (CBZ), and the antiabsence drug, ethosuximide (ETX), were administered separately to determine if they selectively suppressed unilateral- versus bilateral-onset SWDs, respectively." | 1.62 | Sensitivity of unilateral- versus bilateral-onset spike-wave discharges to ethosuximide and carbamazepine in the fluid percussion injury rat model of traumatic brain injury. ( Barth, DS; Dudek, FE; Poulsen, DJ; Smith, ZZ; Tatum, S; Taylor, JA, 2021) |
| " Similar dose-related responses were seen following the week-long dosing protocol for carbamazepine, phenobarbital, and phenytoin, and these responses were associated with drug levels that were in the human therapeutic range." | 1.62 | Chronic limbic epilepsy models for therapy discovery: Protocols to improve efficiency. ( Bertram, EH; Edelbroek, P, 2021) |
| "The effect of VAL vs CMZP/OX on seizure threshold was examined using multivariable regression with adjustment for confounders." | 1.62 | Carbamazepine/oxcarbazepine and valproate have different effects on the electroconvulsive therapy seizure threshold. ( Andrade, C; Ibrahim, FA; Pahuja, E; Thirthalli, J, 2021) |
| "Carbamazepine was ineffective, and seizures were exacerbated with levetiracetam (LEV)." | 1.56 | Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. ( Goji, A; Kagami, S; Mori, T; Tayama, T; Toda, Y, 2020) |
| "This makes assessing change in seizure rates over time difficult." | 1.56 | Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs. ( Bonnett, LJ; Hutton, JL; Marson, AG, 2020) |
| "Carbamazepine was started with seizure control." | 1.56 | Seizures in self-limited epilepsy with centrotemporal spikes: video-EEG documentation. ( Caboclo, LO; Casella, EB; Ferrari-Marinho, T; Hamad, APA; Yacubian, EMT, 2020) |
| "Levetiracetam has replaced sodium valproate as the most frequently prescribed ASM in pediatric patients." | 1.56 | Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018. ( Dai, H; Feng, J; Yu, L; Yu, Z, 2020) |
| "Eight years after the index seizure, 31 % of the children were on AEDs, and this was more common among children with any of the comorbidities studied (OR; 4." | 1.56 | Childhood-onset seizures: A long-term cohort study of use of antiepileptic drugs, and drugs for neuropsychiatric conditions. ( Åmark, P; Åndell, E; Carlsson, S; Pihlström, N; Tedroff, K; Tomson, T, 2020) |
| "Males have a younger age at onset." | 1.51 | Seizures in Down Syndrome: An Update. ( Fatema, K; Rahman, MM, 2019) |
| "Epilepsy was present in 29." | 1.51 | [Epilepsy in children with congenital hemiparesis secondary to perinatal ictus]. ( Alonso, X; Campistol, J; Escofet, C; Fons, C; Macaya, A; Revilla Orías, MD, 2019) |
| "PKC and seizures were readily controlled with small dose of carbamazepine." | 1.51 | [An adult female with proline-rich transmembrane protein 2 related paroxysmal disorders manifesting paroxysmal kinesigenic choreoathetosis and epileptic seizures]. ( Awaya, T; Ikeda, A; Inoue, T; Kato, T; Kuzuya, A; Shimotake, A; Taira, T; Takahashi, R; Tanabe, Y, 2019) |
| "Almost all seizure durations were >20 seconds." | 1.51 | Effect of carbamazepine on spontaneous recurrent seizures recorded from the dentate gyrus in rats with kainate-induced epilepsy. ( Dudek, FE; Grabenstatter, HL, 2019) |
| "Electrically-induced tonic-clonic seizures were experimentally evoked in adult male albino Swiss mice." | 1.51 | New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. ( Gut-Lepiech, A; Karwan, S; Kondrat-Wróbel, MW; Marzeda, P; Plech, T; Wróblewska-Łuczka, P; Łuszczki, JJ, 2019) |
| "Add-on ESL improved seizure control and was overall well-tolerated in adult patients with partial-onset epilepsy." | 1.48 | Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy. ( Cagnetti, C; Foschi, N; Lattanzi, S; Lorusso, A; Provinciali, L; Silvestrini, M, 2018) |
| "The severe sole effects of seizures on the cortical part of bone were reported in our previous study." | 1.48 | Side-Effects of Convulsive Seizures and Anti-Seizure Therapy on Bone in a Rat Model of Epilepsy. ( Boskey, AL; Evis, Z; Garip Ustaoglu, S; Ilbay, G; Severcan, F, 2018) |
| "Seizures are present in over 90% of infants and children with Wolf-Hirschhorn syndrome (WHS)." | 1.48 | A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome. ( Battaglia, A; Carey, JC; Ho, KS; Lortz, A; Markham, LM; Newcomb, T; Olson, LM; Sheng, X; Twede, H; Wassman, ER; Weng, C, 2018) |
| "Carbamazepine was the most chosen antiepileptic drug for secondary prophylaxis, followed by valproate acid, and levetiracetam." | 1.48 | [A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan]. ( Abe, S; Fukuma, K; Higashida, K; Ihara, M; Nagatsuka, K; Okuno, Y; Tanaka, T; Tomari, S; Toyoda, K; Yamagami, H, 2018) |
| "Carbamazepine was the most commonly used first AED, with a retention rate of 52%." | 1.48 | Treatment of epilepsy in multiple sclerosis. ( Burman, J; Dagiasi, I; Kumlien, E; Vall, V; Zelano, J, 2018) |
| "Carbamazepine is known to produce the side effect of euphoria." | 1.48 | A Clinical Study of Toxication Caused by Carbamazepine Abuse in Adolescents. ( Chen, YL; Li, JJ; Liu, CF; Wang, LJ; Xu, W; Zhao, Y, 2018) |
| "Carbamazepine is a valuable pharmacological agent prescribed in treatment of epilepsy and trigeminal neuralgia." | 1.48 | Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. ( Abdel-Bakky, MS; Ali, HM; Badran, MM; Elmowafy, M; Ibrahim, HM; Shalaby, K, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "LGS type of seizures is epilepsy which is due to abnormal vibrations occurring in seizures." | 1.46 | Influence of perfluorocarbons on Carbamazepine and Benzodiazepine for a neuro-lung protective strategy. ( Natchimuthu, V; Ramalingam, M; Ravi, S; Thomas, S, 2017) |
| "Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment." | 1.46 | Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients. ( Brozmanova, H; Grundmann, M; Kacirova, I; Koristkova, B, 2017) |
| "Recurrent and prolonged seizures are harmful for the developing brain, emphasizing the importance of early seizure recognition and effective therapy." | 1.46 | A Distinctive Ictal Amplitude-Integrated Electroencephalography Pattern in Newborns with Neonatal Epilepsy Associated with KCNQ2 Mutations. ( Brilstra, E; Cilio, MR; de Vries, LS; Mendes Ribeiro, J; Striano, P; Vilan, A; Weckhuysen, S; Weeke, LC, 2017) |
| "Catamenial epilepsy is defined as an increase in the frequency of seizures during a particular phase of the menstrual cycle." | 1.46 | Catamenial Epilepsy: The Menstrual Cycle as a Clue to Predict Future Refractory Seizures. ( Khishfe, BF, 2017) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "Carbamazepine was significantly more efficacious than diazepam suppositories in the aFc group (odds ratio = 49." | 1.46 | Clinical Epidemiology and Treatment of Febrile and Afebrile Convulsions With Mild Gastroenteritis: A Multicenter Study. ( Higuchi, Y; Horibe, K; Ichimi, R; Iguchi, K; Kamimaki, I; Koga, H; Komiyama, O; Kubo, T; Mitsuhashi, T; Miyagawa, S; Nakamura, N; Saito, A; Shukuya, A; Takayanagi, T; Tanaka, S; Uchida, Y; Watanabe, K; Yamamoto, S; Yamashita, H; Yokota, I, 2017) |
| "Adequate control of seizures remains an unmet need in epilepsy." | 1.43 | Anticonvulsant activity, crystal structures, and preliminary safety evaluation of N-trans-cinnamoyl derivatives of selected (un)modified aminoalkanols. ( Gunia-Krzyżak, A; Koczurkiewicz, P; Marona, H; Nitek, W; Pękala, E; Szkaradek, N; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E, 2016) |
| "MET)-induced seizures whereas none of them showed neurotoxicity." | 1.43 | New (arylalkyl)azole derivatives showing anticonvulsant effects could have VGSC and/or GABA ( Çalış, Ü; Dalkara, S; Karakurt, A; Kaynak, FB; Sari, S; Uslu, H, 2016) |
| "Antiepileptic prophylaxis reduces early seizures, but their use beyond 1 week does not prevent the development of post-traumatic epilepsy." | 1.43 | Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort. ( Craner, M; Cranley, MR; McGilloway, E, 2016) |
| "Bromide was used in 40." | 1.43 | Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. ( Higurashi, N; Hirose, S; Ishii, A; Kaneko, S; Kurahashi, H; Shi, XY; Tomonoh, Y; Wang, WZ, 2016) |
| "Early Toxic Epidermal Necrolysis (TEN) syndrome was diagnosed by the Burns and Dermatology teams and the culprit drug was discontinued." | 1.43 | Early toxic epidermal necrolysis syndrome post-intra-cranial tumor resection. ( Petrilli, RM; Ramachandren, TK, 2016) |
| " Type I isobolographic analysis for parallel dose-response relationship curves (DRRCs) was used to analyze the 3-drug combination." | 1.43 | Isobolographic Analysis of Interaction for Three-Drug Combination of Carbamazepine, Phenobarbital and Topiramate in the Mouse Maximal Electroshock-Induced Seizure Model. ( Luszczki, JJ, 2016) |
| "Electroconvulsions were evoked in Albino Swiss mice by a current delivered via ear-clip electrodes." | 1.43 | The effects of cimetidine chronic treatment on conventional antiepileptic drugs in mice. ( Barczyński, B; Czuczwar, SJ; Świąder, K; Świąder, MJ; Tomaszewski, M, 2016) |
| "The incidences of convulsion, coma, and respiratory failure were 14 (35%), 10 (25%), and 3 (7." | 1.43 | Severe Carbamazepine Intoxication in Children: Analysis of a 40-Case Series. ( Acikgoz, M; Alacam, A; Alacam, F; Guzel, A; Paksu, MS, 2016) |
| "Levetiracetam was very well tolerated." | 1.42 | Epilepsy in patients with gliomas: incidence and control of seizures. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T, 2015) |
| "In a first step, we examined anti-seizure effects of 6 AEDs on spontaneous recurrent focal electrographic seizures and secondarily generalized convulsive seizures in epileptic mice, showing that the focal nonconvulsive seizures were resistant to carbamazepine and phenytoin, whereas valproate and levetiracetam exerted moderate and phenobarbital and diazepam marked anti-seizure effects." | 1.42 | Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice. ( Bankstahl, M; Klein, S; Löscher, W, 2015) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (25 mA, 500 V, 50 Hz, 0." | 1.42 | Effect of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of classical antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Florek-Luszczki, M; Glensk, M; Glowniak, K; Luszczki, JJ; Pyrka, D; Skalicka-Wozniak, K; Zagaja, M, 2015) |
| "In newly diagnosed patients with Dravet syndrome sodium channel blockers are usually avoided." | 1.42 | Carbamazepine and oxcarbazepine in adult patients with Dravet syndrome: Friend or foe? ( de Louw, AJ; Kleine, BU; Schelhaas, HJ; Snoeijen-Schouwenaars, FM; Tan, IY; van Erp, G; van Mierlo, P; Veendrick, MJ, 2015) |
| "Adult patients with focal epilepsy, who were prescribed with carbamazepine (CBZ), valproate (VPA), lamotrigine (LTG), topiramate (TPM), or oxcarbazepine (OXC) as monotherapy, during the period from January 2004 to June 2012 registered in Wenzhou Epilepsy Follow Up Registry Database (WEFURD), were included in the study." | 1.42 | Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study. ( Bao, YX; Fan, TT; He, RQ; Xu, HQ; Zeng, QY; Zheng, RY; Zhu, P, 2015) |
| "Recurrent seizures requiring either emergency room (ER) visits or hospitalization were used to measure the efficacy of seizure control." | 1.42 | Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. ( Chan, L; Chi, NF; Chien, LN; Chiou, HY; Hu, CJ; Huang, YH; Kuan, YC, 2015) |
| "Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32mA, 6Hz, 3s stimulus duration) delivered via ocular electrodes; type II isobolographic analysis was used to characterize the consequent anticonvulsant interactions between the various drug combinations for fixed-ratios of 1:1, 1:2, 1:5 and 1:10." | 1.40 | Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis. ( Florek-Luszczki, M; Luszczki, JJ; Wlaz, A, 2014) |
| "She was seizure-free after the surgery." | 1.40 | Peri-ictal headache due to epileptiform activity in a disconnected hemisphere. ( Delalande, O; Dvorak, J; Jahodova, A; Komarek, V; Kršek, P; Kyncl, M; Tichy, M; Vydrova, R, 2014) |
| "These three cases confirm that gelastic epilepsy without hypothalamic hamartoma, both in cryptogenic or symptomatic patients (one child showed a dysplastic right parietotemporal lesion), usually has a more benign natural history, and carbamazepine seems to be the most efficacious therapy to obtain both immediate and long-term seizure control." | 1.40 | Gelastic epilepsy without hypothalamic hamartoma: three additional cases. ( Budetta, M; Carpentieri, ML; Parisi, P; Savasta, S; Spartà, MV; Trasimeni, G; Villa, MP; Zavras, N, 2014) |
| "Oral treatment of carbamazepine was started but her seizures were not controlled." | 1.40 | Serial EEG study in a girl with Landau-Kleffner syndrome associated with continuous spikes and waves during slow sleep. ( Arisaka, O; Imataka, G, 2014) |
| "He presented with headache, seizures, confusion, fever and left hemiparesis upon hospitalization in 2006 at Hospital São Marcos." | 1.40 | Cerebral aspergillosis in a patient with leprosy and diabetes: a case report. ( Bezerra, GF; da Silva, MA; Filho, WE; Nascimento, AC; Nascimento, Mdo D; Segundo, JB; Viana, GM; Vidal, FC, 2014) |
| "Partial epilepsy is the most common type of epilepsy in CdLS patients." | 1.39 | Epilepsy in patients with Cornelia de Lange syndrome: a clinical series. ( Agostinelli, S; Capovilla, G; Chiarelli, F; Coppola, G; Curatolo, P; Foiadelli, T; Grosso, S; Parisi, P; Prezioso, G; Romeo, A; Savasta, S; Spalice, A; Striano, P; Verrotti, A, 2013) |
| "We present a female with seizures one month after delivery who had borderline elevated liver enzymes prior to the initiation of OXC treatment." | 1.39 | Acute oxcarbazepine-induced hepatotoxicity in a patient susceptible to developing drug-induced liver injury. ( Bielen, A; Bielen, I; Marusić, M; Planjar-Prvan, M; Sruk, A, 2013) |
| "DRESS syndrome is an idiosyncratic reaction to drugs, which can occur in both adults and children." | 1.39 | Carbamazepine-induced DRESS syndrome in a child: rapid response to pulsed corticosteroids. ( Tan, B; Teng, P, 2013) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 1.39 | Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Florek-Luszczki, M; Karwan, S; Luszczki, JJ; Wlaz, A, 2013) |
| "Among those with Idiopathic Generalized Epilepsy (46%), generalized tonic clonic seizure was encountered in 74% and absence seizure was observed in 13%." | 1.39 | Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital. ( Chowdhury, AH; Chowdhury, RN; Ghose, SK; Habib, M; Haque, B; Hasan, AT; Hoque, A; Khan, SU; Mohammad, QD; Mondal, BA; Rahman, KM, 2013) |
| "Seizures were treated with sodium valproate (n = 11), phenobarbital (n = 3), diazepam (n = 2), lamotrigine (n = 1), and carbamazepine (n = 1)." | 1.39 | Prevalence of seizures in children infected with human immunodeficiency virus. ( Eley, B; Petersen, R; Samia, P; Walker, KG; Wilmshurst, JM, 2013) |
| "Studies of seizure outcome in patients undergoing serial antiepileptic drug trials have all been uncontrolled, with no account made for the spontaneous changes in disease state that could confound the elucidation of drug effects." | 1.39 | Seizure recurrence and remission after switching antiepileptic drugs. ( Mintzer, S; Nei, M; Skidmore, CT; Sperling, MR; Stuckert, E; Wang, SP; Zhan, T, 2013) |
| " Additionally, the effects of acute and chronic administration of both statins on the adverse effect potential of three antiepileptic drugs were assessed in the chimney test (motor performance) and passive avoidance task (long-term memory)." | 1.38 | The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model. ( Czuczwar, SJ; Luszczki, JJ; Stepien, KM; Tomaszewski, M, 2012) |
| "Phenytoin was used in 56 patients (22%) with the majority (n= 43) receiving intravenous phenytoin." | 1.38 | Seizure management at Auckland City Hospital Emergency Department between July and December 2009: time for a change? ( Bergin, P; Jones, P; Rosemergy, I; Walker, E, 2012) |
| "In reflex seizures induced by proprioceptive stimuli, the activated network may be identified as a single anatomo-functional circuit; the sensory-motor network." | 1.38 | Are proprioceptive-induced reflex seizures epileptically-enhanced stretch reflex manifestations? ( Arányi, Z; Erőss, L; Holló, A; Janszky, J; Kamondi, A; Orbay, P; Rásonyi, G; Sólyom, A; Szűcs, A, 2012) |
| "It also proved protection in focal seizures (electric kindling, rats, ip) and it raises seizure threshold." | 1.37 | Synthesis and anticonvulsant activity of trans- and cis-2-(2,6-dimethylphenoxy)-N-(2- or 4-hydroxycyclohexyl)acetamides and their amine analogs. ( Marona, H; Pękala, E; Szneler, E; Walczak, M; Waszkielewicz, AM, 2011) |
| "For unclassified epileptic seizures, no significant differences were found among the three AEDs." | 1.37 | Retrospective analysis of the effectiveness of first-line antiepileptic drugs for generalized onset and unclassified epileptic seizures in Chinese children. ( Ding, CH; Ding, YX; Fang, F; Ma, MS; Meng, LL; Wang, Y; Zou, LP, 2011) |
| " To conclude, long term administration of topiramate impairs cognitive functions during experimental epilepsy while lamotrigine and oxcarbazepine are safer." | 1.37 | Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. ( Agarwal, NB; Agarwal, NK; Mediratta, PK; Sharma, KK, 2011) |
| "Fourteen patients developed seizures during that period and 25 did not." | 1.37 | Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury. ( De Reuck, J, 2011) |
| "A woman diagnosed with juvenile myoclonic epilepsy for over 30 years presented with stereotyped episodes of abnormal sensations in both arms." | 1.37 | Fronto-polar epilepsy masquerading as juvenile myoclonic epilepsy. ( Keezer, MR; Nguyen, DK; Saint-Hilaire, JM, 2011) |
| "Ictal asystole is a presumably rare but potentially fatal complication of seizures, most often of temporal lobe origin." | 1.37 | New onset left frontal lobe seizure presenting with ictal asystole. ( Anyanwu, C; Eldadah, Z; Enkiri, SA; Ghavami, F; Morrissey, RL; Motamedi, GK, 2011) |
| "Hyperammonemia was detected in 8 patients treated with valproic acid." | 1.36 | Serum biotinidase activity in children treated with valproic acid and carbamazepine. ( Castiñeiras-Ramos, DE; Castro-Gago, M; Díaz-Mayo, I; Eirís-Puñal, J; Gómez-Lado, C, 2010) |
| "Lamotrigine treatment had no effect on oxidative stress parameters alone, while it significantly decreased oxidative stress in the pentylenetetrazole-kindled group as compared to the pentylenetetrazole-kindled carbamazepine-treated group." | 1.36 | Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats. ( Arora, T; Banerjee, BD; Garg, GR; Mediratta, PK; Mehta, AK; Sharma, AK; Sharma, KK, 2010) |
| "The aim of this study was to characterize the anticonvulsant effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline (MeTHIQ--an endogenous parkinsonism-preventing substance) in combination with four second-generation antiepileptic drugs (AEDs: lamotrigine [LTG], oxcarbazepine [OXC], pregabalin [PGB], and topiramate [TPM]) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for parallel and non-parallel dose-response relationship curves (DRRCs)." | 1.36 | Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. ( Antkiewicz-Michaluk, L; Czuczwar, SJ; Luszczki, JJ; Raszewski, G, 2010) |
| "To characterize the anticonvulsant effects of pregabalin (PGB - a third-generation antiepileptic drug) in combination with carbamazepine (CBZ - a classical antiepileptic drug) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for non-parallel dose-response relationship curves (DRRCs)." | 1.36 | Interaction of pregabalin with carbamazepine in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. ( Luszczki, JJ, 2010) |
| ", lamotrigine [LTG], oxcarbazepine [OXC] and topiramate [TPM]) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for non-parallel dose-response relationship curves (DRRCs)." | 1.36 | Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. ( Czuczwar, SJ; Filip, D; Luszczki, JJ, 2010) |
| "Sex, age, familial history, type of seizures and AED treatment were noted and EEG monitoring, MRI and CT scanning, and developmental and psychomotor evolution were investigated." | 1.36 | Benign infantile focal epilepsy with midline spikes and waves during sleep: a new epileptic syndrome or a variant of benign focal epilepsy? ( Caraballo, R; Cersósimo, R; Flesler, S; Sakr, D, 2010) |
| "The maximal electroshock seizure (MES) test performed on mice showed a good anticonvulsant activity for some compounds which protected the mice against convulsions in the 50-62." | 1.35 | Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. ( Dogné, JM; Frankart, A; Masereel, B; Rolin, S; Scozzafava, A; Supuran, CT; Thiry, A; Vullo, D; Wouters, J, 2008) |
| "The antiseizure activity of benzodiazepines (BDZs) 1-5 in mice and rats as animal models is described." | 1.35 | Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models. ( Cook, JM; Edwankar, CR; Edwankar, RV; Furtmüller, R; Huang, S; Jain, HD; Majumder, S; Murphree, L; Ramerstorfer, J; Rivas, FM; Roth, BL; Sankar, S; Sieghart, W; Stables, JP; Zhou, H, 2009) |
| "The aggravation of habitual seizures and interictal discharges indicate ENM." | 1.35 | A study on epileptic negative myoclonus in atypical benign partial epilepsy of childhood. ( Bao, X; Chang, X; Liu, X; Qin, J; Wang, S; Wu, Y; Xiong, H; Yang, Z; Zhang, Y, 2009) |
| " The isobolographic analysis for parallel and nonparallel dose-response effects was used in the mouse maximal electroshock seizure (MES) model for evaluation of pharmacodynamic interaction." | 1.35 | Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. ( Czuczwar, SJ; Luszczki, JJ; Raszewski, G; Wu, JZ, 2009) |
| "Seizures were prevented in 50% and 75% of the animals by chronic CBZ and VPC, respectively." | 1.35 | Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. ( Nekrassov, V; Sitges, M, 2008) |
| "Simultaneously, the impact of acute seizures and efflux transport mechanisms on brain distribution was quantified." | 1.35 | Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. ( Clinckers, R; Danhof, M; Della Pasqua, O; Ebinger, G; Michotte, Y; Smolders, I; Voskuyl, RA, 2008) |
| "There was a dramatic reduction in seizure frequency with rapamycin therapy." | 1.35 | Rapamycin reduces seizure frequency in tuberous sclerosis complex. ( Butler, IJ; Koenig, MK; Muncy, J, 2009) |
| "There were 23 patients with convulsions, including 13 with benign convulsions, 9 with febrile seizures, and 1 with epilepsy." | 1.35 | Clinical characteristics of benign convulsions with rotavirus gastroenteritis. ( Furukawa, S; Ichiyama, T; Kajimoto, M; Matsushige, T; Motoyama, M; Shiraishi, M, 2009) |
| "Lobular capillary hemangioma or pyogenic granuloma is a fairly common vascular tumor in the pediatric age group." | 1.35 | Eruptive pyogenic granulomas developing after drug hypersensitivity reaction. ( Palmero, ML; Pope, E, 2009) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| "A total of 344 patients became seizure-free with the first prescribed antiepileptic drug." | 1.35 | Effectiveness of the first antiepileptic drug in the treatment of pediatric epilepsy. ( Ding, CH; Ding, YX; Fang, F; Ma, MS; Ying, W; Zou, LP, 2009) |
| "Levetiracetam was more likely to be used in children who received chemotherapy or radiation therapy (8/14, or 57%) than in those who did not receive adjuvant therapies (3/18, or 17%) (P = 0." | 1.35 | The use of antiepileptic drugs in pediatric brain tumor patients. ( Kan, L; Levy, AS; Maytal, J; Shinnar, S; Sogawa, Y, 2009) |
| " Chronic administration of ETA (12." | 1.35 | Effect of ethacrynic acid on the anticonvulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Swiderska, G; Łukawski, K, 2009) |
| "The significant proportion of seizure-free cases (27%) on duotherapy is suggesting the usefulness of combination therapy in achieving seizure-freedom in epilepsies refractory to single drug treatment." | 1.35 | Seizure-freedom with combination therapy in localization-related epilepsy. ( Auvinen, A; Keränen, T; Kharazmi, E; Peltola, J; Peltola, M; Raitanen, J, 2008) |
| "We report a patient with seizures induced by the sight of moving water in the absence of bright sunlight." | 1.35 | Seizures induced by the sight of moving water. ( Bauer, S; Haag, A; Hamer, HM; Hermsen, A; Knake, S; Rosenow, F; Strzelczyk, A, 2008) |
| "Although intracranial foreign bodies are generally secondary to penetrating trauma or surgical procedures, rarely they also occur as a result of child abuse." | 1.34 | Intracranial sewing needle in a man with seizure: a case of child abuse? ( Ekinci, G; Elmaci, I; Inanici, MA; Tuncer, N; Yayci, N, 2007) |
| "High amplitude with high frequency EMG seizure was observed in parallel with the appearance of tonic extensor (TE) seizure and an intimate relationship was observed between the two parameters." | 1.34 | Effects of certain antiepileptics on behavioral and electromyographic seizure patterns induced by maximal electroshock in mice. ( Ago, J; Ishikawa, T; Kamei, C; Matsumoto, N; Murakami, A; Takechi, K, 2007) |
| " However, these combinations were associated with significant pharmacokinetic interactions, in that LCZ increased brain TPM (94%), OXC (21%), FBM (46%), and LTG (8%) concentrations." | 1.33 | Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005) |
| "One year later he again suffered from convulsions and was treated with carbamazepine in another hospital." | 1.33 | [Carbamazepine-induced pneumonitis definitively diagnosed by accidental readministration]. ( Matsushita, H; Sugama, Y; Uji, M, 2005) |
| "The antiseizure effect of tested combinations was not sex-dependent and not reversed by hydrocortisone pretreatment." | 1.33 | Influence of aminoglutethimide and spironolactone on the efficacy of carbamazepine and diphenylhydantoin against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ, 2005) |
| "Lamotrigine (LTG) was prescribed in 29 patients as add-on therapy." | 1.33 | The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital. ( Ab Rahman, AF; Ibrahim, MI; Ismail, HI; Seng, TB, 2005) |
| " Linear regression analysis of dose-response relationship between the doses of 2-PMPA and their corresponding threshold values allowed the calculation of threshold increasing dose by 20% (TID20), which was 109." | 1.33 | 2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Luszczki, JJ; Mohamed, M, 2006) |
| " Brain AED concentrations were determined to ascertain any pharmacokinetic contribution to the observed antiseizure effect." | 1.33 | Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. ( Andres, MM; Cioczek-Czuczwar, A; Czuczwar, P; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006) |
| " In that control group, TDM was performed in the same pharmacokinetic (PK) laboratory, using the same sampling strategy as in the present study, and the same PK population modelling software was used for data analysis." | 1.33 | Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. ( Belousov, YB; Bondareva, IB; Guekht, AB; Gusev, EI; Jelliffe, RW; Melikyan, EG, 2006) |
| "As for the clinical course, partial motor seizures began at one year of age and ceased at five: our patient has had no seizure recurrence over a 12-year-follow-up." | 1.33 | Taylor-type focal cortical dysplasia: is the epilepsy always resistant to medical treatment? ( Bianchi, MC; Crisanti, AF; Del Giudice, E; Imperati, F; Romano, A; Titomanlio, L; Tosetti, M; Varrone, A, 2006) |
| "Carbamazepine is a poor water soluble drug and its bioavailability is limited by dissolution rate." | 1.33 | Evaluation of in vitro-in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose. ( Adibkia, K; Anoush, M; Barzegar-Jalali, A; Barzegar-Jalali, M; Hanaee, J; Nayebi, AM; Sistanizad, M; Valizadeh, H, 2006) |
| "Seizures following supraventricular tachycardia are uncommon in older children." | 1.32 | A child with supraventricular tachycardia and convulsions. ( Al-Anqoudi, ZA; Al-Maamari, WS; Venugopalan, P, 2003) |
| "There were 73 children with seizures, 80% of whom had a greater than 50% reduction in seizure frequency following the start of simple anticonvulsant medication." | 1.32 | A review of neurological disorders presenting at a paediatric neurology clinic and response to anticonvulsant therapy in Gambian children. ( Allen, S; Burton, KJ, 2003) |
| "With pentylenetetrazol (PTZ) induced seizures pre-treated by CBZ, or SR-3, both CBZ and SR-3 were equally effective in providing seizure control and both were superior to the saline control." | 1.32 | Anticonvulsant efficiency, behavioral performance and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3). ( Mostofsky, DI; Rabinovitz, S; Yehuda, S, 2004) |
| "Musicogenic epilepsy is a rare form of reflex epilepsy." | 1.32 | Ictal SPECT in a case of pure musicogenic epilepsy. ( Gelisse, P; Genton, P; Hassan-Sebbag, N; Padovani, R; Pasquier, J; Thomas, P, 2003) |
| "Epileptic negative myoclonus (ENM), a transient muscular atonic phenomenon time-locked to epileptiform EEG abnormalities, is often observed in children with benign childhood epilepsy with centro-temporal spikes (BECTS)." | 1.32 | Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. ( Bonanni, P; Guerrini, R; Parmeggiani, L; Seri, S, 2004) |
| "The congenital dermal sinus is an abnormal epithelium-lined sinus tract between the skin surface and deeper tissues." | 1.32 | Spinal congenital dermal sinus associated with upper thoracic meningocele. Case Report. ( Kara, NN, 2003) |
| " Adjusting the maintenance dosage of H(2)-histamine antagonists has been recommended in elderly patients since age-related reduction in renal plasma flow, glomerular filtration rate and renal tubular function may be present, which can in turn elevate histamine levels in plasma and cerebrospinal fluid." | 1.31 | H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. ( Bergemann, N; Diebold, K; Mundt, C; Roesch-Ely, D; Sartor, K; von Einsiedel, RW, 2002) |
| "Cefoselis (50 microg/animal)-induced convulsions were prevented by pretreatment with 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), diazepam and phenobarbital (ED(50) values (mg/kg) of 0." | 1.31 | Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors. ( Matsuoka, N; Mochizuki, Y; Mutoh, S; Sugimoto, M; Terai, T; Uchida, I; Yamazaki, S, 2002) |
| "This subset experiences more seizures prior to the initiation of treatment, is more likely to be treated initially with a noncarbamazepine medication, and tends to have a higher frequency of associated conditions." | 1.31 | Atypical benign epilepsy of childhood with rolandic spikes: features of a subset requiring more than one medication for seizure control. ( Al-Twajri, WA; Shevell, MI, 2002) |
| "Oxcarbazepine has been reported to be a preferable antiepileptic drug, when compared to carbamazepine with respect to its effects on lipid metabolism, especially cholesterol, high-density lipoproteins, and low-density lipoproteins." | 1.31 | Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities. ( Papacostas, S, 2000) |
| "Using an amygdala-kindled seizure paradigm, we evaluated the acute and chronic anticonvulsant effects of lamotrigine (LTG)." | 1.31 | Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam. ( Heynen, T; Krupp, E; Li, XL; Post, RM; Weiss, SR, 2000) |
| " Weighting the data for per-patient dosage values fails to discern a color effect." | 1.31 | Is a "color effect" demonstrated for hair analysis of carbamazepine? ( Mieczkowski, T, 2000) |
| "We reported the evolution of seizures, from the beginning of reading-writing dysphasia through increased writing to secondary generalization, in a schoolchild with benign partial seizures." | 1.31 | Ictal increased writing preceded by dysphasic seizures. ( Fujimoto, S; Imahashi, H; Ishikawa, T; Saito, M, 2000) |
| "This study considered seizures, migraine, underlying psychiatric diathesis, and drug toxicity as possible etiologies but after extensive investigation concluded that his symptoms were most likely a drug side effect." | 1.31 | Antiepileptic drug-induced visual hallucinations in a child. ( Benatar, MG; Davis, RG; Sahin, M, 2000) |
| "All patients with seizures or epilepsy were submitted to standard EEG and brain MRI with gadopentetate dimeglumine." | 1.31 | Seizures in multiple sclerosis. ( Dragutinovic, G; Drulovic, J; Dujmovic, I; Ercegovac, M; Levic, Z; Mesaros, S; Peric, V; Sokic, DV; Stojsavljevic, N, 2001) |
| "Amygdala-kindled seizures were inhibited by conventional antiepileptics, their lowest effective doses were: 20 mg/kg for carbamazepine and phenobarbital, 50 mg/kg for diphenylhydantoin, and 100 mg/kg for valproate magnesium." | 1.31 | Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats. ( Borowicz, KK; Czuczwar, SJ; Kleinrok, Z, 2001) |
| " While the therapeutic plasma concentration range of CBZ is only vaguely defined, pharmacokinetic differences in the disposition of CBZ among subjects could be responsible for the inadequate control of seizures in some." | 1.31 | Association of drug levels & pharmacokinetics of carbamazepine with seizure control. ( Puri, V; Tripathi, KD; Vasudev, A, 2000) |
| "ADD and seizure severity were also measured in response to both threshold and suprathreshold kindling stimulation." | 1.31 | Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of acute carbamazepine. ( Gilbert, TH; Teskey, GC, 2001) |
| "To quantify changes in ictal seizure semiology during rapid withdrawal of carbamazepine (CBZ) and valproate (VPA) from a monoregimen in presurgical evaluation." | 1.31 | Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy. ( Hopp, P; Kerling, F; Kirchner, A; Pauli, E; Stefan, H; Wang, Y; Zhou, D, 2002) |
| "One patient had moderate confusion, and the other mild confusion and hypomania." | 1.30 | Combined valproate or carbamazepine and electroconvulsive therapy. ( Baraibar, G; Tohen, M; Zarate, CA, 1997) |
| "After generalized or partial seizures, transient lesions may appear on magnetic resonance (MR) images." | 1.30 | Reversible MRI lesions after seizures. ( Aktan, S; Aykut-Bingol, C; Ince, D; Tekin, S, 1997) |
| "This ethanol-induced increase in seizure rating was unaffected by carbamazepine (30 mg kg(-1)) but significantly reduced at a higher concentration (130 mg kg(-1))." | 1.30 | Effect of chronic ethanol treatment in vivo on excitability in mouse cortical neurones in vitro. ( Boden, PR; Field, MJ; Ibbotson, T, 1997) |
| " For comparison of drug potencies, doses increasing seizure thresholds by 20 or 50% were calculated from dose-response curves." | 1.30 | Anticonvulsant drug effects in the direct cortical ramp-stimulation model in rats: comparison with conventional seizure models. ( Krupp, E; Löscher, W, 1998) |
| "maximal electroshock seizure threshold (MEST) test and MES generated by supramaximal stimulation (50 mA)." | 1.30 | Frontal versus transcorneal stimulation to induce maximal electroshock seizures or kindling in mice and rats. ( Löscher, W; Potschka, H; Wláz, P, 1998) |
| "In the maximal electroshock seizure threshold test, clobenpropit dose-dependently raised the electroconvulsive threshold for tonic (hindlimb extension) seizures, but a significant increase of about 15% was determined only at the high dose of 40 mg/kg i." | 1.30 | Effect of clobenpropit, a centrally acting histamine H3-receptor antagonist, on electroshock- and pentylenetetrazol-induced seizures in mice. ( Fischer, W; van der Goot, H, 1998) |
| "Carbamazepine (CBZ) is an effective anticonvulsant agent." | 1.30 | Exacerbation of epileptic seizures by carbamazepine: report of 10 cases. ( Fraticelli, E; Parmeggiani, A; Rossi, PG, 1998) |
| " CBZ concentrations in hair sections were found to be dependent on the dosage (r = 0." | 1.30 | Carbamazepine levels in head hair of patients under long-term treatment: a method to evaluate the history of drug use. ( Christodoulou, P; Helidonis, E; Michalodimitrakis, M; Paritsis, N; Psillakis, T; Tsatsakis, AM, 1999) |
| "K+ channel blockers are known to induce seizures, but the specific K channel types that can serve as convulsant targets are not well defined." | 1.30 | Induction of seizures by the potent K+ channel-blocking scorpion venom peptide toxins tityustoxin-K(alpha) and pandinustoxin-K(alpha). ( Blaustein, MP; Juhng, KN; Kim, BY; Kokate, TG; Rogawski, MA; Rogowski, RS; Yamaguchi, S, 1999) |
| " This anti-MES activity is achieved with nontoxic doses, with the optimal effect recorded in rats dosed orally with anti-MES ED50 and protective index (PI) values of 25." | 1.29 | Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. ( Bailleux, V; Hamoir, G; Nuyts, JP; Poupaert, JH; Stables, JP; Vallée, L; Vamecq, J, 1995) |
| " On the basis of pharmacokinetic parameters, mean optimal dosages sufficient for maintenance of effective and safe carbamazepine concentrations were calculated." | 1.29 | [Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome]. ( Dubrovina, LIu; Ivanova, ES; Kholodov, LE; Kopanev, IuA; Postnikov, SS; Prityko, AG; Sokolov, AV; Tatarinov, PA; Tishchenkova, IF; Veselov, NK, 1995) |
| "8-CPT did not antagonize the seizure protection afforded by CBZ or SV." | 1.29 | Involvement of adenosine in postictal events in rats given electroshock. ( David, J; Joseph, T; Kulkarni, C, 1994) |
| " Differential effects on the pharmacodynamic parameters were seen." | 1.29 | Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. ( Danhof, M; Hoogerkamp, A; Vis, PW; Voskuyl, RA, 1994) |
| "We report the unusual seizures in a patient with acute lymphoblastic leukemia." | 1.29 | Unusual seizures with a benign course in a case of acute lymphoblastic leukemia of childhood. ( Del Giudice, E; Fiorillo, A; Iovine, A; Ruosi, P; Striano, S, 1993) |
| "Age, sex, race, seizure type, seizure focus, age at onset, duration of epileptic illness, reasons for discontinuing treatment, other medications, and response to treatment of seizures, psychiatric symptoms, and behavioral symptoms were recorded." | 1.29 | Carbamazepine therapy in neuropsychiatric patients. ( Burns, RL; Jenkins, PL; Vallini, AD, 1993) |
| "Nifedipine was found to have anticonvulsant activity in both models but flunarizine only had an anticonvulsant effect in the PTZ seizure incidence/latency test." | 1.29 | Protective effect of flunarizine and nifedipine alone and in combination with anticonvulsant drugs against PTZ-induced seizures in mice. ( Pleuvry, BJ; Rodger, C, 1993) |
| "These seizures were usually precipitated by auditory stimuli such as sudden loud noises." | 1.29 | Reflex seizures in Down syndrome. ( Louis, S; Pueschel, SM, 1993) |
| "In this patient with chronic lymphocytic leukemia, carbamazepine therapy had a significant and reproducible lymphopenic effect that was readily reversible upon discontinuation of the drug." | 1.29 | Lymphopenic effect of carbamazepine in a patient with chronic lymphocytic leukemia. ( Chapron, DJ; Silverman, DA, 1995) |
| "D-Cycloserine (DCS) is a high-efficacy partial agonist at the strychnine-insensitive glycine modulatory site within the N-methyl-D-aspartate (NMDA)-receptor/ionophore complex." | 1.29 | Influence of D-cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice. ( Czuczwar, SJ; Roliński, Z; Wlaź, P, 1996) |
| "Porphyria cutanea tarda is a disorder of heme biosynthesis resulting from a defect or deficiency in the enzyme uroporphyrinogen decarboxylase." | 1.29 | Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. ( Demento, FJ; Fishbane, S; Frei, GL; Maesaka, JK; Ruggian, JC, 1996) |
| "Seizures were attenuated or blocked by treatment with carbamazepine or sodium valproate." | 1.29 | Audiogenic seizures following global ischemia induced by chest compression in Long-Evans rats. ( Iyer, V; Keelen, P; Miller, J; Payne, RS; Reid, KH; Schurr, A; Tseng, M; Young, C, 1996) |
| "Treatment with haloperidol and lithium was unsuccessful but the addition of carbamazepine produced a dramatic response." | 1.29 | A patient with mania and photoconvulsive epilepsy. ( Corbett, AJ; Reid, WG; Roxanas, MG, 1996) |
| "Cerebral cavernous angioma (cavernoma) has previously been treated by resection for all presentations when surgically resectable." | 1.28 | Cerebral cavernous angioma: a potentially benign condition? Successful treatment in 16 cases. ( Churchyard, A; Grainger, K; Khangure, M, 1992) |
| "The bioavailability and serum level fluctuations of three carbamazepine (CBZ, CAS 298-46-4) slow release preparations marketed in Germany were compared in patients with epilepsy." | 1.28 | Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. ( May, T; Schreiber, G; Tiska, G; Wolf, P, 1992) |
| "The kindled-convulsion model was used to assess the development of tolerance and cross tolerance to the anticonvulsant effects of antiepileptic drugs." | 1.28 | Tolerance to the anticonvulsant effects of phenobarbital, trimethadione, and clonazepam in kindled rats: cross tolerance to carbamazepine. ( Hudda, MM; Kim, CK; Pinel, JP; Wong, DJ; Yung, A, 1992) |
| "Seizures were repetitive and death occurred in 10." | 1.28 | Antiepileptic drugs delay the onset of seizures induced by aminophylline in conscious rats. ( David, J; Joseph, T; Kulkarni, C, 1992) |
| "Treatment with carbamazepine attenuated (P less than 0." | 1.28 | Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. ( Browne, TR; Galpern, WR; Greenblatt, DJ; Miller, LG; Shader, RI; Szabo, GK, 1991) |
| "The concentrations of central neuropeptides, somatostatin (SS) and substance-P (SP), were determined in the different brain regions of young-aged male rats after a long-term administration of anticonvulsants Qingyangshen (QYS), Diphenylhydantoin (DPH), and Carbamazepine (CBZ)." | 1.28 | The investigation of antiepileptic action of qingyangshen (QYS)--effect of QYS on the concentrations of neuropeptides in rat brain. ( Kuang, P; Lang, S; Liu, J; Wu, W; Zhang, F, 1991) |
| "Amygdala-kindled seizure thresholds were studied in animals which were or were not tolerant to the anticonvulsant effects of carbamazepine." | 1.28 | Contingent tolerance to carbamazepine is associated with lowering of amygdala-kindled seizure thresholds. ( Haas, K; Post, RM; Weiss, SR, 1991) |
| "Seizures are a recognized manifestation of neurosarcoidosis, but their clinical relevance is not well established." | 1.28 | Clinical implications of seizures in neurosarcoidosis. ( Krumholz, A; Stern, BJ; Stern, EG, 1991) |
| "Pretreatment with adenosinergic agents and MK-801 markedly enhanced the protective effect of the stable analogs of adenosine namely, 2-chloroadenosine and N6-cyclohexyladenosine." | 1.28 | Effect of MK-801 and its interaction with adenosinergic agents and carbamazepine against hypoxic stress-induced convulsions and death in mice. ( Kulkarni, SK; Thorat, SN, 1990) |
| "Carbamazepine induced systemic lupus erythematosus is a very rare phenomenon." | 1.28 | Carbamazepine induced systemic lupus erythematosus. Another warning. ( Beşbaş, N; Oner, A; Topaloğlu, H; Topaloğlu, R, 1990) |
| " In this series chronic exposure to carbamazepine did not appear to increase the risk of coma or respiratory depression for a given toxic serum level and may add some protective effect." | 1.28 | Carbamazepine overdose: a prospective study of serum levels and toxicity. ( Cookson, E; Krenzelok, EP; Spiller, HA, 1990) |
| "Three cases with seizures induced by movement are presented." | 1.28 | [Seizures induced by movement]. ( Hayashi, M; Kabuto, M; Kobayashi, H; Kubota, T; Kutota, T; Nakagawa, T; Noguchi, Y, 1990) |
| "Carbamazepine treatment completely resolved his symptoms, with full normalization of EEG activity." | 1.28 | Nocturnal complex partial seizures precipitated by REM sleep. A case report. ( De Domenico, P; Di Perri, R; Longo, M; Marabello, L; Mento, G; Musolino, R; Silvestri, R, 1989) |
| " Serum concentration values obtained after 1 week of monotherapy, using our dosing regimen, can be used to predict directly the dosing rate needed to obtain a specific serum concentration in most patients." | 1.28 | Time course of carbamazepine autoinduction. The VA Cooperative Study No.118 Group. ( Browne, TR; Collins, JF; Mikati, MA, 1989) |
| "Theophylline pretreatment failed to alter anticonvulsant protection by trimethadione and sodium valproate, but significantly decreased the anticonvulsant effects of carbamazepine and phenobarbital." | 1.27 | Interactions of the anticonvulsant carbamazepine with adenosine receptors. 2. Pharmacological studies. ( Chow, SC; Johnston, GA; Skerritt, JH, 1983) |
| "When phenobarbital was administered for several days, a strong induction of hepatic microsomal enzymes occurred." | 1.27 | Anticonvulsant potency of common antiepileptic drugs in the gerbil. ( Frey, HH; Löscher, W; Reiche, R; Schultz, D, 1983) |
| "Carbamazepine may trigger the onset of Tourette's syndrome in susceptible patients." | 1.27 | Tics and vocalizations in children treated with carbamazepine. ( Glaze, DG; Neglia, JP; Zion, TE, 1984) |
| "Treatment of carbamazepine overdose consists of aggressive orogastric lavage followed by activated charcoal administration with catharsis." | 1.27 | Acute carbamazepine intoxication: clinical spectrum and management. ( May, DC, 1984) |
| "Seizures and delirium tremens were recorded among 292 randomly selected patients admitted to an in-patient alcoholism program." | 1.27 | Should alcohol withdrawal seizures be treated with anti-epileptic drugs? ( Hillbom, ME; Hjelm-Jäger, M, 1984) |
| "However, ethosuximide must act against generalized absence seizures and against pentylenetetrazol-induced seizures by a third, as yet unknown, mechanism." | 1.27 | Anticonvulsant drug mechanisms of action. ( Macdonald, RL; McLean, MJ; Skerritt, JH, 1985) |
| "After large numbers of pretreatment seizures (40, 100), drug response was actually enhanced." | 1.27 | The effect of repeated seizures on anticonvulsant drug response in the kindling model. ( Burnham, WM; Mace, JA, 1987) |
| "Kindled seizures were almost completely blocked by treatment with carbamazepine, whereas the effect of valproic acid was partial, suppressing only generalized seizures." | 1.27 | Effects of carbamazepine and valproic acid on brain immunoreactive somatostatin and gamma-aminobutyric acid in amygdaloid-kindled rats. ( Higuchi, T; Igarashi, Y; Kato, N; Minatogawa, Y; Nagaki, S; Ohshima, H; Takazawa, A; Watanabe, N; Yamazaki, J; Yamazaki, O, 1986) |
| "QUIN seizures showed particular sensitivity to carbamazepine (5 mg/kg) but were resistant to diphenylhydantoin unless a relatively high dose was used (100 mg/kg)." | 1.27 | Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. ( Samanin, R; Tullii, M; Vezzani, A; Wu, HQ, 1986) |
| " In the case of diazepam, clonazepam, ethosuximide or trimethadione, the TE/TF ratio was decreased dose-dependently, but the slope of the dose-response regression line was less steep than that obtained by the administration of PB, PNT, CBZ, VPA or primidone." | 1.27 | [The correlation between concentrations of anticonvulsive drugs in the brain and various parameters of maximal electroshock seizures in mice]. ( Kishita, C, 1986) |
| "Children with seizure disorders frequently are treated with anticonvulsant medications such as clonazepam, valproic acid, carbamazepine, and ethosuximide, which cannot be given parenterally." | 1.27 | Rectal anticonvulsants in pediatric practice. ( Laney, SM; Woody, RC, 1988) |
| " Purely additive interactions were found for the anticonvulsant effect when valproate was combined with carbamazepine as well as with phenobarbital." | 1.27 | Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. ( Bourgeois, BF, 1988) |
| "The EEG during the myoclonic and tonic-clonic seizures showed high-amplitude rhythmic spikes, polyspikes and spike-waves, 1 to 10 c/s, for 40 to 120 sec, often outlasting the sound stimulus." | 1.27 | Audiogenic seizures in Wistar rats before and after repeated auditory stimuli: clinical, pharmacological, and electroencephalographic studies. ( Depaulis, A; Kiesmann, M; Marescaux, C; Micheletti, G; Vergnes, M; Warter, JM, 1988) |
| "Both the fever and the seizures were controlled by anticonvulsant medication, and both recurred under observation when the medication was discontinued." | 1.27 | Complex partial status epilepticus presenting as fever of unknown origin. ( Semel, JD, 1987) |
| "The seizures are characterized by one or two wild running fits which terminate in a tonic dorsiflexion with open mouth, followed by a catatonic state." | 1.27 | Kindling of audiogenic seizures in the rat. ( Depaulis, A; Kiesmann, M; Marescaux, C; Micheletti, G; Vergnes, M; Warter, JM, 1987) |
| "The effects of pregnancy on seizure excitability as well as antiepileptic drug disposition and efficacy were studied in the mouse during late gestation." | 1.27 | Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse. ( Kuhnz, W; Löscher, W; Nau, H, 1985) |
| "According to our convulsion intensity scoring system, these animals have an audiogenic response score (ARS) of 3 and the colony is designated the GEPR-3 colony." | 1.27 | Anticonvulsant drugs and the genetically epilepsy-prone rat. ( Dailey, JW; Jobe, PC, 1985) |
| "These seizures are characterized by tonic spasm in the extremities, often accompanied by painful dysesthesias, and are fleeting, usually lasting no more than two minutes." | 1.27 | Spinal cord seizures in transverse myelopathy: report of two cases. ( Cherrick, AA; Ellenberg, M, 1986) |
| "In a case of phenytoin (PHT) encephalopathy a correlation was found between rising PHT serum levels and increase in seizure frequency." | 1.27 | A case report of phenytoin encephalopathy. Correlation between serum levels, seizure increase and E.E.G. spike and wave activity. ( Sie, O; Zwarts, MJ, 1985) |
| "Her seizures are now treated successfully with phenytoin." | 1.27 | A possible case of carbamazepine-induced pancreatitis. ( Soman, M; Swenson, C, 1985) |
| "The time to seizures was increased nearly five times by clonazepam and over three times by very small amounts of propylene glycol." | 1.26 | Protection from oxygen-induced seizures by clonazepam and propylene glycol. ( Beckman, DL; Crittenden, DJ, 1981) |
| "The diagnosis of functional seizures is difficult and emotional factors may be important in the cause and triggering of seizures." | 1.26 | Differentiating between organic and functional seizures: a common diagnostic problem. ( Chambers, BR; Vajda, FJ, 1981) |
| ", 1974), the problem of its low bioavailability in solid form and its short half-life in monkey were addressed." | 1.26 | Carbamazepine revisited in a monkey model. ( Congdon, WC; DuCharme, LL; Levy, RH; Lockard, JS; Patel, IH, 1979) |
| "The treatment with phenobarbital, diphenylhydantoin and carbamazepine for 7 days decreased the basal cAMP values in CSF and partly inhibited the rise after the convulsions." | 1.26 | Effect of convulsions and anticonvulsive drugs on cerebrospinal fluid cyclic AMP in rabbits. ( Myllylä, VV, 1976) |
| "In a certain percentage of patients seizures are abolished or diminish in frequency only on attaining such a serum level." | 1.26 | [The serum concentration of anticonvulsants -- pharmacokinetic findings and practical therapeutic applications (author's transl)]. ( Deisenhammer, E; Sommer, R, 1979) |
| "Toxic features and convulsions appeared to be related to peak and trough concentrations." | 1.26 | Carbamazepine dose-frequency requirement in children. ( Butcher, GM; Moreland, TA; Rylance, GW, 1979) |
| "Carbamazepine is a suitable substitute for phenobarbital, primidone, and phenytoin, alone or in combination, when used in the treatment of generalized tonic-clonic or partial epilepsy." | 1.26 | Carbamazepine as a substitute treatment of single and compound seizures. ( McFarland, HR, 1978) |
| "Cannabidiol was effective in blocking convulsions when given concurrently with, but not prior to delta9THC." | 1.26 | Anticonvulsant drug antagonism of delta9tetrahydrocannabinol-induced seizures in rabbits. ( Consroe, P; Eisenstein, D; Martin, P, 1977) |
| " In all cases, data on plasma levels were subjected to pharmacokinetic analyses." | 1.26 | Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. ( Assael, BM; Bossi, L; Garattini, S; Gerna, M; Gomeni, R; Morselli, PL, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 163 (20.74) | 18.7374 |
| 1990's | 165 (20.99) | 18.2507 |
| 2000's | 170 (21.63) | 29.6817 |
| 2010's | 219 (27.86) | 24.3611 |
| 2020's | 69 (8.78) | 2.80 |
| Authors | Studies |
|---|---|
| Edafiogho, IO | 2 |
| Hinko, CN | 2 |
| Chang, H | 1 |
| Moore, JA | 2 |
| Mulzac, D | 1 |
| Nicholson, JM | 1 |
| Scott, KR | 1 |
| Pavia, MR | 1 |
| Taylor, CP | 1 |
| Lobbestael, SJ | 1 |
| Hino, K | 1 |
| Nagai, Y | 1 |
| Uno, H | 1 |
| Masuda, Y | 2 |
| Oka, M | 2 |
| Karasawa, T | 2 |
| Chapleo, CB | 1 |
| Myers, PL | 1 |
| Smith, AC | 1 |
| Tulloch, IF | 1 |
| Turner, S | 1 |
| Walter, DS | 1 |
| Hallot, A | 1 |
| Brodin, R | 1 |
| Merlier, J | 1 |
| Brochard, J | 1 |
| Chambon, JP | 1 |
| Biziere, K | 1 |
| Kikumoto, R | 1 |
| Tobe, A | 1 |
| Fukami, H | 1 |
| Ninomiya, K | 1 |
| Egawa, M | 1 |
| Farrar, VA | 1 |
| Ciechanowicz-Rutkowska, M | 1 |
| Grochowski, J | 1 |
| Serda, P | 1 |
| Pilati, T | 1 |
| Filippini, G | 1 |
| el-Assadi, A | 1 |
| Dimmock, JR | 1 |
| Puthucode, RN | 1 |
| Smith, JM | 1 |
| Hetherington, M | 1 |
| Quail, JW | 1 |
| Pugazhenthi, U | 1 |
| Lechler, T | 1 |
| Stables, JP | 7 |
| Carson, JR | 1 |
| Carmosin, RJ | 1 |
| Pitis, PM | 1 |
| Vaught, JL | 1 |
| Almond, HR | 1 |
| Wolf, HH | 1 |
| Swinyard, EA | 1 |
| White, HS | 3 |
| Unverferth, K | 1 |
| Engel, J | 1 |
| Höfgen, N | 1 |
| Rostock, A | 1 |
| Günther, R | 1 |
| Lankau, HJ | 1 |
| Menzer, M | 1 |
| Rolfs, A | 1 |
| Liebscher, J | 1 |
| Müller, B | 1 |
| Hofmann, HJ | 1 |
| Pevarello, P | 1 |
| Bonsignori, A | 1 |
| Dostert, P | 1 |
| Heidempergher, F | 1 |
| Pinciroli, V | 1 |
| Colombo, M | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Post, C | 1 |
| Fariello, RG | 1 |
| Varasi, M | 1 |
| Ucar, H | 1 |
| Van derpoorten, K | 1 |
| Cacciaguerra, S | 1 |
| Spampinato, S | 1 |
| Depovere, P | 1 |
| Isa, M | 1 |
| Masereel, B | 2 |
| Delarge, J | 1 |
| Poupaert, JH | 3 |
| Benes, J | 1 |
| Parada, A | 1 |
| Figueiredo, AA | 1 |
| Alves, PC | 1 |
| Freitas, AP | 1 |
| Learmonth, DA | 1 |
| Cunha, RA | 1 |
| Garrett, J | 1 |
| Soares-da-Silva, P | 2 |
| Xie, ZF | 1 |
| Chai, KY | 2 |
| Piao, HR | 2 |
| Kwak, KC | 1 |
| Quan, ZS | 10 |
| Yogeeswari, P | 1 |
| Sriram, D | 1 |
| Thirumurugan, R | 1 |
| Raghavendran, JV | 1 |
| Sudhan, K | 1 |
| Pavana, RK | 1 |
| Stables, J | 1 |
| Gupta, A | 1 |
| Mishra, P | 2 |
| Kashaw, SK | 2 |
| Jatav, V | 1 |
| Rana, A | 1 |
| Siddiqui, N | 2 |
| Khan, SA | 4 |
| Ehtaishamul Haque, S | 1 |
| Bhat, MA | 1 |
| Azam, F | 1 |
| Alkskas, IA | 1 |
| Khokra, SL | 1 |
| Prakash, O | 1 |
| Thiry, A | 1 |
| Rolin, S | 1 |
| Vullo, D | 1 |
| Frankart, A | 1 |
| Scozzafava, A | 1 |
| Dogné, JM | 1 |
| Wouters, J | 1 |
| Supuran, CT | 1 |
| Marona, H | 4 |
| Pekala, E | 4 |
| Antkiewicz-Michaluk, L | 2 |
| Walczak, M | 2 |
| Szneler, E | 2 |
| Guo, LJ | 1 |
| Wei, CX | 6 |
| Jia, JH | 2 |
| Zhao, LM | 1 |
| Guan, LP | 3 |
| Deng, XQ | 5 |
| Sui, X | 2 |
| Rivas, FM | 1 |
| Murphree, L | 1 |
| Edwankar, RV | 1 |
| Edwankar, CR | 1 |
| Huang, S | 2 |
| Jain, HD | 1 |
| Zhou, H | 1 |
| Majumder, S | 1 |
| Sankar, S | 1 |
| Roth, BL | 1 |
| Ramerstorfer, J | 1 |
| Furtmüller, R | 1 |
| Sieghart, W | 1 |
| Cook, JM | 1 |
| Kashaw, V | 1 |
| Jain, NK | 1 |
| Quan, YC | 1 |
| Li, FN | 3 |
| Sun, ZG | 1 |
| Kaushik, D | 1 |
| Chawla, G | 1 |
| He, X | 3 |
| Zhong, M | 3 |
| Zhang, T | 4 |
| Wu, W | 3 |
| Wu, Z | 3 |
| Yang, J | 2 |
| Xiao, Y | 3 |
| Pan, Y | 1 |
| Qiu, G | 2 |
| Hu, X | 3 |
| Quan, LN | 1 |
| Song, MX | 2 |
| Waszkielewicz, AM | 3 |
| Babu, M | 1 |
| Pitchumani, K | 1 |
| Ramesh, P | 2 |
| Guo, H | 1 |
| Hen, N | 1 |
| Bialer, M | 2 |
| Yagen, B | 1 |
| Karakurt, A | 2 |
| Alagöz, MA | 1 |
| Sayoğlu, B | 1 |
| Calış, U | 2 |
| Dalkara, S | 2 |
| Hassan, MZ | 1 |
| Amir, M | 1 |
| Rajak, H | 1 |
| Singh Thakur, B | 1 |
| Singh, A | 1 |
| Raghuvanshi, K | 1 |
| Sah, AK | 1 |
| Veerasamy, R | 1 |
| Sharma, PC | 1 |
| Singh Pawar, R | 1 |
| Kharya, MD | 1 |
| Malik, S | 1 |
| Bahare, RS | 1 |
| Wang, SB | 2 |
| Jin, P | 1 |
| Mishra, RK | 1 |
| Baker, MT | 1 |
| Kumari, S | 1 |
| Mishra, CB | 1 |
| Tiwari, M | 1 |
| Kamiński, K | 4 |
| Rapacz, A | 5 |
| Łuszczki, JJ | 10 |
| Latacz, G | 2 |
| Obniska, J | 3 |
| Kieć-Kononowicz, K | 2 |
| Filipek, B | 3 |
| Zagaja, M | 5 |
| Andres-Mach, M | 5 |
| Tanaka, T | 2 |
| Yajima, N | 1 |
| Tanitame, A | 1 |
| Kiyoshi, T | 1 |
| Miura, Y | 1 |
| Edayadulla, N | 1 |
| Gunia-Krzyżak, A | 2 |
| Żesławska, E | 2 |
| Słoczyńska, K | 2 |
| Koczurkiewicz, P | 1 |
| Nitek, W | 2 |
| Żelaszczyk, D | 2 |
| Szkaradek, N | 1 |
| Abram, M | 1 |
| Sari, S | 1 |
| Uslu, H | 1 |
| Kaynak, FB | 1 |
| Pańczyk, K | 1 |
| Grover, G | 1 |
| Nath, R | 1 |
| Bhatia, R | 1 |
| Akhtar, MJ | 1 |
| Pukhalskaya, T | 1 |
| El Hussein, S | 1 |
| Viamontes, CG | 1 |
| Castillo Gonzalez, J | 1 |
| Najjar, F | 1 |
| Cook, EH | 1 |
| Bernal Cobo, R | 1 |
| Giraldo Tapias, LM | 1 |
| Gómez Escobar, T | 1 |
| Rueda Cárdenas, LF | 1 |
| Zapata Berruecos, JF | 1 |
| Vásquez Trespalacios, EM | 1 |
| Giraldo Castrillón, YM | 1 |
| Rojas-Gualdrón, DF | 1 |
| Foster, E | 1 |
| Chen, Z | 2 |
| Vaughan, DN | 1 |
| Tailby, C | 1 |
| Carney, PW | 1 |
| D'Souza, W | 1 |
| Au Yong, HM | 1 |
| Nicolo, JP | 1 |
| Pellinen, J | 1 |
| Carrillo de Albornoz, S | 1 |
| Liew, D | 1 |
| O'Brien, TJ | 4 |
| Kwan, P | 1 |
| Ademi, Z | 1 |
| Chalasani, N | 1 |
| Bonkovsky, HL | 1 |
| Stine, JG | 1 |
| Gu, J | 1 |
| Barnhart, H | 1 |
| Jacobsen, E | 1 |
| Björnsson, E | 1 |
| Fontana, RJ | 1 |
| Kleiner, DE | 1 |
| Hoofnagle, JH | 1 |
| Brigo, F | 2 |
| Igwe, SC | 2 |
| Bragazzi, NL | 2 |
| Lattanzi, S | 3 |
| Bahji, A | 1 |
| Bach, P | 1 |
| Danilewitz, M | 1 |
| Crockford, D | 1 |
| El-Guebaly, N | 1 |
| Devoe, DJ | 1 |
| Saitz, R | 1 |
| Wang, BC | 1 |
| Chiu, HY | 1 |
| Luh, HT | 1 |
| Lin, CJ | 1 |
| Hsieh, SH | 1 |
| Chen, TJ | 1 |
| Wu, CR | 1 |
| Chen, PY | 1 |
| Ryvlin, P | 2 |
| Dimova, S | 2 |
| Elmoufti, S | 2 |
| Floricel, F | 2 |
| Laloyaux, C | 2 |
| Nondonfaz, X | 1 |
| Biton, V | 1 |
| Ohta, K | 1 |
| Okanishi, T | 1 |
| Kanai, S | 1 |
| Nakamura, Y | 1 |
| Fujimoto, A | 1 |
| Maegaki, Y | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Schabert, VF | 1 |
| Stern, S | 1 |
| Ferrari, L | 2 |
| Wade, CT | 1 |
| Willke, RJ | 1 |
| Hauser, WA | 1 |
| Dell'Isola, GB | 1 |
| Mencaroni, E | 1 |
| Fattorusso, A | 1 |
| Tascini, G | 1 |
| Prontera, P | 1 |
| Imperatore, V | 1 |
| Di Cara, G | 1 |
| Striano, P | 3 |
| Verrotti, A | 2 |
| Green, SF | 1 |
| Hare, N | 1 |
| Kassam, M | 1 |
| Rugg-Gunn, F | 1 |
| Koepp, MJ | 1 |
| Sander, JW | 3 |
| Rajakulendran, S | 1 |
| Yao, N | 1 |
| Huang, A | 1 |
| Song, H | 1 |
| Stelzle, D | 1 |
| Kaducu, J | 1 |
| Schmidt, V | 1 |
| Welte, TM | 1 |
| Ngowi, BJ | 1 |
| Matuja, W | 1 |
| Escheu, G | 1 |
| Hauke, P | 1 |
| Richter, V | 1 |
| Ovuga, E | 1 |
| Pfausler, B | 1 |
| Schmutzhard, E | 1 |
| Amos, A | 1 |
| Harrison, W | 1 |
| Keller, L | 1 |
| Winkler, AS | 1 |
| Ueno, T | 1 |
| Katagai, A | 1 |
| Okudera, R | 1 |
| Fujita, M | 1 |
| Tomiyama, M | 1 |
| Mensah, JA | 1 |
| Johnson, K | 1 |
| Reilly, CA | 1 |
| Wilcox, KS | 1 |
| Rower, JE | 1 |
| Metcalf, CS | 1 |
| Ghazala, E | 1 |
| Shahin, DA | 1 |
| Wahba, Y | 1 |
| Chang, A | 1 |
| Chang, Y | 1 |
| Wang, SJ | 1 |
| Usman, AB | 1 |
| Emmanuel, P | 1 |
| Namuya, NP | 1 |
| Manchan, DB | 1 |
| C Dahiru, AM | 1 |
| Raheem, N | 1 |
| Usman, AU | 1 |
| Hirayama, K | 1 |
| LoPinto-Khoury, C | 1 |
| Borowicz-Reutt, K | 1 |
| Banach, M | 6 |
| Fairclough, S | 1 |
| Goodden, J | 1 |
| Chumas, P | 1 |
| Mathew, R | 1 |
| Maguire, M | 1 |
| Bernat, P | 1 |
| Kołodziejczyk, P | 2 |
| Tutka, P | 3 |
| Kośmider, K | 1 |
| Kamieniak, M | 1 |
| Czuczwar, SJ | 42 |
| Miziak, B | 1 |
| Mesraoua, B | 1 |
| Perucca, E | 8 |
| Tomson, T | 3 |
| Asadi-Pooya, AA | 2 |
| Sokolov, E | 1 |
| Dietrich, J | 1 |
| Cole, AJ | 1 |
| Ziganshina, LE | 1 |
| Abakumova, T | 1 |
| Hoyle, CHV | 1 |
| Vashi, V | 1 |
| Rosenfeld, WE | 1 |
| Kamin, M | 1 |
| Terada, K | 1 |
| Kubota, Y | 1 |
| Chellun, D | 1 |
| Bojar, H | 1 |
| Jankiewicz, K | 2 |
| Florek-Łuszczki, M | 4 |
| Chmielewski, J | 2 |
| Skalicka-Woźniak, K | 3 |
| Johnson-Davis, KL | 1 |
| Thomas, RL | 1 |
| Rahman, MM | 1 |
| Fatema, K | 1 |
| Rawat, C | 1 |
| Kukal, S | 1 |
| Kushwaha, S | 1 |
| Agarwal, R | 1 |
| Sharma, S | 2 |
| Srivastava, AK | 1 |
| Kukreti, R | 2 |
| Sanoria, A | 1 |
| Arora, R | 1 |
| Dokania, P | 1 |
| Revilla Orías, MD | 1 |
| Alonso, X | 1 |
| Campistol, J | 1 |
| Macaya, A | 1 |
| Escofet, C | 1 |
| Fons, C | 1 |
| Zavala-Tecuapetla, C | 1 |
| Orozco-Suarez, S | 1 |
| Manjarrez, J | 1 |
| Cuellar-Herrera, M | 1 |
| Vega-Garcia, A | 1 |
| Buzoianu-Anguiano, V | 1 |
| Moseley, BD | 2 |
| Otoul, C | 1 |
| Staelens, L | 1 |
| Stockis, A | 2 |
| Steinhoff, BJ | 1 |
| Bacher, M | 1 |
| Blickhan, M | 1 |
| Bernedo, V | 1 |
| Dietmann, D | 1 |
| Intravooth, T | 1 |
| Kornmeier, R | 1 |
| Kurth, C | 1 |
| Mahn, P | 1 |
| Schneider, M | 1 |
| Stockinger, J | 1 |
| Staack, AM | 1 |
| de Jong, VMT | 1 |
| Moons, KGM | 1 |
| Riley, RD | 1 |
| Tudur Smith, C | 5 |
| Marson, AG | 14 |
| Eijkemans, MJC | 1 |
| Debray, TPA | 1 |
| Keni, RR | 1 |
| Jose, M | 1 |
| A S, R | 1 |
| Baishya, J | 1 |
| Sankara Sarma, P | 1 |
| Thomas, SV | 1 |
| Li, Y | 2 |
| Li, B | 1 |
| Li, J | 1 |
| Wang, L | 4 |
| Jiang, Z | 1 |
| Khan, N | 1 |
| Shah, FA | 1 |
| Rana, I | 1 |
| Ansari, MM | 1 |
| Din, FU | 1 |
| Rizvi, SZH | 1 |
| Aman, W | 1 |
| Lee, GY | 1 |
| Lee, ES | 1 |
| Kim, JK | 1 |
| Zeb, A | 1 |
| Borowicz-Reutt, KK | 4 |
| Rudkowska, M | 1 |
| Fox, J | 1 |
| Ajinkya, S | 1 |
| Lekoubou, A | 1 |
| Tayama, T | 1 |
| Mori, T | 1 |
| Goji, A | 1 |
| Toda, Y | 1 |
| Kagami, S | 1 |
| Bonnett, LJ | 1 |
| Hutton, JL | 1 |
| Greenhalgh, J | 4 |
| Weston, J | 4 |
| Dundar, Y | 2 |
| Nevitt, SJ | 4 |
| Chanteux, H | 1 |
| Nicolas, JM | 1 |
| Gidal, B | 1 |
| Lu, PL | 1 |
| Hodes, JF | 1 |
| Zheng, X | 1 |
| Hu, XY | 1 |
| Ferrari-Marinho, T | 1 |
| Hamad, APA | 1 |
| Casella, EB | 1 |
| Yacubian, EMT | 1 |
| Caboclo, LO | 1 |
| Fırat, O | 1 |
| Yalçın, N | 1 |
| Demirkan, K | 1 |
| Koneval, Z | 1 |
| Knox, KM | 1 |
| Memon, A | 1 |
| Zierath, DK | 1 |
| Barker-Haliski, M | 1 |
| Krarup, S | 1 |
| Mertz, C | 1 |
| Jakobsen, E | 1 |
| Lindholm, SEH | 1 |
| Pinborg, LH | 1 |
| Bak, LK | 1 |
| Łukawski, K | 2 |
| Raszewski, G | 3 |
| Yu, L | 1 |
| Feng, J | 1 |
| Yu, Z | 2 |
| Dai, H | 1 |
| Zhang, W | 1 |
| Bu, H | 1 |
| Han, X | 1 |
| He, J | 1 |
| Jia, L | 1 |
| Wang, W | 2 |
| Åndell, E | 1 |
| Åmark, P | 1 |
| Pihlström, N | 1 |
| Tedroff, K | 1 |
| Carlsson, S | 1 |
| Yamamoto, Y | 1 |
| Shiratani, Y | 1 |
| Asai, S | 1 |
| Usui, N | 1 |
| Nishida, T | 1 |
| Imai, K | 1 |
| Kagawa, Y | 1 |
| Takahashi, Y | 1 |
| Drabik, M | 1 |
| Głuszak, M | 1 |
| Wróblewska-Łuczka, P | 2 |
| Plewa, Z | 1 |
| Jankiewicz, M | 1 |
| Kozińska, J | 1 |
| Plech, T | 2 |
| Vajda, FJE | 1 |
| Graham, JE | 1 |
| Hitchcock, AA | 1 |
| Mitchell, J | 1 |
| Horgan, D | 1 |
| Lander, CM | 1 |
| Eadie, MJ | 1 |
| Kim, H | 1 |
| Kim, SH | 2 |
| Kim, JB | 1 |
| Kumar, J | 1 |
| Meena, J | 1 |
| Yadav, J | 1 |
| Saini, L | 1 |
| Müller, RM | 1 |
| Herziger, B | 1 |
| Jeschke, S | 1 |
| Neininger, MP | 1 |
| Bertsche, T | 1 |
| Bertsche, A | 1 |
| Nogueira, V | 1 |
| Mendes, MA | 1 |
| Pereira, I | 1 |
| Teixeira, J | 1 |
| Jiménez-Villegas, MJ | 1 |
| Lozano-García, L | 1 |
| Carrizosa-Moog, J | 1 |
| Tatum, S | 1 |
| Smith, ZZ | 1 |
| Taylor, JA | 1 |
| Poulsen, DJ | 1 |
| Dudek, FE | 4 |
| Barth, DS | 1 |
| Panda, PK | 1 |
| Sharawat, IK | 1 |
| Panda, P | 1 |
| Dawman, L | 1 |
| Kasinathan, A | 1 |
| Bertram, EH | 1 |
| Edelbroek, P | 1 |
| Pahuja, E | 1 |
| Thirthalli, J | 1 |
| Ibrahim, FA | 1 |
| Andrade, C | 1 |
| Xu, ZE | 1 |
| Li, WB | 1 |
| Qiao, MY | 1 |
| Cui, HT | 1 |
| Zhao, LZ | 1 |
| Chen, QX | 1 |
| Miao, JK | 1 |
| Antunes, NJ | 1 |
| van Dijkman, SC | 1 |
| Lanchote, VL | 1 |
| Wichert-Ana, L | 1 |
| Coelho, EB | 1 |
| Alexandre Junior, V | 1 |
| Takayanagui, OM | 1 |
| Tozatto, E | 1 |
| van Hasselt, JGC | 1 |
| Della Pasqua, O | 2 |
| Natchimuthu, V | 1 |
| Thomas, S | 1 |
| Ramalingam, M | 1 |
| Ravi, S | 1 |
| Grundmann, M | 1 |
| Koristkova, B | 1 |
| Brozmanova, H | 1 |
| Kacirova, I | 1 |
| Cagnetti, C | 1 |
| Foschi, N | 1 |
| Lorusso, A | 1 |
| Provinciali, L | 2 |
| Silvestrini, M | 1 |
| Garip Ustaoglu, S | 1 |
| Evis, Z | 1 |
| Ilbay, G | 1 |
| Boskey, AL | 1 |
| Severcan, F | 1 |
| Vilan, A | 1 |
| Mendes Ribeiro, J | 1 |
| Weckhuysen, S | 1 |
| Weeke, LC | 1 |
| Brilstra, E | 1 |
| de Vries, LS | 1 |
| Cilio, MR | 1 |
| Vickery, PB | 1 |
| Tillery, EE | 1 |
| DeFalco, AP | 1 |
| Maiti, R | 2 |
| Mishra, BR | 2 |
| Sanyal, S | 1 |
| Mohapatra, D | 1 |
| Parida, S | 1 |
| Mishra, A | 2 |
| Häfele, CA | 1 |
| Freitas, MP | 1 |
| Gervini, BL | 1 |
| de Carvalho, RM | 1 |
| Rombaldi, AJ | 1 |
| Jing, C | 1 |
| Sun, L | 1 |
| Wang, Z | 2 |
| Chu, C | 1 |
| Lin, W | 1 |
| Popławska, M | 1 |
| Mahmoud, SH | 1 |
| Buxton, J | 1 |
| Qin, J | 2 |
| Wang, Y | 3 |
| Huang, XF | 1 |
| Zhang, YQ | 1 |
| Fang, F | 3 |
| Chen, YB | 1 |
| Lin, ZD | 1 |
| Deng, YC | 1 |
| Yin, F | 1 |
| Jiang, L | 1 |
| Wu, Y | 2 |
| Hu, XS | 1 |
| Ho, KS | 1 |
| Markham, LM | 1 |
| Twede, H | 1 |
| Lortz, A | 1 |
| Olson, LM | 1 |
| Sheng, X | 1 |
| Weng, C | 1 |
| Wassman, ER | 2 |
| Newcomb, T | 1 |
| Carey, JC | 1 |
| Battaglia, A | 1 |
| Shorvon, SD | 1 |
| Bermejo, PE | 1 |
| Gibbs, AA | 1 |
| Huberfeld, G | 1 |
| Kälviäinen, R | 1 |
| Higashida, K | 1 |
| Yamagami, H | 1 |
| Tomari, S | 1 |
| Fukuma, K | 1 |
| Okuno, Y | 1 |
| Abe, S | 1 |
| Nagatsuka, K | 1 |
| Toyoda, K | 1 |
| Ihara, M | 1 |
| Dagiasi, I | 1 |
| Vall, V | 1 |
| Kumlien, E | 1 |
| Burman, J | 1 |
| Zelano, J | 1 |
| Shakir, S | 1 |
| Ali, N | 1 |
| Nazish, H | 1 |
| Chemaly, N | 1 |
| Nehlig, A | 1 |
| Chiron, C | 1 |
| Nabbout, R | 1 |
| Thangaratinam, S | 1 |
| Marlin, N | 1 |
| Newton, S | 1 |
| Weckesser, A | 1 |
| Bagary, M | 1 |
| Greenhill, L | 1 |
| Rikunenko, R | 1 |
| D'Amico, M | 1 |
| Rogozińska, E | 1 |
| Kelso, A | 1 |
| Hard, K | 1 |
| Coleman, J | 1 |
| Moss, N | 1 |
| Roberts, T | 1 |
| Middleton, L | 1 |
| Dodds, J | 1 |
| Pullen, A | 1 |
| Eldridge, S | 1 |
| Pirie, A | 1 |
| Denny, E | 1 |
| McCorry, D | 1 |
| Khan, KS | 1 |
| Xu, W | 1 |
| Chen, YL | 1 |
| Zhao, Y | 1 |
| Wang, LJ | 1 |
| Li, JJ | 1 |
| Liu, CF | 1 |
| Alam, M | 1 |
| Haq, MAU | 1 |
| Ali, F | 1 |
| Mehwish, H | 1 |
| Nawab, K | 1 |
| Arya, R | 2 |
| Giridharan, N | 1 |
| Anand, V | 2 |
| Garg, SK | 2 |
| Sathyaprabha, TN | 1 |
| Koot, LAM | 1 |
| Hermans, BHM | 1 |
| Adoor, M | 1 |
| Sinha, S | 1 |
| Kramer, BW | 1 |
| Raju, TR | 1 |
| Satishchandra, P | 1 |
| Delhaas, T | 1 |
| Jena, M | 1 |
| Nath, S | 1 |
| Srinivasan, A | 1 |
| Elmowafy, M | 1 |
| Shalaby, K | 1 |
| Badran, MM | 1 |
| Ali, HM | 1 |
| Abdel-Bakky, MS | 1 |
| Ibrahim, HM | 1 |
| Abou-Khalil, B | 1 |
| Klein, P | 1 |
| Shah, A | 1 |
| Specchio, LM | 1 |
| Gama, H | 1 |
| Rocha, F | 1 |
| Blum, D | 1 |
| Grinnell, T | 1 |
| Cheng, H | 1 |
| Jung, J | 1 |
| Mróz, K | 1 |
| Mróz, T | 1 |
| Buszewicz, G | 1 |
| Aebisher, D | 1 |
| Bartusik-Aebisher, D | 1 |
| Sawicka, KM | 1 |
| Wawryniuk, A | 1 |
| Daniluk, J | 2 |
| Karwan, S | 3 |
| Zhang, L | 2 |
| Zhu, X | 1 |
| Zou, X | 1 |
| Chen, L | 1 |
| Hill, AC | 1 |
| Thomson, KE | 1 |
| Newell, TG | 1 |
| Yang, H | 1 |
| Zhang, R | 1 |
| Jia, C | 1 |
| Chen, M | 1 |
| Yin, W | 1 |
| Wei, L | 1 |
| Jiao, H | 1 |
| Tanabe, Y | 1 |
| Taira, T | 1 |
| Shimotake, A | 1 |
| Inoue, T | 1 |
| Awaya, T | 1 |
| Kato, T | 1 |
| Kuzuya, A | 1 |
| Ikeda, A | 3 |
| Takahashi, R | 1 |
| Grabenstatter, HL | 2 |
| Marzeda, P | 1 |
| Gut-Lepiech, A | 1 |
| Kondrat-Wróbel, MW | 2 |
| Forouzesh, M | 1 |
| Eidi, H | 1 |
| Mirzaghafour, SE | 1 |
| Reimers, A | 1 |
| Ljung, H | 1 |
| Mir, A | 1 |
| Chaudhary, M | 1 |
| Alkhaldi, H | 1 |
| Alhazmi, R | 1 |
| Albaradie, R | 1 |
| Housawi, Y | 1 |
| Nolan, SJ | 2 |
| Pulman, J | 2 |
| Wilson, KL | 1 |
| Alexander, JM | 1 |
| Agostinelli, S | 1 |
| Prezioso, G | 1 |
| Coppola, G | 1 |
| Capovilla, G | 1 |
| Romeo, A | 1 |
| Parisi, P | 2 |
| Grosso, S | 1 |
| Spalice, A | 2 |
| Foiadelli, T | 1 |
| Curatolo, P | 1 |
| Chiarelli, F | 1 |
| Savasta, S | 2 |
| Varade, P | 1 |
| Rayes, M | 1 |
| Basha, M | 1 |
| Watson, C | 1 |
| Planjar-Prvan, M | 1 |
| Bielen, A | 1 |
| Sruk, A | 1 |
| Marusić, M | 1 |
| Bielen, I | 1 |
| Vilibić, M | 1 |
| Jukić, V | 1 |
| Vidović, A | 1 |
| Brecić, P | 1 |
| Ferraria, N | 1 |
| Castro, S | 1 |
| Amaral, D | 1 |
| Lopes, L | 1 |
| Karlov, VA | 1 |
| Geĭbatova, LG | 1 |
| Battino, D | 1 |
| Bonizzoni, E | 1 |
| Craig, J | 1 |
| Lindhout, D | 1 |
| Sabers, A | 2 |
| Vajda, F | 1 |
| Nakano, K | 1 |
| Kobayashi, K | 1 |
| Maniwa, S | 1 |
| Kodani, N | 1 |
| Ohtsuka, Y | 2 |
| Zheng, Y | 1 |
| Cao, X | 1 |
| Liu, DC | 1 |
| Shu, B | 1 |
| Teng, P | 1 |
| Tan, B | 1 |
| Atanasković-Marković, M | 1 |
| Medjo, B | 1 |
| Gavrović-Jankulović, M | 1 |
| Ćirković Veličković, T | 1 |
| Nikolić, D | 1 |
| Nestorović, B | 1 |
| Luszczki, JJ | 28 |
| Wlaz, A | 2 |
| Florek-Luszczki, M | 4 |
| Jeffrey, M | 1 |
| Lang, M | 1 |
| Gane, J | 1 |
| Chow, E | 1 |
| Wu, C | 1 |
| Habib, M | 1 |
| Khan, SU | 1 |
| Hoque, A | 1 |
| Mondal, BA | 1 |
| Hasan, AT | 1 |
| Chowdhury, RN | 1 |
| Haque, B | 1 |
| Rahman, KM | 1 |
| Chowdhury, AH | 1 |
| Ghose, SK | 1 |
| Mohammad, QD | 1 |
| Patel, V | 1 |
| Cordato, DJ | 1 |
| Malkan, A | 1 |
| Beran, RG | 3 |
| Kenyon, K | 1 |
| Mintzer, S | 2 |
| Nei, M | 2 |
| Franco, V | 1 |
| Iudice, A | 1 |
| Grillo, E | 1 |
| Citraro, R | 3 |
| De Sarro, G | 3 |
| Russo, E | 3 |
| Markoula, S | 1 |
| Teotonio, R | 1 |
| Ratnaraj, N | 4 |
| Duncan, JS | 2 |
| Patsalos, PN | 4 |
| Stepanova, D | 1 |
| Heerey, A | 1 |
| Nash, P | 1 |
| Hennessy, M | 1 |
| Vydrova, R | 1 |
| Kršek, P | 1 |
| Kyncl, M | 1 |
| Jahodova, A | 1 |
| Dvorak, J | 1 |
| Komarek, V | 1 |
| Delalande, O | 1 |
| Tichy, M | 1 |
| Wang, P | 1 |
| Zhou, Q | 1 |
| Sheng, Y | 1 |
| Tang, B | 1 |
| Liu, Z | 1 |
| Zhou, B | 1 |
| Wijesurendra, RS | 1 |
| Carey, M | 1 |
| Butterworth, RJ | 1 |
| Khiani, R | 1 |
| Budetta, M | 1 |
| Spartà, MV | 1 |
| Carpentieri, ML | 1 |
| Trasimeni, G | 1 |
| Zavras, N | 1 |
| Villa, MP | 1 |
| Imataka, G | 1 |
| Arisaka, O | 1 |
| Matsumura, N | 1 |
| Nakaki, T | 1 |
| Iuchi, T | 1 |
| Hasegawa, Y | 1 |
| Kawasaki, K | 1 |
| Sakaida, T | 1 |
| Michael, BD | 1 |
| Segundo, JB | 1 |
| da Silva, MA | 1 |
| Filho, WE | 1 |
| Nascimento, AC | 1 |
| Vidal, FC | 1 |
| Bezerra, GF | 1 |
| Viana, GM | 1 |
| Nascimento, Mdo D | 1 |
| Shazadi, K | 1 |
| Petrovski, S | 1 |
| Roten, A | 1 |
| Miller, H | 1 |
| Huggins, RM | 1 |
| Brodie, MJ | 4 |
| Pirmohamed, M | 1 |
| Johnson, MR | 1 |
| Sills, GJ | 1 |
| Aggarwal, R | 1 |
| Sharma, M | 2 |
| Modi, M | 1 |
| Garg, VK | 1 |
| Salaria, M | 1 |
| Hanrath, MA | 1 |
| Swart, EL | 1 |
| Klein, S | 1 |
| Bankstahl, M | 1 |
| Löscher, W | 8 |
| Topcu, H | 1 |
| Gokcinar, D | 1 |
| Akcaboy, ZN | 1 |
| Karabeyoglu, I | 1 |
| Unal, T | 1 |
| Shen, H | 1 |
| Wu, T | 1 |
| Wang, J | 1 |
| Ren, C | 1 |
| Chen, H | 1 |
| Don, W | 1 |
| Zolkowska, D | 3 |
| Prisinzano, TE | 1 |
| Baumann, MH | 1 |
| Cranley, MR | 1 |
| Craner, M | 1 |
| McGilloway, E | 1 |
| Ali, R | 1 |
| Kania, K | 1 |
| Niśkiewicz, I | 1 |
| Wierzbicka-Wichniak, A | 1 |
| Kozubski, W | 1 |
| Tokarz-Kupczyk, E | 1 |
| Gefroh-Grimes, HA | 1 |
| Gidal, BE | 1 |
| Pyrka, D | 2 |
| Glowniak, K | 1 |
| Glensk, M | 1 |
| Snoeijen-Schouwenaars, FM | 1 |
| Veendrick, MJ | 1 |
| van Mierlo, P | 1 |
| van Erp, G | 1 |
| de Louw, AJ | 1 |
| Kleine, BU | 1 |
| Schelhaas, HJ | 1 |
| Tan, IY | 1 |
| Leclercq, K | 1 |
| Kaminski, RM | 2 |
| Zeng, QY | 1 |
| Fan, TT | 1 |
| Zhu, P | 1 |
| He, RQ | 1 |
| Bao, YX | 1 |
| Zheng, RY | 1 |
| Xu, HQ | 1 |
| Huang, YH | 1 |
| Chi, NF | 1 |
| Kuan, YC | 1 |
| Chan, L | 1 |
| Hu, CJ | 1 |
| Chiou, HY | 1 |
| Chien, LN | 1 |
| Janszky, J | 2 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Shi, XY | 1 |
| Tomonoh, Y | 1 |
| Wang, WZ | 1 |
| Ishii, A | 1 |
| Higurashi, N | 1 |
| Kurahashi, H | 1 |
| Kaneko, S | 2 |
| Hirose, S | 1 |
| Lerche, H | 1 |
| Lotay, N | 1 |
| DeRossett, S | 1 |
| Edwards, S | 1 |
| Brandt, C | 1 |
| Faux, BM | 1 |
| Suhr, AW | 1 |
| Hsieh, DT | 1 |
| Singh, T | 1 |
| Mathew, A | 1 |
| Chen, CY | 1 |
| Xiao, F | 1 |
| Liu, JL | 1 |
| Lee, SA | 2 |
| Kim, MJ | 1 |
| Lee, HW | 1 |
| Heo, K | 2 |
| Shin, DJ | 1 |
| Song, HK | 2 |
| Kim, OJ | 1 |
| Kim, SO | 1 |
| Lee, BI | 2 |
| Malik, Y | 1 |
| Dar, JA | 1 |
| Almadani, AA | 1 |
| Ramachandren, TK | 1 |
| Petrilli, RM | 1 |
| Piskorska, B | 1 |
| Abou-Khalil, BW | 3 |
| Świąder, MJ | 1 |
| Barczyński, B | 1 |
| Tomaszewski, M | 2 |
| Świąder, K | 1 |
| Pontes, JC | 1 |
| Lima, TZ | 1 |
| Queiroz, CM | 1 |
| Cinini, SM | 1 |
| Blanco, MM | 1 |
| Mello, LE | 1 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Pohlmann-Eden, B | 1 |
| Noack-Rink, M | 1 |
| Ramirez, F | 1 |
| Tofighy, A | 1 |
| Werhahn, KJ | 1 |
| Wild, I | 1 |
| Trinka, E | 1 |
| Khishfe, BF | 1 |
| Patrzylas, P | 1 |
| Szpringer, M | 1 |
| Żółkowska, D | 2 |
| Wieshmann, UC | 1 |
| Baker, G | 1 |
| Acikgoz, M | 1 |
| Paksu, MS | 1 |
| Guzel, A | 1 |
| Alacam, A | 1 |
| Alacam, F | 1 |
| Higuchi, Y | 1 |
| Kubo, T | 1 |
| Mitsuhashi, T | 1 |
| Nakamura, N | 1 |
| Yokota, I | 1 |
| Komiyama, O | 1 |
| Kamimaki, I | 1 |
| Yamamoto, S | 2 |
| Uchida, Y | 1 |
| Watanabe, K | 1 |
| Yamashita, H | 1 |
| Tanaka, S | 1 |
| Iguchi, K | 1 |
| Ichimi, R | 1 |
| Miyagawa, S | 1 |
| Takayanagi, T | 1 |
| Koga, H | 1 |
| Shukuya, A | 1 |
| Saito, A | 1 |
| Horibe, K | 1 |
| Takeuchi, M | 1 |
| Yano, I | 1 |
| Ito, S | 2 |
| Sugimoto, M | 2 |
| Yonezawa, A | 1 |
| Matsubara, K | 1 |
| León Ruiz, M | 1 |
| Rodríguez Sarasa, ML | 1 |
| Sanjuán Rodríguez, L | 1 |
| Pérez Nieves, MT | 1 |
| Ibáñez Estéllez, F | 1 |
| Arce Arce, S | 1 |
| García-Albea Ristol, E | 1 |
| Benito-León, J | 1 |
| Bernardo, S | 1 |
| Marchionni, E | 1 |
| Prudente, S | 1 |
| De Liso, P | 1 |
| Giancotti, A | 1 |
| Manganaro, L | 1 |
| Pizzuti, A | 1 |
| Mäkinen, J | 1 |
| Rainesalo, S | 1 |
| Raitanen, J | 2 |
| Peltola, J | 2 |
| Yang, Z | 1 |
| Liu, X | 1 |
| Zhang, Y | 1 |
| Bao, X | 1 |
| Chang, X | 1 |
| Wang, S | 2 |
| Xiong, H | 1 |
| Sun, MZ | 2 |
| Deckers, CL | 1 |
| Liu, YX | 2 |
| Wade, JF | 1 |
| Dang, CV | 1 |
| Nelson, L | 1 |
| Wasserberger, J | 1 |
| Wu, JZ | 1 |
| Güven, H | 1 |
| Delibaş, S | 1 |
| Comoğlu, SS | 1 |
| D'Orazio, JL | 1 |
| Nekrassov, V | 2 |
| Sitges, M | 2 |
| Clinckers, R | 2 |
| Smolders, I | 3 |
| Michotte, Y | 3 |
| Ebinger, G | 3 |
| Danhof, M | 2 |
| Voskuyl, RA | 2 |
| Harden, CL | 2 |
| Sethi, NK | 1 |
| Bring, P | 1 |
| Ensom, MH | 1 |
| Nishimura, A | 1 |
| Honda, N | 1 |
| Sugioka, N | 1 |
| Takada, K | 1 |
| Shibata, N | 1 |
| Bondarenko, II | 2 |
| Muncy, J | 1 |
| Butler, IJ | 1 |
| Koenig, MK | 1 |
| Galimberti, CA | 1 |
| Ossola, M | 1 |
| Colnaghi, S | 1 |
| Arbasino, C | 1 |
| Motoyama, M | 1 |
| Ichiyama, T | 2 |
| Matsushige, T | 1 |
| Kajimoto, M | 1 |
| Shiraishi, M | 1 |
| Furukawa, S | 2 |
| Leśkiewicz, M | 1 |
| Budziszewska, B | 1 |
| Lasoń, W | 1 |
| Palmero, ML | 1 |
| Pope, E | 1 |
| Petrenaite, V | 1 |
| Hansen-Schwartz, J | 1 |
| Tayal, V | 1 |
| Kalra, BS | 1 |
| Chawla, S | 1 |
| George, J | 1 |
| Rose, D | 1 |
| Hazrati, LN | 1 |
| Majl, L | 1 |
| Hodaie, M | 1 |
| Alfaro-Rodríguez, A | 3 |
| González-Piña, R | 3 |
| Arch-Tirado, E | 2 |
| Carrasco-Portugal, M | 1 |
| Pérez-Guillé, B | 1 |
| Soriano-Rosales, RE | 1 |
| Padilla-Martin, K | 1 |
| Uribe-Escamilla, R | 3 |
| Labra-Ruiz, N | 1 |
| Höcht, C | 1 |
| Lazarowski, A | 1 |
| Gonzalez, NN | 1 |
| Mayer, MA | 1 |
| Opezzo, JA | 1 |
| Taira, CA | 1 |
| Girardi, E | 1 |
| van Breemen, MS | 1 |
| Rijsman, RM | 1 |
| Taphoorn, MJ | 1 |
| Walchenbach, R | 1 |
| Zwinkels, H | 1 |
| Vecht, CJ | 1 |
| Del Felice, A | 1 |
| Zanoni, T | 1 |
| Avesani, M | 1 |
| Formaggio, E | 1 |
| Storti, S | 1 |
| Fiaschi, A | 1 |
| Moretto, G | 1 |
| Manganotti, P | 1 |
| Kocharov, SL | 2 |
| Castro-Gago, M | 2 |
| Gómez-Lado, C | 2 |
| Eirís-Puñal, J | 1 |
| Díaz-Mayo, I | 1 |
| Castiñeiras-Ramos, DE | 2 |
| Yiannopoulou, KG | 1 |
| Kounenou, D | 1 |
| Papageorgiou, CC | 1 |
| Ma, MS | 2 |
| Ding, YX | 2 |
| Ying, W | 1 |
| Ding, CH | 2 |
| Zou, LP | 2 |
| Sogawa, Y | 1 |
| Kan, L | 1 |
| Levy, AS | 1 |
| Maytal, J | 1 |
| Shinnar, S | 1 |
| D'Antuono, M | 1 |
| Köhling, R | 1 |
| Ricalzone, S | 1 |
| Gotman, J | 1 |
| Biagini, G | 1 |
| Avoli, M | 1 |
| Asnis, D | 1 |
| Kazakov, J | 1 |
| Toronjadze, T | 1 |
| Bern, C | 1 |
| Garcia, HH | 1 |
| McAuliffe, I | 1 |
| Bishop, H | 1 |
| Lee, L | 1 |
| Grossmann, R | 1 |
| Garcia, MA | 1 |
| Di John, D | 1 |
| Swiderska, G | 1 |
| Fujiwara, A | 1 |
| Watanabe, Y | 1 |
| Takechi, K | 2 |
| Ishikawa, T | 3 |
| Kaida, Y | 1 |
| Akagi, M | 1 |
| Kamei, C | 2 |
| Akula, KK | 1 |
| Dhir, A | 1 |
| Kulkarni, SK | 2 |
| Arora, T | 1 |
| Mehta, AK | 1 |
| Sharma, KK | 2 |
| Mediratta, PK | 2 |
| Banerjee, BD | 1 |
| Garg, GR | 1 |
| Sharma, AK | 1 |
| Wang, K | 1 |
| Xu, Z | 1 |
| Xiong, G | 1 |
| Benyan, L | 1 |
| Mula, M | 1 |
| Tanabe, T | 1 |
| Okumura, A | 1 |
| Komatsu, M | 1 |
| Kubota, T | 2 |
| Nakajima, M | 1 |
| Shimakawa, S | 1 |
| Kim, WJ | 1 |
| Kim, SE | 1 |
| No, SK | 1 |
| D'Aleo, G | 1 |
| Rifici, C | 1 |
| Kofler, M | 1 |
| Sessa, E | 1 |
| Saltuari, L | 1 |
| Bramanti, P | 1 |
| Meng, LL | 1 |
| Filip, D | 1 |
| Flesler, S | 1 |
| Sakr, D | 1 |
| Cersósimo, R | 1 |
| Caraballo, R | 1 |
| Cioczek, JD | 1 |
| Kominek, M | 1 |
| Bondareva, IB | 2 |
| Jelliffe, RW | 2 |
| Andreeva, OV | 1 |
| Bondareva, KI | 1 |
| Oguni, H | 1 |
| Gifford, RM | 1 |
| Post, RM | 14 |
| Weiss, SR | 12 |
| Misiuta-Krzesinska, M | 1 |
| Florek, M | 1 |
| Agarwal, NB | 1 |
| Agarwal, NK | 1 |
| De Reuck, J | 1 |
| Balogh, A | 1 |
| Szentesi, A | 1 |
| Jánosi, I | 1 |
| Scicchitano, F | 2 |
| De Fazio, S | 2 |
| Raggio, R | 1 |
| Mainardi, P | 1 |
| Andrade, DM | 1 |
| Tai, P | 1 |
| Dalmau, J | 1 |
| Wennberg, R | 1 |
| Dicaire, C | 1 |
| Bérubé, ER | 1 |
| Dumont, I | 1 |
| Furtado, M | 1 |
| Garofolo, F | 1 |
| Perrotta, I | 1 |
| Perrota, I | 1 |
| Di Paola, ED | 1 |
| Constanti, A | 1 |
| Pérez-Gay, L | 1 |
| Otero-Martínez, S | 1 |
| Rodríguez-Segade, S | 2 |
| Elger, C | 1 |
| Halász, P | 1 |
| Falcão, A | 1 |
| Almeida, L | 1 |
| Ramakrishnan, L | 1 |
| Desaer, C | 1 |
| Bueno-Nava, A | 1 |
| Ávila-Luna, A | 1 |
| Vargas-Sánchez, J | 1 |
| Karmon, Y | 1 |
| Inbar, E | 1 |
| Gadoth, N | 1 |
| Sarkar, A | 1 |
| Dejesus, M | 1 |
| Bellamy, B | 1 |
| Newton, HB | 1 |
| Lo, SS | 1 |
| Toledo, M | 1 |
| Munuera, J | 1 |
| Salas-Puig, X | 1 |
| Santamarina, E | 1 |
| Lacuey, N | 1 |
| Rovira, A | 1 |
| Keezer, MR | 1 |
| Saint-Hilaire, JM | 1 |
| Nguyen, DK | 1 |
| Enkiri, SA | 1 |
| Ghavami, F | 1 |
| Anyanwu, C | 1 |
| Eldadah, Z | 1 |
| Morrissey, RL | 1 |
| Motamedi, GK | 1 |
| Lyseng-Williamson, KA | 1 |
| Stepien, KM | 1 |
| Ali, A | 1 |
| Dua, Y | 1 |
| Constance, JE | 1 |
| Franklin, MR | 1 |
| Degruyter, MA | 1 |
| Cook, MJ | 1 |
| Milia, A | 1 |
| Pilia, G | 1 |
| Mascia, MG | 1 |
| Firinu, S | 1 |
| Ozaras, N | 1 |
| Goksugur, N | 1 |
| Eroglu, S | 1 |
| Tabak, O | 1 |
| Canbakan, B | 1 |
| Ozaras, R | 1 |
| Cansu, A | 1 |
| Serdaroglu, A | 1 |
| Biberoglu, G | 1 |
| Tumer, L | 1 |
| Hirfanoglu, TL | 1 |
| Ezgu, FS | 1 |
| Hasanoglu, A | 1 |
| Katyal, J | 1 |
| Sarangal, V | 1 |
| Gupta, YK | 3 |
| Zhou, BT | 1 |
| Zhou, QH | 1 |
| Yin, JY | 1 |
| Li, GL | 1 |
| Xu, XJ | 1 |
| Qu, J | 1 |
| Liu, D | 1 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Taher, AT | 1 |
| Arabi, M | 1 |
| Sibai, H | 1 |
| Nasreddine, W | 1 |
| Otrock, ZK | 1 |
| Musallam, KM | 1 |
| Beydoun, A | 1 |
| Tang, X | 1 |
| Zhang, X | 1 |
| Grover, S | 1 |
| Birnbaum, AK | 1 |
| Conway, JM | 1 |
| Strege, MA | 1 |
| Leppik, IE | 5 |
| Rosemergy, I | 1 |
| Bergin, P | 1 |
| Jones, P | 1 |
| Walker, E | 1 |
| Szűcs, A | 1 |
| Rásonyi, G | 1 |
| Orbay, P | 1 |
| Sólyom, A | 1 |
| Holló, A | 1 |
| Arányi, Z | 1 |
| Erőss, L | 1 |
| Kamondi, A | 1 |
| Nair, R | 1 |
| Kumar, AC | 1 |
| Priya, VK | 1 |
| Yadav, CM | 1 |
| Raju, PY | 1 |
| Samia, P | 1 |
| Petersen, R | 1 |
| Walker, KG | 1 |
| Eley, B | 1 |
| Wilmshurst, JM | 1 |
| Korff, CM | 1 |
| Vulliemoz, S | 1 |
| Picard, F | 1 |
| Fluss, J | 1 |
| Park, HJ | 1 |
| Kim, SK | 1 |
| Chung, JH | 1 |
| Kim, JW | 1 |
| Venci, JV | 1 |
| Rowcliffe, MM | 1 |
| Wollenberg, L | 1 |
| Rainka, MM | 1 |
| Gengo, FM | 1 |
| Wang, SP | 1 |
| Skidmore, CT | 1 |
| Zhan, T | 1 |
| Stuckert, E | 1 |
| Sperling, MR | 1 |
| Beghi, E | 1 |
| Corradini, I | 1 |
| Donzelli, A | 1 |
| Antonucci, F | 1 |
| Welzl, H | 1 |
| Loos, M | 1 |
| Martucci, R | 1 |
| De Astis, S | 1 |
| Pattini, L | 1 |
| Inverardi, F | 1 |
| Wolfer, D | 1 |
| Caleo, M | 1 |
| Bozzi, Y | 1 |
| Verderio, C | 1 |
| Frassoni, C | 1 |
| Braida, D | 1 |
| Clerici, M | 1 |
| Lipp, HP | 1 |
| Sala, M | 1 |
| Matteoli, M | 1 |
| Pahuja, M | 1 |
| Kleekal, T | 1 |
| Reeta, KH | 1 |
| Tripathi, M | 1 |
| Consoli, D | 1 |
| Bosco, D | 1 |
| Postorino, P | 1 |
| Galati, F | 1 |
| Plastino, M | 1 |
| Perticoni, GF | 1 |
| Ottonello, GA | 1 |
| Passarella, B | 1 |
| Ricci, S | 1 |
| Neri, G | 1 |
| Toni, D | 1 |
| Illing, PT | 1 |
| Vivian, JP | 1 |
| Purcell, AW | 1 |
| Rossjohn, J | 1 |
| McCluskey, J | 1 |
| Aldana, BI | 1 |
| Gómez, CD | 1 |
| Yu, W | 1 |
| Calos, M | 1 |
| Pilitsis, J | 1 |
| Shin, DS | 1 |
| Akhavan-Sigari, R | 1 |
| Rohde, V | 1 |
| Abili, M | 1 |
| Thussu, A | 3 |
| Arora, A | 1 |
| Prabhakar, S | 2 |
| Lal, V | 1 |
| Sawhney, IM | 2 |
| von Einsiedel, RW | 1 |
| Roesch-Ely, D | 1 |
| Diebold, K | 1 |
| Sartor, K | 1 |
| Mundt, C | 1 |
| Bergemann, N | 1 |
| van Rijn, CM | 1 |
| Wang, Mz | 1 |
| Yamazaki, S | 1 |
| Mochizuki, Y | 1 |
| Terai, T | 1 |
| Uchida, I | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Premachandra, BN | 1 |
| Radparvar, A | 1 |
| Burman, K | 1 |
| Williams, IK | 1 |
| Oto, M | 1 |
| Russell, AJ | 1 |
| McGonigal, A | 1 |
| Duncan, R | 1 |
| Girija, AS | 1 |
| Al-Twajri, WA | 1 |
| Shevell, MI | 1 |
| Privitera, MD | 1 |
| Mattson, RH | 4 |
| Chadwick, DW | 3 |
| Neto, W | 1 |
| Venugopalan, P | 1 |
| Al-Anqoudi, ZA | 1 |
| Al-Maamari, WS | 1 |
| Schmidt, D | 1 |
| Smith, BW | 1 |
| Burton, KJ | 1 |
| Allen, S | 1 |
| Dogu, O | 1 |
| Sevim, S | 1 |
| Kaleagasi, HS | 1 |
| JONGMANS, JW | 1 |
| HAJNSEK, F | 1 |
| SARTORIUS, N | 1 |
| Gül, U | 1 |
| Kiliç, A | 1 |
| Dursun, A | 1 |
| Chapman, K | 1 |
| Holland, K | 1 |
| Erenberg, G | 1 |
| Zeller, A | 1 |
| Schaub, N | 1 |
| Steffen, I | 1 |
| Battegay, E | 1 |
| Hirsch, HH | 1 |
| Bircher, AJ | 1 |
| Rabinovitz, S | 1 |
| Mostofsky, DI | 1 |
| Yehuda, S | 1 |
| Deering, SH | 1 |
| Thompson, K | 1 |
| Taylor, J | 1 |
| Hueppchen, N | 1 |
| Hogan, RE | 1 |
| Garnett, WR | 1 |
| Thadani, VM | 1 |
| Gelisse, P | 1 |
| Thomas, P | 1 |
| Padovani, R | 1 |
| Hassan-Sebbag, N | 1 |
| Pasquier, J | 1 |
| Genton, P | 1 |
| Kaminow, L | 1 |
| Schimschock, JR | 1 |
| Hammer, AE | 1 |
| Vuong, A | 1 |
| Kaufman, KR | 1 |
| Gerner, R | 1 |
| Parmeggiani, L | 1 |
| Seri, S | 1 |
| Bonanni, P | 1 |
| Guerrini, R | 1 |
| Misra, UK | 1 |
| Kalita, J | 1 |
| Rathore, C | 1 |
| Affolter, N | 1 |
| Krähenbühl, S | 1 |
| Schlienger, RG | 1 |
| Kozicka, M | 1 |
| Kleinrok, Z | 14 |
| Marsden, D | 1 |
| Libretto, SE | 1 |
| Hsu, D | 1 |
| Sandborg, C | 1 |
| Hahn, JS | 1 |
| Rasmussen, M | 1 |
| Kara, NN | 1 |
| Wakamoto, H | 1 |
| Kume, A | 1 |
| Nakano, N | 1 |
| Duman, O | 1 |
| Balta, G | 1 |
| Metinsoy, M | 1 |
| Haspolat, S | 1 |
| Borowicz, KK | 12 |
| Rwiader, M | 1 |
| Drelewska, E | 1 |
| Arban, R | 1 |
| Maraia, G | 1 |
| Brackenborough, K | 1 |
| Winyard, L | 1 |
| Wilson, A | 1 |
| Gerrard, P | 1 |
| Large, C | 1 |
| Smith, CT | 1 |
| Williamson, PR | 2 |
| Jedrzejczak, J | 1 |
| Uji, M | 1 |
| Sugama, Y | 1 |
| Matsushita, H | 1 |
| Wang-Tilz, Y | 1 |
| Tilz, C | 1 |
| Wang, B | 1 |
| Pauli, E | 2 |
| Koebnick, C | 1 |
| Stefan, H | 2 |
| Schiavino, D | 1 |
| Nucera, E | 1 |
| Buonomo, A | 1 |
| Musumeci, S | 1 |
| Pollastrini, E | 1 |
| Roncallo, C | 1 |
| Lombardo, C | 1 |
| Alonzi, C | 1 |
| Pecora, V | 1 |
| Corradini, C | 1 |
| De Pasquale, T | 1 |
| Patriarca, G | 1 |
| Meurs, A | 1 |
| Andres, MM | 2 |
| Montouris, G | 1 |
| Stoner, SC | 1 |
| Lea, JW | 1 |
| Wolf, AL | 1 |
| Berges, AA | 1 |
| Aggarwal, A | 1 |
| Kumar, M | 1 |
| Faridi, MM | 1 |
| Li, Q | 1 |
| Jin, CL | 1 |
| Xu, LS | 1 |
| Zhu-Ge, ZB | 1 |
| Yang, LX | 1 |
| Liu, LY | 1 |
| Sheridan, RL | 1 |
| Liu, V | 1 |
| Anupindi, S | 1 |
| Matsufuji, H | 1 |
| Suenaga, N | 1 |
| Nishikawa, M | 1 |
| Hayashi, T | 1 |
| Ab Rahman, AF | 1 |
| Ibrahim, MI | 1 |
| Ismail, HI | 1 |
| Seng, TB | 1 |
| Mise, S | 2 |
| Jukić, I | 1 |
| Tonkić, A | 1 |
| Titlić, M | 1 |
| Mohamed, M | 1 |
| Czuczwar, P | 1 |
| Cioczek-Czuczwar, A | 1 |
| Sakai, Y | 1 |
| Kira, R | 1 |
| Torisu, H | 1 |
| Yasumoto, S | 1 |
| Saito, M | 2 |
| Kusuhara, K | 1 |
| Hara, T | 1 |
| Tuncer, N | 1 |
| Yayci, N | 1 |
| Ekinci, G | 1 |
| Inanici, MA | 1 |
| Elmaci, I | 1 |
| Kikumoto, K | 1 |
| Yoshinaga, H | 1 |
| Ito, M | 1 |
| Endoh, F | 1 |
| Akiyama, T | 1 |
| Nedelman, JR | 1 |
| Rubin, DB | 1 |
| Sheiner, LB | 1 |
| Gamble, C | 1 |
| Fischer, L | 1 |
| Korfel, A | 1 |
| Stoltenburg-Didinger, G | 1 |
| Ransco, C | 1 |
| Thiel, E | 1 |
| Gusev, EI | 1 |
| Guekht, AB | 1 |
| Melikyan, EG | 1 |
| Belousov, YB | 1 |
| Mauro, AM | 1 |
| Bomprezzi, C | 1 |
| Morresi, S | 1 |
| Formica, F | 1 |
| Iacoangeli, M | 1 |
| Scerrati, M | 1 |
| Durmaz, C | 1 |
| Tulgar Kinik, S | 1 |
| Ozyürek, E | 1 |
| Erol, I | 1 |
| Canan, O | 1 |
| Alehan, F | 1 |
| Novelli, A | 1 |
| Groppetti, A | 1 |
| Rossoni, G | 1 |
| Manfredi, B | 1 |
| Ferrero-Gutiérrez, A | 1 |
| Pérez-Gómez, A | 1 |
| Desogus, CM | 1 |
| Fernández-Sánchez, MT | 1 |
| Del Giudice, E | 2 |
| Bianchi, MC | 1 |
| Tosetti, M | 1 |
| Varrone, A | 1 |
| Romano, A | 1 |
| Crisanti, AF | 1 |
| Titomanlio, L | 1 |
| Imperati, F | 1 |
| Barzegar-Jalali, M | 1 |
| Nayebi, AM | 1 |
| Valizadeh, H | 1 |
| Hanaee, J | 1 |
| Barzegar-Jalali, A | 1 |
| Adibkia, K | 1 |
| Anoush, M | 1 |
| Sistanizad, M | 1 |
| Palmieri, A | 1 |
| den Heijer, T | 1 |
| Boon, AJ | 1 |
| Mota-Rojas, D | 1 |
| Sánchez-Aparicio, P | 1 |
| Alonso-Spilsbury, M | 1 |
| Manent, JB | 1 |
| Jorquera, I | 1 |
| Mazzucchelli, I | 1 |
| Depaulis, A | 3 |
| Ben-Ari, Y | 1 |
| Represa, A | 1 |
| Murakami, A | 1 |
| Ago, J | 1 |
| Matsumoto, N | 1 |
| Furmanek-Karwowska, K | 2 |
| Sawicka, K | 1 |
| Jaszczyk, B | 1 |
| Malek, R | 1 |
| Blanchard, C | 1 |
| Nicolas, X | 1 |
| Zagnoli, F | 1 |
| Granier, H | 1 |
| Talarmin, F | 1 |
| Bellard, S | 1 |
| Morawska, M | 1 |
| Zarczuk, R | 1 |
| Lukasik, D | 1 |
| Avner, M | 1 |
| Finkelstein, Y | 1 |
| Hackam, D | 1 |
| Koren, G | 2 |
| Clark, S | 1 |
| Misirlioğlu, ED | 1 |
| Aliefendioğlu, D | 1 |
| Doğru, MT | 1 |
| Sanli, C | 1 |
| Oktay, A | 1 |
| Peltola, M | 1 |
| Keränen, T | 1 |
| Kharazmi, E | 1 |
| Auvinen, A | 1 |
| Chattopadhyay, A | 1 |
| Khandelwal, N | 1 |
| Cerar, D | 1 |
| Avsic-Zupanc, T | 1 |
| Jereb, M | 1 |
| Strle, F | 1 |
| Danysz, W | 1 |
| Azar, NJ | 2 |
| Song, Y | 2 |
| Rosenzweig, I | 1 |
| Manford, M | 1 |
| Salawu, F | 1 |
| Danburam, A | 1 |
| Bauer, S | 1 |
| Knake, S | 1 |
| Haag, A | 1 |
| Hermsen, A | 1 |
| Strzelczyk, A | 1 |
| Hamer, HM | 1 |
| Rosenow, F | 1 |
| Lautz, TB | 1 |
| Finegold, MJ | 1 |
| Chin, AC | 1 |
| Superina, RA | 1 |
| Chrościńska-Krawczyk, M | 1 |
| Błaszczyk, B | 1 |
| Wright, AT | 1 |
| Wilder, BJ | 2 |
| Bruni, J | 3 |
| Woody, RC | 2 |
| Skerritt, JH | 2 |
| Johnston, GA | 1 |
| Chow, SC | 1 |
| Smith, DB | 3 |
| Delgado Escueta, AV | 2 |
| Cramer, JA | 3 |
| Ramsay, RE | 2 |
| Berger, JR | 1 |
| Frey, HH | 1 |
| Reiche, R | 1 |
| Schultz, D | 1 |
| Porter, RJ | 1 |
| Theodore, WH | 2 |
| Mancall, EL | 1 |
| Covington, TR | 1 |
| Alonso, RJ | 1 |
| Bourgeois, BF | 2 |
| Wad, N | 1 |
| Lesser, RP | 1 |
| Pippenger, CE | 1 |
| Lüders, H | 1 |
| Dinner, DS | 1 |
| Albright, PS | 2 |
| Neglia, JP | 1 |
| Glaze, DG | 1 |
| Zion, TE | 1 |
| Shaw, MD | 1 |
| Foy, P | 1 |
| Chadwick, D | 2 |
| Collins, JF | 2 |
| Giroud, M | 1 |
| Dumas, R | 1 |
| Langevin, P | 1 |
| May, DC | 1 |
| Rush, JA | 1 |
| Hillbom, ME | 1 |
| Hjelm-Jäger, M | 1 |
| Johnston, MV | 1 |
| Freeman, JM | 1 |
| Aminoff, MJ | 1 |
| Turski, L | 2 |
| Turski, W | 2 |
| Bustamante, L | 1 |
| Lueders, H | 1 |
| Pippenger, C | 1 |
| Goldensohn, ES | 1 |
| Beckman, DL | 1 |
| Crittenden, DJ | 1 |
| Vajda, FJ | 1 |
| Chambers, BR | 1 |
| Carl, GF | 1 |
| Mares, P | 2 |
| Hlavatá, J | 1 |
| Lisková, K | 1 |
| Mudrochová, M | 1 |
| Sternebring, B | 1 |
| Holm, R | 1 |
| Wadstein, J | 1 |
| Koivikko, MJ | 1 |
| Välikangas, SL | 1 |
| Mellanby, J | 1 |
| Sillanpää, M | 1 |
| Block, SH | 1 |
| Monaco, F | 2 |
| Piredda, S | 1 |
| Traccis, S | 1 |
| Frassetto, M | 1 |
| Mutani, R | 1 |
| Thompson, PJ | 1 |
| Trimble, MR | 1 |
| Maheshwari, MC | 2 |
| Padmini, R | 1 |
| Lai, CW | 1 |
| Peters, HA | 1 |
| Ravindran, M | 1 |
| Bolden, RO | 1 |
| Felsenthal, G | 1 |
| Cohen, BS | 1 |
| Murphy, JE | 1 |
| Stewart, RB | 1 |
| Springer, PK | 1 |
| Oana, Y | 1 |
| Arai, M | 1 |
| Miura, S | 1 |
| Drenck, NE | 1 |
| Risbo, A | 1 |
| Bailleux, V | 1 |
| Vallée, L | 1 |
| Nuyts, JP | 1 |
| Hamoir, G | 1 |
| Vamecq, J | 1 |
| Kholodov, LE | 1 |
| Prityko, AG | 1 |
| Ivanova, ES | 1 |
| Sokolov, AV | 1 |
| Tishchenkova, IF | 1 |
| Dubrovina, LIu | 1 |
| Postnikov, SS | 1 |
| Tatarinov, PA | 1 |
| Kopanev, IuA | 1 |
| Veselov, NK | 1 |
| Wamil, AW | 2 |
| Schmutz, M | 3 |
| Portet, C | 2 |
| Feldmann, KF | 2 |
| McLean, MJ | 5 |
| Wali, RS | 1 |
| Patil, PA | 1 |
| Clark, M | 1 |
| Massenburg, GS | 1 |
| Becker, A | 1 |
| Grecksch, G | 1 |
| Piönnigs, B | 1 |
| Ostner, C | 1 |
| Miyamoto, A | 1 |
| Takahashi, S | 1 |
| Oki, J | 1 |
| Itoh, J | 1 |
| Cho, K | 1 |
| Shibata, K | 1 |
| Tsugawa, S | 1 |
| Ohtsuji, M | 1 |
| Kondo, T | 2 |
| Ohshima, T | 1 |
| Pietrasiewicz, T | 1 |
| Czechowska, G | 1 |
| Dziki, M | 2 |
| Turski, WA | 1 |
| Rosen, JB | 1 |
| Hutton, JM | 1 |
| Chai, C | 1 |
| Killeen, AA | 1 |
| Hornfeldt, CS | 1 |
| Larson, AA | 1 |
| Smith, KR | 1 |
| Goulding, PM | 1 |
| Wilderman, D | 1 |
| Goldfader, PR | 1 |
| Holterman-Hommes, P | 1 |
| Wei, F | 1 |
| Seidleck, BK | 1 |
| Thurkauf, A | 3 |
| Witkin, JM | 1 |
| Brugger, F | 1 |
| Gentsch, C | 1 |
| Olpe, HR | 2 |
| Denicoff, KD | 1 |
| Meglathery, SB | 1 |
| Tandeciarz, SI | 1 |
| Rataud, J | 1 |
| Debarnot, F | 1 |
| Mary, V | 1 |
| Pratt, J | 1 |
| Stutzmann, JM | 1 |
| Sälke-Kellermann, A | 1 |
| Baier, H | 1 |
| Rambeck, B | 1 |
| Boenigk, HE | 1 |
| Wolf, P | 4 |
| Kulkarni, C | 2 |
| David, J | 3 |
| Joseph, T | 3 |
| de Romanis, F | 1 |
| Sopranzi, N | 1 |
| Hoogerkamp, A | 1 |
| Vis, PW | 1 |
| So, EL | 1 |
| Ruggles, KH | 1 |
| Cascino, GD | 1 |
| Ahmann, PA | 1 |
| Weatherford, KW | 1 |
| Sohn, E | 1 |
| Berger, A | 1 |
| Lewis, R | 1 |
| Gilman, JT | 2 |
| Alvarez, LA | 1 |
| Duchowny, M | 1 |
| Bonay, M | 1 |
| Jonville-Bera, AP | 1 |
| Diot, P | 1 |
| Lemarie, E | 1 |
| Lavandier, M | 1 |
| Autret, E | 1 |
| Brinciotti, M | 1 |
| Ferrucci, G | 1 |
| Trasatti, G | 1 |
| Priori, R | 1 |
| Squilloni, E | 1 |
| Valesini, G | 1 |
| Okada, M | 1 |
| Hirano, T | 1 |
| Otani, K | 1 |
| Fukushima, Y | 1 |
| Ohashi, T | 1 |
| Fujimoto, M | 1 |
| Shimizu, H | 1 |
| Atsumi, T | 1 |
| Varney, NR | 1 |
| Garvey, MJ | 1 |
| Cook, BL | 1 |
| Campbell, DA | 1 |
| Roberts, RJ | 1 |
| Ruosi, P | 1 |
| Fiorillo, A | 1 |
| Iovine, A | 1 |
| Striano, S | 1 |
| Ruiz-Falcó Rojas, ML | 1 |
| Gutiérrez-Solana, LG | 1 |
| Arias Alvarez, MA | 1 |
| Barrio Nicolás, A | 1 |
| López-Terradas Covisa, JM | 1 |
| Burns, RL | 2 |
| Jenkins, PL | 1 |
| Vallini, AD | 2 |
| Weilburg, JB | 1 |
| Schachter, S | 1 |
| Sachs, GS | 1 |
| Worth, J | 1 |
| Pollack, MH | 1 |
| Ives, JR | 1 |
| Schomer, DL | 2 |
| Marley, RJ | 2 |
| Shimosato, K | 1 |
| Frieman, M | 1 |
| Goldberg, SR | 2 |
| Rodger, C | 1 |
| Pleuvry, BJ | 1 |
| Pueschel, SM | 1 |
| Louis, S | 2 |
| Defebvre, L | 1 |
| Fillebeen, C | 1 |
| Ketelers, JY | 1 |
| Dupard, T | 1 |
| Leys, D | 1 |
| Silverman, DA | 1 |
| Chapron, DJ | 1 |
| Surks, MI | 1 |
| DeFesi, CR | 1 |
| Kitano, Y | 1 |
| Usui, C | 1 |
| Takasuna, K | 1 |
| Hirohashi, M | 1 |
| Nomura, M | 1 |
| Lahtinen, H | 1 |
| Ylinen, A | 1 |
| Lukkarinen, U | 1 |
| Sirviö, J | 1 |
| Miettinen, R | 1 |
| Riekkinen, P | 1 |
| Wlaź, P | 3 |
| Roliński, Z | 2 |
| Ruggian, JC | 1 |
| Fishbane, S | 1 |
| Demento, FJ | 1 |
| Maesaka, JK | 1 |
| Frei, GL | 1 |
| Reid, KH | 1 |
| Young, C | 1 |
| Schurr, A | 1 |
| Tseng, M | 1 |
| Payne, RS | 1 |
| Keelen, P | 1 |
| Miller, J | 1 |
| Iyer, V | 1 |
| Marcoux, AW | 1 |
| Gasior, M | 2 |
| Borowicz, K | 1 |
| Singh, B | 1 |
| Singh, P | 1 |
| al Hifzi, I | 1 |
| Khan, M | 1 |
| Majeed-Saidan, M | 1 |
| Korolkiewicz, R | 1 |
| Mlynarczyk, M | 1 |
| Kelley, MT | 1 |
| Walson, PD | 1 |
| Cox, S | 1 |
| Dusci, LJ | 1 |
| Van Belle, K | 1 |
| Roxanas, MG | 1 |
| Corbett, AJ | 1 |
| Reid, WG | 1 |
| Harvey, CA | 1 |
| Barnes, TR | 1 |
| Zarate, CA | 1 |
| Tohen, M | 1 |
| Baraibar, G | 1 |
| Brewerton, TD | 1 |
| Aykut-Bingol, C | 1 |
| Tekin, S | 1 |
| Ince, D | 1 |
| Aktan, S | 1 |
| Koenigsberger, MR | 1 |
| Caballar-Gonzaga, FJ | 1 |
| Dierkes, T | 1 |
| Dailey, JW | 2 |
| Reith, ME | 1 |
| Yan, QS | 1 |
| Li, MY | 1 |
| Jobe, PC | 2 |
| Selby, R | 1 |
| Nisbet-Brown, E | 1 |
| Basran, RK | 1 |
| Chang, L | 1 |
| Olivieri, NF | 1 |
| Parihar, PS | 1 |
| Shibasaki, H | 2 |
| Shiozaki, A | 1 |
| Kimura, J | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Ibbotson, T | 1 |
| Field, MJ | 1 |
| Boden, PR | 1 |
| Katsumori, H | 1 |
| Minabe, Y | 2 |
| Osawa, M | 1 |
| Ashby, CR | 1 |
| Fukuo, Y | 1 |
| Abe, T | 1 |
| Hayasaka, S | 1 |
| Morimoto, K | 2 |
| Sato, H | 1 |
| Sato, K | 2 |
| Sato, S | 1 |
| Yamada, N | 2 |
| Levy, RH | 2 |
| Paramesh, H | 1 |
| Satish, DA | 1 |
| Khatib, SA | 1 |
| Jain, M | 1 |
| Kanyonyo, MR | 1 |
| Lambert, DM | 1 |
| Chattergoon, DS | 1 |
| Verjee, Z | 1 |
| Anderson, M | 1 |
| Johnson, D | 1 |
| McGuigan, MA | 1 |
| Gram, L | 1 |
| Avanzini, G | 1 |
| Dulac, O | 1 |
| Starownik, R | 1 |
| Krupp, E | 2 |
| Potschka, H | 1 |
| Matagne, A | 1 |
| Klitgaard, H | 1 |
| Otsuki, K | 1 |
| Kuroda, S | 1 |
| Joseph, S | 1 |
| Lackner, TE | 1 |
| Cloyd, JC | 2 |
| Thomas, LW | 1 |
| Anhut, H | 1 |
| Greiner, MJ | 1 |
| Alexander, J | 1 |
| Murray, GH | 1 |
| Garofalo, EA | 2 |
| Pierce, MW | 1 |
| Tan, LC | 1 |
| Tan, AK | 1 |
| Tjia, H | 1 |
| Fischer, W | 1 |
| van der Goot, H | 1 |
| Parmeggiani, A | 1 |
| Fraticelli, E | 1 |
| Rossi, PG | 1 |
| Psillakis, T | 1 |
| Tsatsakis, AM | 1 |
| Christodoulou, P | 1 |
| Michalodimitrakis, M | 1 |
| Paritsis, N | 1 |
| Helidonis, E | 1 |
| El-Serag, HB | 1 |
| Johnston, DE | 1 |
| Morales-Diaz, M | 1 |
| Pinilla-Roa, E | 1 |
| Ruiz, I | 1 |
| Gustavson, LE | 1 |
| Cato, A | 1 |
| Boellner, SW | 1 |
| Cao, GX | 1 |
| Qian, JX | 1 |
| Guenther, HJ | 1 |
| Sommerville, KW | 1 |
| Juhng, KN | 1 |
| Kokate, TG | 1 |
| Yamaguchi, S | 2 |
| Kim, BY | 1 |
| Rogowski, RS | 1 |
| Blaustein, MP | 1 |
| Rogawski, MA | 3 |
| van Ginneken, EE | 1 |
| van der Meer, JW | 1 |
| Netten, PM | 1 |
| Malhotra, J | 1 |
| Zamponi, N | 1 |
| Cardinali, C | 1 |
| Thabet, H | 1 |
| Brahmi, N | 1 |
| Zagdoudi, I | 1 |
| Amamou, M | 1 |
| Hédhili, A | 1 |
| Ben Salah, N | 1 |
| Yacoub, M | 1 |
| Kaminski, R | 1 |
| Jasinski, M | 1 |
| Jagiello-Wojtowicz, E | 1 |
| Hashimoto, LN | 1 |
| Bass, WT | 1 |
| Green, GA | 1 |
| Werner, AL | 1 |
| Reagan, TJ | 1 |
| Rashid, S | 1 |
| Lee, I | 1 |
| Anderson, AE | 1 |
| Hrachovy, RA | 1 |
| Swann, JW | 1 |
| Fiedler, M | 1 |
| Papacostas, S | 1 |
| Lazarova, M | 1 |
| Petkova, B | 1 |
| Staneva-Stoycheva, D | 1 |
| Heynen, T | 1 |
| Li, XL | 1 |
| Roze, E | 1 |
| Oubary, P | 1 |
| Chédru, F | 1 |
| Hugen, PW | 1 |
| Burger, DM | 1 |
| Brinkman, K | 1 |
| ter Hofstede, HJ | 1 |
| Schuurman, R | 1 |
| Koopmans, PP | 1 |
| Hekster, YA | 1 |
| Zuo, CH | 1 |
| Zhao, DY | 1 |
| Wu, XR | 1 |
| Schuerer, DJ | 1 |
| Brophy, PD | 1 |
| Maxvold, NJ | 1 |
| Kudelka, T | 1 |
| Bunchman, TE | 1 |
| Mieczkowski, T | 1 |
| Mihály, A | 1 |
| Shihab-Eldeen, A | 1 |
| Owunwanne, A | 1 |
| Gopinath, S | 1 |
| Ayesha, A | 1 |
| Mathew, M | 1 |
| Fujimoto, S | 1 |
| Imahashi, H | 1 |
| González-Maciel, A | 2 |
| Reynoso-Robles, R | 2 |
| Romero, RM | 2 |
| Huerta, B | 1 |
| González, V | 1 |
| Vargas, L | 2 |
| Ayala-Guerrero, F | 2 |
| Benatar, MG | 1 |
| Sahin, M | 1 |
| Davis, RG | 1 |
| Burman, W | 1 |
| Orr, L | 1 |
| DeToledo, JC | 1 |
| Lowe, MR | 1 |
| Greiner, M | 1 |
| Mateu-de Antonio, J | 1 |
| Grau, S | 1 |
| Gimeno-Bayón, JL | 1 |
| Carmona, A | 1 |
| Sokic, DV | 1 |
| Stojsavljevic, N | 1 |
| Drulovic, J | 1 |
| Dujmovic, I | 1 |
| Mesaros, S | 1 |
| Ercegovac, M | 1 |
| Peric, V | 1 |
| Dragutinovic, G | 1 |
| Levic, Z | 1 |
| Vasudev, A | 1 |
| Tripathi, KD | 1 |
| Puri, V | 1 |
| Temkin, NR | 1 |
| Wellington, K | 1 |
| Goa, KL | 1 |
| Gilbert, TH | 1 |
| Teskey, GC | 1 |
| Erbayraktar, S | 1 |
| Tekinsoy, B | 1 |
| Acar, F | 1 |
| Acar, U | 1 |
| Spiller, HA | 2 |
| Kochen, S | 1 |
| Giagante, B | 1 |
| Oddo, S | 1 |
| Łuszczki, J | 1 |
| De Santis, A | 1 |
| Villani, R | 1 |
| Sinisi, M | 1 |
| Stocchetti, N | 1 |
| Aithala, G | 1 |
| Sztriha, L | 1 |
| Zhou, D | 1 |
| Hopp, P | 1 |
| Kerling, F | 1 |
| Kirchner, A | 1 |
| Pierach, CA | 1 |
| Vorob'eva, OV | 1 |
| Korabel'nikova, EA | 1 |
| Eeg-Olofsson, O | 1 |
| Lockard, JS | 1 |
| DuCharme, LL | 1 |
| Congdon, WC | 1 |
| Patel, IH | 1 |
| Utsui, Y | 1 |
| Shiraishi, Y | 1 |
| Yoshida, K | 2 |
| Shimizu, M | 2 |
| Crunelli, V | 2 |
| Bernasconi, S | 1 |
| Samanin, R | 4 |
| Feit, H | 1 |
| Myllylä, VV | 1 |
| Julien, RM | 2 |
| Hollister, RP | 1 |
| Wada, JA | 3 |
| Sato, M | 2 |
| Wake, A | 2 |
| Green, JR | 1 |
| Troupin, AS | 3 |
| Meldrum, BS | 2 |
| Palmer, GC | 1 |
| Jones, DJ | 1 |
| Medina, MA | 1 |
| Stavinoha, WB | 1 |
| Vol'f, MSh | 1 |
| Horton, RW | 1 |
| Toseland, PA | 1 |
| Fowler, GW | 1 |
| Addy, DP | 1 |
| Deisenhammer, E | 1 |
| Sommer, R | 1 |
| Ito, T | 1 |
| Hori, M | 1 |
| Swanson, PD | 1 |
| Jacome, D | 1 |
| Crosley, CJ | 1 |
| Swender, PT | 1 |
| Rylance, GW | 2 |
| Moreland, TA | 2 |
| Butcher, GM | 1 |
| Froissart, M | 1 |
| Mizon, JP | 1 |
| Jacquemart, F | 1 |
| Chu, NS | 1 |
| Quattrone, A | 2 |
| McFarland, HR | 1 |
| Callaghan, N | 1 |
| O'Callaghan, M | 1 |
| Duggan, B | 1 |
| Feely, M | 1 |
| Penry, JK | 1 |
| Osawa, T | 1 |
| Corcoran, ME | 1 |
| Consroe, P | 1 |
| Martin, P | 1 |
| Eisenstein, D | 1 |
| Assael, BM | 1 |
| Bossi, L | 1 |
| Garattini, S | 1 |
| Gerna, M | 1 |
| Gomeni, R | 1 |
| Morselli, PL | 1 |
| Cereghino, JJ | 1 |
| Ojemann, LM | 1 |
| Iprus-Shotter, AV | 1 |
| Asher, J | 1 |
| Mayhew, LA | 1 |
| Hanzel, TE | 1 |
| Ferron, FR | 1 |
| Kalachnik, JE | 1 |
| Harder, SR | 1 |
| Dzianott, A | 1 |
| Stasiuk, G | 1 |
| Korczowski, R | 1 |
| Horneff, G | 1 |
| Lenard, HG | 1 |
| Wahn, V | 1 |
| Churchyard, A | 1 |
| Khangure, M | 1 |
| Grainger, K | 1 |
| May, T | 1 |
| Tiska, G | 1 |
| Schreiber, G | 1 |
| Parada, J | 1 |
| Cavalheiro, EA | 1 |
| Edge, W | 1 |
| Edmonds, J | 1 |
| Mana, MJ | 1 |
| Kim, CK | 2 |
| Pinel, JP | 2 |
| Hudda, MM | 1 |
| Wong, DJ | 1 |
| Yung, A | 1 |
| Grant, KA | 1 |
| Snell, LD | 1 |
| Tabakoff, B | 1 |
| Stommel, EW | 1 |
| Bihler, J | 1 |
| Swenson, R | 1 |
| Luther, M | 1 |
| Reeves, AG | 1 |
| Shaughnessy, AF | 1 |
| Mosley, MR | 1 |
| Welty, TE | 2 |
| Pickering, PR | 1 |
| Hale, BC | 1 |
| Arazi, R | 1 |
| Nijdam, JR | 1 |
| Doorschot, CH | 1 |
| van Bavel, LP | 1 |
| Loonen, AJ | 1 |
| Peterson, SL | 2 |
| Galpern, WR | 1 |
| Miller, LG | 1 |
| Greenblatt, DJ | 1 |
| Szabo, GK | 1 |
| Browne, TR | 2 |
| Shader, RI | 1 |
| Anttila, VJ | 1 |
| Valtonen, M | 1 |
| Kuang, P | 1 |
| Lang, S | 1 |
| Liu, J | 1 |
| Zhang, F | 1 |
| Porter, JE | 1 |
| Haas, K | 1 |
| Murphy, JM | 1 |
| Mashman, J | 1 |
| Miller, JD | 1 |
| Bell, JB | 1 |
| Rodriguez Mosquera, M | 1 |
| Iglesias, A | 1 |
| Sáez, A | 1 |
| Vidal, C | 1 |
| Soto Alvarez, J | 1 |
| Sacristan Del Castillo, JA | 1 |
| Alsar Ortiz, MJ | 1 |
| Obembe, A | 1 |
| Koppel, BS | 1 |
| Daras, M | 1 |
| Krumholz, A | 1 |
| Stern, BJ | 1 |
| Stern, EG | 1 |
| McKee, PJ | 1 |
| McGinn, G | 1 |
| Larkin, JG | 1 |
| Jones, SM | 1 |
| Rice, KC | 1 |
| Monn, JA | 1 |
| Shapira, OM | 1 |
| Feld, S | 1 |
| Mor, E | 1 |
| Konichezky, S | 1 |
| Hug, G | 1 |
| McGraw, CA | 1 |
| Bates, SR | 1 |
| Landrigan, EA | 1 |
| Dupuis, RE | 1 |
| Miranda-Massari, J | 1 |
| Bahls, FH | 1 |
| Ozuna, J | 1 |
| Ritchie, DE | 1 |
| Betticher, DC | 1 |
| Wolfisberg, HP | 1 |
| Krapf, R | 1 |
| Reshef, A | 1 |
| Bitterman, N | 1 |
| Kerem, D | 1 |
| Thorat, SN | 1 |
| Altshuler, LL | 1 |
| Devinsky, O | 1 |
| Theodore, W | 1 |
| Scheyer, RD | 1 |
| Toftness, BR | 1 |
| Hochholzer, JM | 1 |
| Kassahun, K | 1 |
| Farrell, K | 1 |
| Zheng, JJ | 1 |
| Abbott, F | 1 |
| Oner, A | 1 |
| Topaloğlu, R | 1 |
| Beşbaş, N | 1 |
| Topaloğlu, H | 1 |
| Krenzelok, EP | 1 |
| Cookson, E | 1 |
| Nolting, B | 1 |
| Fassbender, CP | 1 |
| Hönack, D | 1 |
| Bardy, AH | 1 |
| Hiilesmaa, VK | 1 |
| Teramo, K | 1 |
| Neuvonen, PJ | 1 |
| Emori, K | 1 |
| Trzeciakowski, JP | 1 |
| Frye, GD | 1 |
| Adams, HR | 1 |
| Miles, MV | 1 |
| Lawless, ST | 1 |
| Tennison, MB | 1 |
| Zaritsky, AL | 1 |
| Greenwood, RS | 1 |
| Mohapatro, AK | 1 |
| Jain, S | 1 |
| Goulatia, RK | 1 |
| Kabuto, M | 1 |
| Hayashi, M | 1 |
| Kobayashi, H | 1 |
| Noguchi, Y | 1 |
| Nakagawa, T | 1 |
| Kutota, T | 1 |
| Costello, M | 1 |
| Nutt, DJ | 1 |
| Tandeciarz, S | 1 |
| Macdonald, RL | 2 |
| Mace, JA | 1 |
| Burnham, WM | 1 |
| de la Peña, CA | 1 |
| Tutor, JC | 1 |
| Paz, JM | 1 |
| Fernandez, MP | 1 |
| Rozas, I | 1 |
| Del Río, R | 1 |
| Camfield, P | 2 |
| Camfield, C | 1 |
| Dooley, J | 1 |
| Smith, E | 1 |
| Garner, B | 1 |
| Ebeid, MR | 1 |
| Feldman, S | 1 |
| Parks, B | 1 |
| Parker, P | 1 |
| Velísek, L | 1 |
| Roztocilová, L | 1 |
| Kubová, H | 1 |
| Pledger, GW | 1 |
| Langee, HR | 1 |
| Drory, VE | 1 |
| Yust, I | 1 |
| Korczyn, AD | 1 |
| Janusz, W | 1 |
| Szczepanik, B | 1 |
| Wamil, A | 1 |
| Mishra, D | 1 |
| Singh, G | 1 |
| Pandey, SS | 1 |
| Chen, LS | 1 |
| Millington, DS | 1 |
| Maltby, DA | 1 |
| McNamara, JO | 1 |
| Silvestri, R | 1 |
| De Domenico, P | 1 |
| Musolino, R | 1 |
| Mento, G | 1 |
| Marabello, L | 1 |
| Longo, M | 1 |
| Di Perri, R | 1 |
| Mikati, MA | 2 |
| Schachter, SC | 1 |
| Keally, M | 1 |
| Osborne-Shafer, P | 1 |
| Seaman, CA | 1 |
| Sheridan, PH | 1 |
| Ashworth, M | 1 |
| Kupferberg, H | 1 |
| Valakas, A | 1 |
| Macphee, GJ | 1 |
| McInnes, GT | 1 |
| Thompson, GG | 1 |
| Higuchi, T | 1 |
| Yamazaki, O | 1 |
| Takazawa, A | 1 |
| Kato, N | 1 |
| Watanabe, N | 1 |
| Minatogawa, Y | 1 |
| Yamazaki, J | 1 |
| Ohshima, H | 1 |
| Nagaki, S | 1 |
| Igarashi, Y | 1 |
| Sachdeo, RC | 1 |
| Belendiuk, G | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Shandra, AA | 1 |
| Vezzani, A | 1 |
| Wu, HQ | 1 |
| Tullii, M | 1 |
| DeLorenzo, RJ | 1 |
| Kishita, C | 1 |
| Philippart, M | 1 |
| Schwarz, SS | 1 |
| Freed, WJ | 1 |
| Laney, SM | 1 |
| Hess, CW | 1 |
| Neppe, VM | 2 |
| Tucker, GJ | 1 |
| Mitchell, WG | 1 |
| Crawford, TO | 1 |
| Dreifuss, FE | 1 |
| Porter, R | 1 |
| Bowman, T | 1 |
| Santilli, N | 1 |
| Jacobs, M | 1 |
| Crosby, C | 1 |
| Cloyd, J | 1 |
| Stackman, J | 1 |
| Graves, N | 1 |
| Weaver, DF | 1 |
| Fraser, A | 1 |
| Popoli, P | 1 |
| Benedetti, M | 1 |
| Scotti de Carolis, A | 1 |
| Beattie, B | 1 |
| Biller, J | 1 |
| Mehlhaus, B | 1 |
| Murray, M | 1 |
| Kaplan, C | 1 |
| Kiesmann, M | 2 |
| Marescaux, C | 2 |
| Vergnes, M | 2 |
| Micheletti, G | 2 |
| Warter, JM | 2 |
| Stoudemire, A | 1 |
| Ninan, PT | 1 |
| Wooten, V | 1 |
| Brundage, RC | 1 |
| Graves, NM | 1 |
| Arnstein, E | 1 |
| MacKintosh, DA | 1 |
| Baird-Lampert, J | 1 |
| Buchanan, N | 1 |
| Semel, JD | 1 |
| Tan, CT | 1 |
| Low, ET | 1 |
| Rosenthal, RE | 1 |
| Emsellem, HA | 1 |
| Kline, PP | 1 |
| Chrousos, GA | 1 |
| Cowdry, R | 1 |
| Schuelein, M | 1 |
| Abdul-Rahim, AS | 1 |
| Matsuo, V | 1 |
| Currie, JN | 1 |
| Nau, H | 1 |
| Kuhnz, W | 1 |
| Snead, OC | 1 |
| Hosey, LC | 1 |
| Fröscher, W | 1 |
| Burr, W | 1 |
| Penin, H | 1 |
| Vohl, J | 1 |
| Bülau, P | 1 |
| Kreiten, K | 1 |
| Taylor, SM | 1 |
| Bennett, GD | 1 |
| Abbott, LC | 1 |
| Finnell, RH | 1 |
| Cherrick, AA | 1 |
| Ellenberg, M | 1 |
| Delafuente, JC | 1 |
| Smith, JL | 1 |
| Sacks, E | 1 |
| Marangos, PJ | 1 |
| Patel, J | 1 |
| Zwarts, MJ | 1 |
| Sie, O | 1 |
| Soman, M | 1 |
| Swenson, C | 1 |
| Assmus, H | 1 |
| Kutt, H | 1 |
| Kuroiwa, Y | 1 |
| Varkey, K | 1 |
| Raman, PT | 1 |
| Bhaktaviziam, A | 1 |
| Taori, GM | 1 |
| Babington, RG | 1 |
| Horovitz, ZP | 1 |
| Tyler, HR | 1 |
| Mistler, O | 1 |
| Brune, F | 1 |
| Busch, H | 1 |
| Bilikiewicz, T | 1 |
| Bilikiewicz, A | 1 |
| dos Reis, MA | 1 |
| Riddell, D | 1 |
| Leonard, BE | 1 |
| Espir, ML | 1 |
| Millac, P | 1 |
| Fernandez, VE | 1 |
| Roedenbeck, SD | 1 |
| Santos, J | 1 |
| Maxion, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures[NCT00464269] | Phase 3 | 400 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures[NCT01261325] | Phase 3 | 768 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.[NCT00490035] | Phase 3 | 399 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures[NCT02705768] | Phase 4 | 90 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?[NCT03054285] | Phase 4 | 2,300 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197] | Phase 4 | 104 participants (Actual) | Interventional | 2018-08-06 | Completed | ||
| A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/[NCT00175903] | Phase 3 | 1,701 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy[NCT03475225] | Phase 3 | 400 participants (Anticipated) | Interventional | 2018-04-30 | Not yet recruiting | ||
| Monitoring of Seizures, EEG and Serum Antiepileptic Drug Concentrations in Patients With Uncontrolled Epilepsy[NCT00001149] | 900 participants | Observational | 1975-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"There are three different types of seizures:~Type I: Partial seizures~Type II: Generalized seizures~Type III: Unclassified epileptic seizures.~All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)*7/(Total number of days with no missing seizure count in the TP)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | seizures per week (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.80 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.96 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.77 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.79 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.26 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 6.36 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 3.37 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 1.97 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 7.03 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 7.73 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.06 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.14 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.69 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 2.07 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.97 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 6.41 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 2.24 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.94 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 0.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 8.1 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 6.9 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 7.3 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.5 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 7.44 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 7.32 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 6.55 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 7.99 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 5.36 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.97 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 4.82 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.81 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 1.02 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | -2.61 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 0.73 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 6.07 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 5.49 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 3.39 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.66 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.33 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 9.36 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 3.34 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.69 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.97 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 3.88 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.07 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 5.19 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.88 |
"Partial (Type I) seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to generalized tonic-clonic convulsions.~Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as:~(Total Type I seizures over the TP)*7/(Total number of days with no missing seizure count in the TP)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | seizures per week (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.80 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.96 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.70 |
"Percent change from Baseline was calculated as percent reduction by:~(weekly seizure frequency Baseline - weekly seizure frequency Treatment)*100/(weekly seizure frequency Baseline).~The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | Percent change in POS frequency (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 17.75 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 19.95 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 22.52 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 30.47 |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 56.3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 50.0 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 77.8 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 63.6 |
The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 14 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 17 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 19 |
The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 5 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 4 |
The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 28 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 30 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 34 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 37 |
"Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: <-25 %, -25 % to <25 %, 25 % to <50 %, 50 % to <75 %, 75 % to <100 %, and 100 %.~Subjects having zero for Baseline seizure frequency per week were classified in the <-25 % category." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| <-25 % | -25 % to < 25 % | 25 % to < 50 % | 50 % to < 75 % | 75 % to < 100 % | 100 % | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 14.1 | 38.4 | 24.2 | 15.2 | 6.1 | 2.0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 21.9 | 31.3 | 25.0 | 12.5 | 8.3 | 1.0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 9.9 | 31.7 | 25.7 | 19.8 | 8.9 | 4.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 14.6 | 44.8 | 24.0 | 12.5 | 4.2 | 0 |
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.' (NCT00464269)
Timeframe: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 17.2 | 18.2 | 31.3 | 32.3 | 1.0 | 0 | 0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 12.2 | 18.9 | 24.4 | 34.4 | 2.2 | 7.8 | 0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 16.3 | 27.6 | 24.5 | 25.5 | 2.0 | 3.1 | 1.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 12.6 | 20.0 | 21.1 | 41.1 | 3.2 | 1.1 | 1.1 |
Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?' (NCT00464269)
Timeframe: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 18.8 | 26.3 | 21.3 | 27.5 | 1.3 | 3.8 | 1.3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 19.8 | 24.7 | 18.5 | 23.5 | 6.2 | 7.4 | 0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 26.7 | 19.8 | 22.1 | 23.3 | 4.7 | 1.2 | 2.3 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 15.5 | 25.0 | 23.8 | 28.6 | 4.8 | 1.2 | 1.2 |
The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 23 | 76 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 21 | 75 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 33 | 68 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 16 | 80 |
"Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as:~(total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Seizure-free | No seizures but non-completer | Not seizure-free | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.0 | 1.0 | 98.0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.0 | 0 | 99.0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 4.0 | 0 | 96.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 0 | 0 | 100.0 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | number of seizures/ 28-day (Median) |
|---|---|
| Placebo | 8.7 |
| Brivaracetam 100 mg/Day | 6.3 |
| Brivaracetam 200 mg/Day | 5.8 |
(NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | percentage of change (Median) |
|---|---|
| Placebo | 17.6 |
| Brivaracetam 100 mg/Day | 37.2 |
| Brivaracetam 200 mg/Day | 35.6 |
Primary endpoint: United States of America (FDA) (NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | Percentage of reduction (Number) |
|---|---|
| Brivaracetam 100 mg/Day | 22.8 |
| Brivaracetam 200 mg/Day | 23.2 |
| Placebo | 0 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 16 |
| Brivaracetam 100 mg/Day | 21 |
| Brivaracetam 200 mg/Day | 23 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 3 |
| Brivaracetam 100 mg/Day | 5 |
| Brivaracetam 200 mg/Day | 6 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 32 |
| Brivaracetam 100 mg/Day | 37 |
| Brivaracetam 200 mg/Day | 43 |
Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration. (NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | Percentage of subjects (Number) | |
|---|---|---|
| Responders | Non-Responders | |
| Brivaracetam 100 mg/Day | 38.9 | 61.1 |
| Brivaracetam 200 mg/Day | 37.8 | 62.2 |
| Placebo | 21.6 | 78.4 |
(NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | percentage of subjects (Number) | |||||
|---|---|---|---|---|---|---|
| <-25 % | -25 % to <25 % | 25 % to <50 % | 50 % to <75 % | 75 % to <100 % | 100 % | |
| Brivaracetam 100 mg/Day | 14.3 | 28.6 | 18.3 | 19.0 | 13.9 | 6.0 |
| Brivaracetam 200 mg/Day | 10.8 | 29.3 | 22.1 | 18.1 | 13.7 | 6.0 |
| Placebo | 16.6 | 40.5 | 21.2 | 13.9 | 6.9 | 0.8 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | percentage of subjects (Number) | ||
|---|---|---|---|
| Seizure free | No seizures but discontinued | Not seizure free | |
| Brivaracetam 100 mg/Day | 5.2 | 1.2 | 93.7 |
| Brivaracetam 200 mg/Day | 4.0 | 1.2 | 94.8 |
| Placebo | 0.8 | 0.4 | 98.8 |
There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III). (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Times per week (Median) |
|---|---|
| Placebo | 1.75 |
| Brivaracetam 20 mg/Day | 1.34 |
| Brivaracetam 50 mg/Day | 1.49 |
| Brivaracetam 100 mg/Day | 1.26 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 1.80 |
| Brivaracetam 20 mg/Day | 5.36 |
| Brivaracetam 50 mg/Day | 1.02 |
| Brivaracetam 100 mg/Day | 0.69 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Brivaracetam 20 mg/Day | 3.35 |
| Brivaracetam 50 mg/Day | 3.09 |
| Brivaracetam 100 mg/Day | 3.50 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.80 |
| Brivaracetam 20 mg/Day | 3.75 |
| Brivaracetam 50 mg/Day | 3.13 |
| Brivaracetam 100 mg/Day | -2.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.49 |
| Brivaracetam 20 mg/Day | 3.53 |
| Brivaracetam 50 mg/Day | 1.95 |
| Brivaracetam 100 mg/Day | 1.99 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 6.6 |
| Brivaracetam 20 mg/Day | 6.9 |
| Brivaracetam 50 mg/Day | 9.7 |
| Brivaracetam 100 mg/Day | 4.9 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -1.54 |
| Brivaracetam 20 mg/Day | -0.59 |
| Brivaracetam 50 mg/Day | -0.41 |
| Brivaracetam 100 mg/Day | 0.08 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.65 |
| Brivaracetam 20 mg/Day | -0.10 |
| Brivaracetam 50 mg/Day | 0.26 |
| Brivaracetam 100 mg/Day | -0.24 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.92 |
| Brivaracetam 20 mg/Day | 3.64 |
| Brivaracetam 50 mg/Day | -0.85 |
| Brivaracetam 100 mg/Day | 3.00 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 5.11 |
| Brivaracetam 20 mg/Day | 4.52 |
| Brivaracetam 50 mg/Day | 4.55 |
| Brivaracetam 100 mg/Day | 2.24 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 8.25 |
| Brivaracetam 20 mg/Day | 6.23 |
| Brivaracetam 50 mg/Day | 5.34 |
| Brivaracetam 100 mg/Day | 8.04 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.29 |
| Brivaracetam 20 mg/Day | 4.50 |
| Brivaracetam 50 mg/Day | 3.09 |
| Brivaracetam 100 mg/Day | 1.78 |
"The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: Assess the Overall change in the severity of patient's illness, compared to start of study medication." (NCT00490035)
Timeframe: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.78 |
| Brivaracetam 20 mg/Day | 4.99 |
| Brivaracetam 50 mg/Day | 4.99 |
| Brivaracetam 100 mg/Day | 5.34 |
Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Seizure Frequency per Week (Median) |
|---|---|
| Placebo | 1.75 |
| Brivaracetam 20 mg/Day | 1.34 |
| Brivaracetam 50 mg/Day | 1.49 |
| Brivaracetam 100 mg/Day | 1.26 |
"The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: Overall, has there been a change in your seizures since the start of the study medication?" (NCT00490035)
Timeframe: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.93 |
| Brivaracetam 20 mg/Day | 5.17 |
| Brivaracetam 50 mg/Day | 5.04 |
| Brivaracetam 100 mg/Day | 5.47 |
The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) * 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percent change in seizures per week (Median) |
|---|---|
| Placebo | -17.03 |
| Brivaracetam 20 mg/Day | -30.03 |
| Brivaracetam 50 mg/Day | -26.83 |
| Brivaracetam 100 mg/Day | -32.45 |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.9 |
| Brivaracetam 20 mg/Day | 47.2 |
| Brivaracetam 50 mg/Day | 62.5 |
| Brivaracetam 100 mg/Day | 41.0 |
The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 19 |
| Brivaracetam 20 mg/Day | 25 |
| Brivaracetam 50 mg/Day | 24 |
| Brivaracetam 100 mg/Day | 24 |
The time to first Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 4 |
| Brivaracetam 20 mg/Day | 6 |
| Brivaracetam 50 mg/Day | 6 |
| Brivaracetam 100 mg/Day | 4 |
The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 39 |
| Brivaracetam 20 mg/Day | 49 |
| Brivaracetam 50 mg/Day | 40 |
| Brivaracetam 100 mg/Day | 46 |
"The categories are:~<= 25 %~- 25 % to < 25 %~25 % to < 50 %~50 % to < 75 %~75 % to < 100 %~100 %" (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| <= 25 % | - 25 % to < 25 % | 25 % to < 50 % | 50 % to < 75 % | 75 % to < 100 % | 100 % | |
| Brivaracetam 100 mg/Day | 10.0 | 33.0 | 21.0 | 14.0 | 18.0 | 4.0 |
| Brivaracetam 20 mg/Day | 10.1 | 35.4 | 27.3 | 18.2 | 7.1 | 2.0 |
| Brivaracetam 50 mg/Day | 15.2 | 33.3 | 24.2 | 17.2 | 9.1 | 1.0 |
| Placebo | 19.0 | 41.0 | 20.0 | 12.0 | 8.0 | 0 |
"Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.~The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a >= 50 % reduction in seizure frequency per week from Baseline." (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Non-responders | Responders | |
| Brivaracetam 100 mg/Day | 64.0 | 36.0 |
| Brivaracetam 20 mg/Day | 72.7 | 27.3 |
| Brivaracetam 50 mg/Day | 72.7 | 27.3 |
| Placebo | 80.0 | 20.0 |
Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Seizure free | No Seizures but non-completer | Not Seizure-free | |
| Brivaracetam 100 mg/Day | 4.0 | 0 | 96.0 |
| Brivaracetam 20 mg/Day | 2.0 | 0 | 98.0 |
| Brivaracetam 50 mg/Day | 0 | 1.0 | 99.0 |
| Placebo | 0 | 0 | 100.0 |
78 reviews available for carbamazepine and Absence Seizure
| Article | Year |
|---|---|
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
Topics: Animals; Anticonvulsants; Heterocyclic Compounds; Humans; Molecular Structure; Seizures; Structure-A | 2020 |
Clonazepam monotherapy for treating people with newly diagnosed epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child; Clonazepam; Epilepsy; Humans; Seizures | 2022 |
Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Benzodiazepines; Carbamazepine; Diazepam; Female; Hu | 2022 |
Comparative efficacy of prophylactic anticonvulsant drugs following traumatic brain injury: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Anticonvulsants; Brain Injuries, Traumatic; Carbamazepine; Child; Humans; Levetiracetam; Network Met | 2022 |
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Characteristics of people with epilepsy in three Eastern African countries - a pooled analysis.
Topics: Adult; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Neur | 2022 |
Second Generation of Antiepileptic Drugs and Oxidative Stress.
Topics: Anticonvulsants; Carbamazepine; Diazepam; Epilepsy; Epilepsy, Generalized; Fructose; Gabapentin; Hum | 2023 |
Should antiseizure medications be withdrawn after an extended period of seizure freedom in individuals with adult-onset epilepsy?
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; | 2023 |
The complexities underlying epilepsy in people with glioblastoma.
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Glioblastoma; | 2023 |
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Clonazepam monotherapy for treating people with newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Clonazepam; Epilepsy; Humans; Quality of Life; Randomi | 2019 |
Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example.
Topics: Bayes Theorem; Carbamazepine; Data Interpretation, Statistical; Humans; Meta-Analysis as Topic; Prop | 2020 |
A potential cause of adolescent onset Dyke-Davidoff-Masson syndrome: A case report.
Topics: Brain Diseases; Carbamazepine; China; Chronic Disease; Female; Humans; Intellectual Disability; Magn | 2019 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2020 |
A review of the drug-drug interactions of the antiepileptic drug brivaracetam.
Topics: Anticonvulsants; Brain; Carbamazepine; Drug Interactions; Humans; Pyrrolidinones; Seizures | 2020 |
Efficacy and Safety of Phenobarbitone as First-Line Treatment for Neonatal Seizure: A Systematic Review and Meta-Analysis.
Topics: Anticonvulsants; Carbamazepine; Humans; Infant, Newborn; Phenobarbital; Phenytoin; Seizures | 2021 |
Update on first unprovoked seizure in children and adults: A narrative review.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsies, Partial; Epilepsy, | 2021 |
Clinico-laboratory characteristics and outcome of patients with eucalyptus oil-induced/provoked seizures: A case series and systematic review of the published patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Eucalyptus | 2021 |
Comparative efficacy of anti-epileptic drugs for neonatal seizures: A network meta-analysis.
Topics: Anticonvulsants; Carbamazepine; Humans; Infant, Newborn; Network Meta-Analysis; Pharmaceutical Prepa | 2021 |
Intravenous Carbamazepine for Adults With Seizures.
Topics: Administration, Intravenous; Adult; Anticonvulsants; Carbamazepine; Drug Interactions; Humans; Seizu | 2018 |
Seizures and Choice of Antiepileptic Drugs Following Subarachnoid Hemorrhage: A Review.
Topics: Anticonvulsants; Carbamazepine; Humans; Incidence; Levetiracetam; Phenytoin; Seizures; Subarachnoid | 2017 |
Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Drug and Narcotic Control; Drug-Related Side Effect | 2018 |
Antiepileptic drugs as prophylaxis for postcraniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Levetiracetam; Phenobarbital; Phenyt | 2018 |
Clobazam monotherapy for focal or generalized seizures.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsies, Par | 2018 |
Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, | 2018 |
Levetiracetam versus carbamazepine in treatment of rolandic epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Electroencephalography; Epilepsy, Rolandic; | 2019 |
An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Humans; Se | 2019 |
Epilepsy in patients with EAST syndrome caused by mutation in the KCNJ10.
Topics: Anticonvulsants; Brain; Carbamazepine; Cerebellar Ataxia; Child; Child, Preschool; Epilepsy; Female; | 2019 |
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
Topics: Anticonvulsants; Carbamazepine; Child; Epilepsy; Humans; Phenytoin; Randomized Controlled Trials as | 2019 |
Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Humans; I | 2013 |
Antiepileptic drugs as prophylaxis for post-craniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Phenobarbital; Phenytoin; Randomized | 2013 |
Seizures and intracranial hemorrhage.
Topics: Anticonvulsants; Carbamazepine; Congenital Abnormalities; Eclampsia; Epilepsy; Female; Folic Acid; H | 2013 |
Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures.
Topics: Animals; Anticonvulsants; Carbamazepine; Clinical Trials, Phase III as Topic; Epilepsy, Generalized; | 2014 |
Isobolographic analysis of the mechanisms of action of anticonvulsants from a combination effect.
Topics: Animals; Anticonvulsants; Binding Sites; Carbamazepine; Dose-Response Relationship, Drug; Drug Thera | 2014 |
Clobazam monotherapy for partial-onset or generalized-onset seizures.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsies, Par | 2014 |
Antiepileptic drugs as prophylaxis for post-craniotomy seizures.
Topics: Anticonvulsants; Carbamazepine; Craniotomy; Humans; Isoxazoles; Phenobarbital; Phenytoin; Randomized | 2015 |
Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.
Topics: Animals; Anticonvulsants; Brain Neoplasms; Carbamazepine; Humans; Levetiracetam; Piracetam; Seizures | 2016 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
Antiepileptic drugs for seizure control in people with neurocysticercosis.
Topics: Adolescent; Adult; Anticonvulsants; Brain Diseases; Carbamazepine; Child; Child, Preschool; Epilepsy | 2015 |
Antiepileptic Drugs.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; O | 2016 |
Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, | 2016 |
Guidelines for seizure management in palliative care: Proposal for an updated clinical practice model based on a systematic literature review.
Topics: Anticonvulsants; Carbamazepine; Guidelines as Topic; Humans; Levetiracetam; Palliative Care; Seizure | 2019 |
Emergent complications of the newer anticonvulsants.
Topics: Acidosis; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Overdose; Fructo | 2010 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.
Topics: Algorithms; Anticonvulsants; Carbamazepine; Drug Monitoring; Humans; Hydroxylation; Oxcarbazepine; S | 2008 |
[Endocrine effects of antiepileptic drugs].
Topics: Anticonvulsants; Carbamazepine; Endocrine System Diseases; Estradiol; Female; Hormones; Humans; Leve | 2008 |
New antiepileptic drugs: molecular targets.
Topics: Action Potentials; Animals; Anticonvulsants; Barbiturates; Carbamazepine; Clinical Trials as Topic; | 2009 |
Treatment of benign focal epilepsies in children: when and how should be treated?
Topics: Age of Onset; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsies, Partial; Ep | 2011 |
Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.
Topics: Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Tolerance | 2011 |
Spotlight on levetiracetam in epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chemotherapy, Adjuvant; Epilepsy; Humans; Levetiracetam; Piracetam; | 2011 |
Practical neurology--5: Recurrent unresponsive episodes and seizures.
Topics: Blood Chemical Analysis; Carbamazepine; Diagnosis, Differential; Electroencephalography; Female; Fol | 2011 |
Human leukocyte antigen-associated drug hypersensitivity.
Topics: Animals; Anti-HIV Agents; Anticonvulsants; Antigen Presentation; Autoantigens; Carbamazepine; Dideox | 2013 |
Drug hypersensitivity syndrome to carbamazepine and human herpes virus 6 infection: case report and literature review.
Topics: Adult; Base Sequence; Carbamazepine; Drug Hypersensitivity; Female; Follow-Up Studies; Herpesvirus 6 | 2003 |
Phenytoin and carbamazepine cross reactivity: report of a case and review of literature.
Topics: Anticonvulsants; Carbamazepine; Child; Drug Eruptions; Drug Interactions; Humans; Male; Oral Ulcer; | 2003 |
Safety of the newer antiepileptic drug oxcarbazepine during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Carbamazepine; Female; Humans; Oxcarba | 2005 |
A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Disease-Free Survival; Double-Blind Method; Epilepsies | 2006 |
[Caffeine and antiepileptic drugs: experimental and clinical data].
Topics: Animals; Anticonvulsants; Caffeine; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactio | 2007 |
Oxcarbazepine: mechanisms of action.
Topics: Action Potentials; Animals; Anticonvulsants; Carbamazepine; Cells, Cultured; Disease Models, Animal; | 1994 |
A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.
Topics: Affect; Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Disease Progression; Dr | 1996 |
The phenomenology of psychosis associated with complex partial seizure disorder.
Topics: Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Clinical Trials as Topic; C | 1997 |
[Neonatal seizures: the beginning and interruption of the treatment].
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Humans; Phenobarbital; Seizures; Treatment Outcome | 1997 |
Does carbamazepine have a narrow therapeutic plasma concentration range?
Topics: Anticonvulsants; Canada; Carbamazepine; Chemistry, Pharmaceutical; Epilepsy; Humans; Seizures; Unite | 1998 |
Antiepileptic drugs as a cause of worsening seizures.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; | 1998 |
Status-like recurrent pilomotor seizures: case report and review of the literature.
Topics: Aged; Anticonvulsants; Carbamazepine; Diabetes Complications; Electroencephalography; Humans; Hyperg | 2000 |
Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.
Topics: Anticonvulsants; Brain Diseases; Brain Injuries; Carbamazepine; Controlled Clinical Trials as Topic; | 2001 |
Oxcarbazepine: an update of its efficacy in the management of epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clinical Trials as Topic; Humans; Ox | 2001 |
Management of carbamazepine overdose.
Topics: Anticonvulsants; Arrhythmias, Cardiac; Carbamazepine; Child; Drug Overdose; Hemoperfusion; Humans; S | 2001 |
Pharmacological prophylaxis in the kindling model of epilepsy.
Topics: Amygdala; Anesthetics, Local; Animals; Antidepressive Agents, Tricyclic; Atropine; Aziridines; Carba | 1977 |
Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic.
Topics: Amygdala; Carbamazepine; Female; Humans; Kindling, Neurologic; Male; Mental Disorders; Models, Neuro | 1992 |
Rational use of antiepileptic drug levels.
Topics: Carbamazepine; Half-Life; Humans; Phenobarbital; Phenytoin; Seizures; Valproic Acid | 1992 |
Carbamazepine dosing for pediatric seizure disorders: the highs and lows.
Topics: Adolescent; Carbamazepine; Child; Child, Preschool; Humans; Infant; Seizures | 1991 |
Anticonvulsants: pharmacotherapeutic issues in the critically ill patient.
Topics: Anticonvulsants; Benzodiazepines; Brain Injuries; Carbamazepine; Central Nervous System Diseases; Ep | 1991 |
Carbamazepine update.
Topics: Adult; Carbamazepine; Child; Drug Administration Schedule; Drug Interactions; Half-Life; Humans; Sei | 1989 |
A molecular approach to the calcium signal in brain: relationship to synaptic modulation and seizure discharge.
Topics: Animals; Anticonvulsants; Benzodiazepines; Binding, Competitive; Brain; Calcium; Calmodulin; Carbama | 1986 |
[Therapy of brain-related minor seizures].
Topics: Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, Myoclonic; Epilepsies, Partial; | 1988 |
Modern perspectives on epilepsy in relation to psychiatry: behavioral disturbances of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Kindling, Neurologic; Psychotic Disorders; Seizure | 1988 |
Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment.
Topics: Acute Disease; Adolescent; Adult; Animals; Black People; Brain Diseases; Calcinosis; Carbamazepine; | 1988 |
Advances in neurology.
Topics: Analgesics; Anticoagulants; Brain; Brain Neoplasms; Carbamazepine; Cerebrovascular Disorders; Contra | 1968 |
48 trials available for carbamazepine and Absence Seizure
| Article | Year |
|---|---|
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial.
Topics: Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Delayed-Action Preparations; Double-Blind Me | 2023 |
Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Female; Humans; | 2019 |
Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Topics: Adult; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availabi | 2017 |
Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: A randomized controlled trial.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Female; Follow-Up Studies; Humans; Male; Middle A | 2017 |
AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies.
Topics: Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Monitoring; Epilepsy; Female; Humans; Lamo | 2018 |
Effect of anti-seizure drugs on serum S100B in patients with focal seizure: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Biomarkers; Carbamazepine; Epilepsies, Partial; Female; Humans; Male; Oxcarb | 2018 |
Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Dibenzazepines; Diplopia; Dose-Response Re | 2018 |
Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Topics: Aged; Anticonvulsants; Carbamates; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
The effect of recurrent seizures on cognitive, behavioral, and quality-of-life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Cognition; Epilepsies, Partial; Female; Follow-Up Studies; Hu | 2015 |
Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Levetiracetam; Ma | 2016 |
Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Drug Therapy, Combination; Epilepsies, Par | 2009 |
Experience in the use of the anticonvulsant pregabalin as an add-on therapy in patients with partial epilepsy with polymorphic seizures.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Carbamazepine; Databases as Topic; Drug Therapy, C | 2010 |
Clinical trial of minimal treatment for clustering seizures in cases of convulsions with mild gastroenteritis.
Topics: Adolescent; Adult; Anesthetics, Local; Anticonvulsants; Carbamazepine; Child; Electroencephalography | 2011 |
[Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; | 2010 |
[Comparative efficacy of carbamazepine, valproic acid and topiramate in symptomatic and cryptogenic occipital lobe epilepsy in children].
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Brain Injuries; Carbamazepine; Child; Epilepsies, Part | 2010 |
Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Dibenzazepines; Dose-Response Relationship, Drug; Female; Hum | 2011 |
Interaction profile of Zizyphus jujuba with phenytoin, phenobarbitone, and carbamazepine in maximal electroshock-induced seizures in rats.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Chi-Square Distribution; Chromat | 2012 |
Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Female; Humans; | 2012 |
Acute symptomatic seizures due to single CT lesions: how long to treat with antiepileptic drugs?
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Brain Diseases; Carbamazepine; Child; Child, Pres | 2002 |
Apparent increase in type I 5'-deiodinase activity induced by antiepileptic medication in mentally retarded subjects.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Hormones; Humans; Intellectual Disability; Iodide Per | 2002 |
Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Double-Blind M | 2003 |
Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Drug Administr | 2003 |
Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Evaluation | 2003 |
Tiagabine as add-on therapy may be more effective with valproic acid--open label, multicentre study of patients with focal epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Carbamazepine; Child; Data Interpretation, St | 2005 |
Changes of seizures activity during rapid withdrawal of lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, C | 2005 |
Effect of carbamazepine on serum lipids and liver function tests.
Topics: Alkaline Phosphatase; Anticonvulsants; Bilirubin; Carbamazepine; Child; Child, Preschool; Cholestero | 2005 |
Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Carbamazepine; Cerebral Cortex; Child; Child, Prescho | 2008 |
Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults.
Topics: Adult; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Epilepsy; History, 20th Century; Hu | 1983 |
A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults.
Topics: Adolescent; Adult; Aged; Carbamazepine; Double-Blind Method; Epilepsies, Partial; Epilepsy, Tonic-Cl | 1983 |
Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study.
Topics: Adult; Attention; Brain Injuries; Carbamazepine; Cognition; Double-Blind Method; Emotions; Female; H | 1994 |
[Gamma-vinyl-GABA: first experiences in Italy. II].
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; | 1994 |
Treatment of neonatal seizures with carbamazepine.
Topics: Carbamazepine; Humans; Infant; Infant, Newborn; Seizures | 1996 |
A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Child; | 1998 |
Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Drug Combinations; Epilepsy; Female; Human | 1999 |
Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dizziness; Drug Interactions; Drug Monitoring; Dr | 1998 |
Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children.
Topics: Administration, Oral; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; | 1999 |
Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 2000 |
Spike-and-wave complexes and seizure exacerbation caused by carbamazepine.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsies, Partia | 2002 |
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Cerebellar Neoplasms; Craniotomy; Female; H | 2002 |
A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients.
Topics: Adult; Aged; Behavior; Carbamazepine; Delayed-Action Preparations; Double-Blind Method; Female; Huma | 1992 |
A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood.
Topics: Carbamazepine; Child; Child, Preschool; Drug Eruptions; Female; Humans; Male; Patient Compliance; Ra | 1989 |
Carbamazepine for 1st seizure.
Topics: Carbamazepine; Clinical Trials as Topic; Humans; Research Design; Seizures | 1989 |
Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.
Topics: Adult; Carbamazepine; Clinical Trials as Topic; Dizziness; Double-Blind Method; Drug Synergism; Drug | 1986 |
A controlled study of progabide in partial seizures: methodology and results.
Topics: Adolescent; Adult; Carbamazepine; Clinical Trials as Topic; Female; gamma-Aminobutyric Acid; Humans; | 1987 |
Effect of progabide on serum phenytoin and carbamazepine concentrations.
Topics: Adult; Carbamazepine; Convulsants; Double-Blind Method; Drug Evaluation; Female; gamma-Aminobutyric | 1987 |
Painful tonic seizure in multiple sclerosis.
Topics: Adult; Animals; Brain Stem; Carbamazepine; Cerebellum; Cerebral Cortex; Clinical Trials as Topic; De | 1974 |
Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol).
Topics: Administration, Oral; Adult; Carbamazepine; Dibenzazepines; Female; Humans; Male; Middle Aged; Multi | 1970 |
660 other studies available for carbamazepine and Absence Seizure
| Article | Year |
|---|---|
Synthesis and anticonvulsant activity of enaminones.
Topics: Amines; Animals; Anticonvulsants; Drug Evaluation, Preclinical; Electric Stimulation; Kindling, Neur | 1992 |
6-Alkyl-N,N-disubstituted-2-pyridinamines as anticonvulsant agents.
Topics: Aminopyridines; Animals; Ataxia; Blepharoptosis; Chemical Phenomena; Chemistry; Electroshock; Kindli | 1989 |
A novel class of potential central nervous system agents. 3-Phenyl-2-(1-piperazinyl)-5H-1-benzazepines.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Body Temperature Regulation; Brain; E | 1988 |
Substituted 1,3,4-thiadiazoles with anticonvulsant activity. 3. Guanidines.
Topics: Animals; Chemical Phenomena; Chemistry; Electroshock; Guanidines; Mice; Pentylenetetrazole; Rats; Se | 1987 |
Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyridazines in animal models of epilepsy.
Topics: Animals; Anticonvulsants; Bicuculline; Disease Models, Animal; Dose-Response Relationship, Drug; Ele | 1986 |
Substituted (omega-aminoalkoxy) stilbene derivatives as a new class of anticonvulsants.
Topics: Animals; Anticonvulsants; Biological Assay; Drug Evaluation, Preclinical; Electroshock; Indicators a | 1984 |
Synthesis and CLOGP correlation of imidooxy anticonvulsants.
Topics: Animals; Anticonvulsants; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Electrosh | 1993 |
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
Topics: Animals; Anticonvulsants; Binding Sites; Crystallography, X-Ray; Dose-Response Relationship, Drug; D | 1996 |
Aroyl(aminoacyl)pyrroles, a new class of anticonvulsant agents.
Topics: Anesthesia; Animals; Anticonvulsants; Bicuculline; Calcium; Cerebellum; Electroshock; Mice; Models, | 1997 |
Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Indicators and Reagents; M | 1998 |
Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Bicuculline; Drug Design; Electroshock; Indicators | 1998 |
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
Topics: Animals; Anticonvulsants; Electric Stimulation; Injections, Intraperitoneal; Male; Mice; Oxazoles; R | 1998 |
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
Topics: Amides; Animals; Anticonvulsants; Azepines; Calcium Channel Blockers; Calcium Channels; Cerebral Cor | 1999 |
Synthesis and anticonvulsant activity of 7-alkoxyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Mice; Neurotoxicity Syndromes; Quinolines; Seizure | 2005 |
Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Benzamides; Chemical and Drug Induced Liver | 2005 |
Synthesis and anticonvulsant activity of some novel 3-aryl amino/amino-4-aryl-5-imino-Delta2-1,2,4-thiadiazoline.
Topics: Animals; Anticonvulsants; Electroshock; Immobility Response, Tonic; Injections, Intraperitoneal; Mal | 2008 |
N-{[(6-substituted-1,3-benzothiazole-2-yl)amino]carbonothioyl}-2/4-substituted benzamides: synthesis and pharmacological evaluation.
Topics: Animals; Anticonvulsants; Benzamides; Benzothiazoles; Central Nervous System Depressants; Chemical a | 2008 |
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
Topics: Animals; Anticonvulsants; Brain Chemistry; Glutathione Peroxidase; Malondialdehyde; Mice; Motor Acti | 2009 |
Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; C | 2008 |
Anticonvulsant activity of some xanthone derivatives.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Mice; Molecular Structure; | 2008 |
Design and synthesis of 5-alkoxy-[1,2,4]triazolo[4,3-a]quinoline derivatives with anticonvulsant activity.
Topics: Animals; Anticonvulsants; Drug Design; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mic | 2009 |
Synthesis and anticonvulsant activity of N-(2-hydroxyethyl) cinnamamide derivatives.
Topics: 3-Mercaptopropionic Acid; Animals; Anticonvulsants; Cinnamates; Electroshock; Isoniazid; Mice; Penty | 2009 |
Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models.
Topics: Animals; Anticonvulsants; Benzodiazepines; Convulsants; Hippocampus; Kindling, Neurologic; Ligands; | 2009 |
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea.
Topics: Animals; Anticonvulsants; Behavior, Animal; Central Nervous System Depressants; Male; Mice; Molecula | 2009 |
Synthesis and anticonvulsant activity of a new 6-alkoxy-[1,2,4]triazolo[4,3-b]pyridazine.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, | 2010 |
Design and synthesis of 10-alkoxy-5, 6-dihydro-triazolo[4,3-d]benzo[f][1,4]oxazepine derivatives with anticonvulsant activity.
Topics: Animals; Anticonvulsants; Central Nervous System; Drug Design; Mice; Oxazepines; Oxygen; Seizures; S | 2010 |
Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents.
Topics: Animals; Anticonvulsants; Behavior, Animal; Drug Design; Electroshock; Male; Mice; Nervous System; P | 2010 |
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
Topics: Amides; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Hydantoins; Mice; | 2010 |
Synthesis and anticonvulsant activity of 7-phenyl-6,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-ones and their derivatives.
Topics: 3-Mercaptopropionic Acid; Animals; Anticonvulsants; Bicuculline; Electroshock; Isoniazid; Mice; Pent | 2011 |
Synthesis and anticonvulsant activity of trans- and cis-2-(2,6-dimethylphenoxy)-N-(2- or 4-hydroxycyclohexyl)acetamides and their amine analogs.
Topics: Acetamides; Amines; Animals; Anticonvulsants; Mice; Rats; Seizures | 2011 |
Design and synthesis of 3,5-diarylpiperidin-2,6-diones as anticonvulsant agents.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinica | 2012 |
Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
Topics: Animals; Anticonvulsants; Biological Assay; Electroshock; Heptanes; Magnetic Resonance Spectroscopy; | 2012 |
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
Topics: Animals; Anticonvulsants; Carbamates; Male; Mice; Neurotoxicity Syndromes; Rats; Rats, Sprague-Dawle | 2012 |
Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
Topics: Animals; Anticonvulsants; Chemistry Techniques, Synthetic; Hydrazines; Male; Mice; Motor Activity; R | 2012 |
Synthesis of some novel 1-(2-naphthyl)-2-(imidazol-1-yl)ethanone oxime ester derivatives and evaluation of their anticonvulsant activity.
Topics: Animals; Anticonvulsants; Electroshock; Esters; Imidazoles; Isomerism; Mice; Motor Activity; Naphazo | 2012 |
Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.
Topics: Acrylamide; Amides; Animals; Anticonvulsants; Benzothiazoles; Brain; Dose-Response Relationship, Dru | 2012 |
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
Topics: Acyclic Monoterpenes; Animals; Anticonvulsants; Binding Sites; Cyclohexenes; Disease Models, Animal; | 2013 |
Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Disease Models, | 2013 |
Synthesis and anticonvulsant activity of novel purine derivatives.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Mice; Motor Activity; Pentylenetetra | 2014 |
Seizure prevention by the naturally occurring phenols, carvacrol and thymol in a partial seizure-psychomotor model.
Topics: Animals; Anticonvulsants; Cymenes; Disease Models, Animal; Monoterpenes; Phenols; Psychomotor Perfor | 2014 |
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
Topics: Animals; Anticonvulsants; Carbamates; Drug Design; Electroshock; Epilepsy; Mice; Pentylenetetrazole; | 2015 |
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
Topics: Amides; Animals; Anticonvulsants; Benzylamines; Convulsants; Disease Models, Animal; Dose-Response R | 2015 |
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Ele | 2015 |
Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
Topics: Animals; Anticonvulsants; Crystallography, X-Ray; Cyclic S-Oxides; Disease Models, Animal; Dose-Resp | 2015 |
Anticonvulsant activity, crystal structures, and preliminary safety evaluation of N-trans-cinnamoyl derivatives of selected (un)modified aminoalkanols.
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Drug Evalu | 2016 |
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Elec | 2016 |
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
Topics: Amides; Animals; Anticonvulsants; Calcium Channels; Drug Design; Humans; Injections, Intraperitoneal | 2016 |
New (arylalkyl)azole derivatives showing anticonvulsant effects could have VGSC and/or GABA
Topics: Animals; Anticonvulsants; Azoles; Calcium Channels; Drug Design; Male; Mice; Molecular Docking Simul | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Respo | 2017 |
Hematologic findings in drug reaction with eosinophilia and systemic symptoms (DRESS).
Topics: Anticonvulsants; Carbamazepine; Drug Hypersensitivity Syndrome; Humans; Male; Middle Aged; Seizures; | 2021 |
Maternal Duplication 15q11-13 Syndrome with Autism Spectrum Disorder: Mood Stabilization by Carbamazepine.
Topics: Anticonvulsants; Antimanic Agents; Autism Spectrum Disorder; Benzodiazepines; Carbamazepine; Humans; | 2022 |
Factors involved in time reduction between seizure relapses in patients with epilepsy attending emergency rooms in Medellín, Colombia.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Colombia; Emergency Service, Hospital; Epilepsies, Parti | 2022 |
Prospective multisite cohort study of patient-reported outcomes in adults with new-onset seizures.
Topics: Adolescent; Adult; Anticonvulsants; Australia; Carbamazepine; Cohort Studies; Epilepsies, Partial; E | 2022 |
Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
Topics: Adult; Anticonvulsants; Carbamazepine; Chemical and Drug Induced Liver Injury; Chemical and Drug Ind | 2022 |
Stimulus-induced focal motor seizure in a pediatric patient with carbamazepine overdose.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Drug Overdose; Epilepsies, Partial; Female; | 2022 |
Incidence of mental health conditions by seizure control among adults with epilepsy in the United States.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Epilepsy, Ge | 2022 |
Expanding the genetic and clinical characteristics of Protocadherin 19 gene mutations.
Topics: Cadherins; Carbamazepine; Child, Preschool; Clonazepam; Epilepsy; Female; Humans; Infant; Mutation; | 2022 |
Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Drug Therapy, Combination; Drug-Related Sid | 2022 |
Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child; Epilepsy; Humans; Oxcarbazepine; Seizures | 2022 |
Carbamazepine-induced convulsive status epilepticus in benign adult familial myoclonic epilepsy: a case report.
Topics: Adult; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, Myoclonic; Humans; Seizur | 2023 |
Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach.
Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Epilepsy; Levetiracetam; Male; M | 2022 |
Polymorphisms of the sodium voltage-gated channel, alpha subunit 1 (SCN1A -A3184G) gene among children with non-lesional epilepsy: a case-control study.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Epilepsy; Genotype; Humans; | 2022 |
Rutin prevents seizures in kainic acid-treated rats: evidence of glutamate levels, inflammation and neuronal loss modulation.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amino Acid Transport Systems; Animals; Ant | 2022 |
Dyke-davidoff-masson syndrome: A case report of an adolescent boy at a tertiary hospital in Adamawa, North-Eastern Nigeria.
Topics: Adolescent; Adult; Amides; Aphasia, Broca; Atrophy; Carbamazepine; Child; Child, Preschool; Humans; | 2022 |
Long-Term Effects of Antiseizure Medications.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Phenytoin; Seizures | 2022 |
Ranolazine Interacts Antagonistically with Some Classical Antiepileptic Drugs-An Isobolographic Analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease Models, Animal; Dose-Res | 2022 |
Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure.
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Freedom; Glioma; Humans; Levetiraceta | 2023 |
Interaction of Varenicline with Classic Antiseizure Medications in the Mouse Maximal Electroshock-Induced Seizure Model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, | 2023 |
Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Humans; Seizures | 2023 |
Anticonvulsant effects of isopimpinellin and its interactions with classic antiseizure medications and borneol in the mouse tonic-clonic seizure model: an isobolographic transformation.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2023 |
Quantification of Oxcarbazepine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans | 2024 |
Seizures in Down Syndrome: An Update.
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Down Syndrome; Epilepsies, Partial; Epileps | 2019 |
Elevated serum alkaline phosphatase in epilepsy: effect of age and treatment.
Topics: Adolescent; Adult; Age Factors; Alkaline Phosphatase; Anticonvulsants; Carbamazepine; Child; Child, | 2020 |
Bilateral acute angle closure as presenting feature of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).
Topics: Acute Disease; Adult; Anterior Eye Segment; Anticonvulsants; Carbamazepine; Drug Hypersensitivity Sy | 2019 |
[Epilepsy in children with congenital hemiparesis secondary to perinatal ictus].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Infan | 2019 |
Activation of adenosine receptors modulates the efflux transporters in brain capillaries and restores the anticonvulsant effect of carbamazepine in carbamazepine resistant rats developed by window-pentylenetetrazole kindling.
Topics: Animals; Anticonvulsants; Brain; Capillaries; Carbamazepine; Disease Models, Animal; Drug Resistant | 2020 |
Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? - A case series.
Topics: Adult; Carbamazepine; Epilepsies, Partial; Female; Humans; Male; Middle Aged; Pyrrolidinones; Seizur | 2020 |
Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Folic Acid; Humans; India; Lamotrigine; Levetiracetam | 2020 |
Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Drug Carriers | 2020 |
Nebivolol attenuates the anticonvulsant action of carbamazepine and phenobarbital against the maximal electroshock-induced seizures in mice.
Topics: Adrenergic beta-1 Receptor Agonists; Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal | 2020 |
Patterns of antiepileptic drug use among elderly patients with epilepsy: 2004-2015.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2020 |
Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome.
Topics: Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy; Humans; Lacosamide; Lamotri | 2020 |
Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Epilepsies, Partial; Epilepsy, Generalized | 2020 |
Reversible Splenial Lesion Syndrome with Some Novel Causes and Clinical Manifestations.
Topics: Adult; Anticonvulsants; Brain Diseases; Carbamazepine; Causality; Corpus Callosum; Female; Headache; | 2020 |
Seizures in self-limited epilepsy with centrotemporal spikes: video-EEG documentation.
Topics: Carbamazepine; Child; Documentation; Electroencephalography; Epilepsy, Rolandic; Humans; Male; Seizu | 2020 |
COVID-19 & antiepileptic drugs: Should we pay attention?
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Carbamazepine; Coronavirus I | 2020 |
Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.
Topics: Animals; Animals, Outbred Strains; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Cornea; | 2020 |
Distinct effects on cAMP signaling of carbamazepine and its structural derivatives do not correlate with their clinical efficacy in epilepsy.
Topics: Adenylyl Cyclases; Anticonvulsants; Calcium Signaling; Carbamazepine; Cyclic AMP; Cyclic AMP Respons | 2020 |
Effect of aliskiren on the anticonvulsant activity of antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
Topics: Amides; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease Models, Animal; | 2020 |
Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; China; Epilepsy; Female; Humans | 2020 |
Development and validation of a predictive model for the diagnosis of neural antibody-mediated epilepsy/ seizure in patients with new-onset seizure or established epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy, Generalized; Female; Humans; M | 2020 |
Childhood-onset seizures: A long-term cohort study of use of antiepileptic drugs, and drugs for neuropsychiatric conditions.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Comorbidity; Drug-Related Side | 2020 |
Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Drug Interactions; Drug Monitoring; Drug T | 2020 |
Anticonvulsant Effectiveness and Neurotoxicity Profile of 4-butyl-5-[(4-chloro-2-methylphenoxy)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione (TPL-16) in Mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Drug Synergism; Male; Mice; Muscle Strength; Phenobarbital; | 2021 |
Antiepileptic drugs and depression during pregnancy in women with epilepsy.
Topics: Adult; Anticonvulsants; Australia; Carbamazepine; Depression; Epilepsy; Female; Humans; Levetiraceta | 2020 |
Antihistamines as a common cause of new-onset seizures: a single-center observational study.
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; | 2021 |
Acute and chronic treatment with moclobemide, a reversible MAO-inhibitor, potentiates the antielectroshock activity of conventional antiepileptic drugs in mice.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, | 2021 |
Knowledge of epilepsy among German pharmacists.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; L | 2021 |
Disulfiram-induced epileptic seizures.
Topics: Anticonvulsants; Carbamazepine; Disulfiram; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, To | 2021 |
Sensitivity of unilateral- versus bilateral-onset spike-wave discharges to ethosuximide and carbamazepine in the fluid percussion injury rat model of traumatic brain injury.
Topics: Animals; Anticonvulsants; Brain Injuries, Traumatic; Carbamazepine; Disease Models, Animal; Electroc | 2021 |
Chronic limbic epilepsy models for therapy discovery: Protocols to improve efficiency.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Epilepsy; Levetiracetam; Pharmaceut | 2021 |
Carbamazepine/oxcarbazepine and valproate have different effects on the electroconvulsive therapy seizure threshold.
Topics: Carbamazepine; Electroconvulsive Therapy; Humans; Oxcarbazepine; Seizures; Valproic Acid | 2021 |
Influence of perfluorocarbons on Carbamazepine and Benzodiazepine for a neuro-lung protective strategy.
Topics: Benzodiazepines; Carbamazepine; Drug Compounding; Emulsions; Fluorocarbons; Humans; Lung; Neuroprote | 2017 |
Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Clonazepam; Drug Interactions; Drug Monitoring; Drug Therapy, | 2017 |
Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Dibenzazepines; Drug Therapy, Combination; Epilepsies, Partia | 2018 |
Side-Effects of Convulsive Seizures and Anti-Seizure Therapy on Bone in a Rat Model of Epilepsy.
Topics: Animals; Anticonvulsants; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcium; Carbamaze | 2018 |
A Distinctive Ictal Amplitude-Integrated Electroencephalography Pattern in Newborns with Neonatal Epilepsy Associated with KCNQ2 Mutations.
Topics: Anticonvulsants; Brain; Brain Waves; Carbamazepine; DNA Mutational Analysis; Electroencephalography; | 2017 |
Who are the individuals diagnosed with epilepsy using the Public Health System in the city of Pelotas, southern Brazil?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Anxiety; Brazil; Carbamazepine; Child; Cross-Sectional Stu | 2018 |
Reversible splenial lesion syndrome due to oxcarbazepine withdrawal: case report and literature review.
Topics: Adult; Anticonvulsants; Brain Diseases; Carbamazepine; Corpus Callosum; Disease Management; Humans; | 2018 |
Amiodarone, a multi-channel blocker, enhances anticonvulsive effect of carbamazepine in the mouse maximal electroshock model.
Topics: Amiodarone; Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Re | 2018 |
Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study.
Topics: Administration, Oral; Age Factors; Anticonvulsants; Carbamazepine; Child, Preschool; China; Dose-Res | 2018 |
A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clobazam; Female; Humans | 2018 |
[A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Japan; Levetiracetam; Male; Piracetam; Sei | 2018 |
Treatment of epilepsy in multiple sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Disability Evaluation; Electronic He | 2018 |
Carbamazepine Verses Valproic Acid as Monotherapy in Epileptic Patients.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Chromatography, Liquid; Epilepsy; Female; | 2018 |
Electrocorticographic telemetric recording in unrestrained mouse pups.
Topics: Animals; Behavior, Animal; Brain; Carbamazepine; Electrocorticography; Epilepsy; Female; Male; Mice, | 2018 |
A Clinical Study of Toxication Caused by Carbamazepine Abuse in Adolescents.
Topics: Adolescent; Carbamazepine; Child; Coma; Drug Overdose; Female; Humans; Male; Renal Dialysis; Respira | 2018 |
Dyke-Davidoff-Masson Syndrome: An Unusual Cause of Status Epilepticus and Refractory Seizures.
Topics: Adolescent; Atrophy; Brain; Carbamazepine; Female; Humans; Levetiracetam; Magnetic Resonance Imaging | 2018 |
Effects of Chronic Carbamazepine Treatment on the ECG in Patients with Focal Seizures.
Topics: Adolescent; Adult; Anticonvulsants; Arrhythmias, Cardiac; Carbamazepine; Cross-Sectional Studies; Dr | 2018 |
Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation.
Topics: Animals; Anticonvulsants; Carbamazepine; Drug Carriers; Drug Liberation; Male; Nanostructures; Rats, | 2018 |
Effects of androsterone on the protective action of various antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Androgens; Androsterone; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease | 2019 |
Influence of dronedarone (a class III antiarrhythmic drug) on the anticonvulsant potency of four classical antiepileptic drugs in the tonic-clonic seizure model in mice.
Topics: Animals; Anti-Arrhythmia Agents; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Disease Mo | 2019 |
Factors predicting uncontrolled seizures in epilepsy with auditory features.
Topics: Adult; Anticonvulsants; Auditory Pathways; Carbamazepine; Databases, Bibliographic; Dose-Response Re | 2019 |
Correction of medication nonadherence results in better seizure outcomes than dose escalation in a novel preclinical epilepsy model of adherence.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Electroencephalography; Epilepsy; M | 2019 |
Neuronal protective effect of Songling Xuemaikang capsules alone and in combination with carbamazepine on epilepsy in kainic acid-kindled rats.
Topics: Animals; Anticonvulsants; Apoptosis; Carbamazepine; Caspase 9; Cognition; Drug Therapy, Combination; | 2019 |
[An adult female with proline-rich transmembrane protein 2 related paroxysmal disorders manifesting paroxysmal kinesigenic choreoathetosis and epileptic seizures].
Topics: Carbamazepine; Dystonia; Electroencephalography; Female; Humans; Membrane Proteins; Mutation; Nerve | 2019 |
Effect of carbamazepine on spontaneous recurrent seizures recorded from the dentate gyrus in rats with kainate-induced epilepsy.
Topics: Animals; Anticonvulsants; Carbamazepine; Convulsants; Dentate Gyrus; Disease Models, Animal; Epileps | 2019 |
New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Drug Synergism; | 2019 |
Epilepsy in patients with Cornelia de Lange syndrome: a clinical series.
Topics: Adolescent; Carbamazepine; Child; Child, Preschool; De Lange Syndrome; Electroencephalography; Epile | 2013 |
Pearls and oy-sters: ictal syncope in a patient with temporal lobe epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Electrocardiography; Electroencephalography; Epilepsy, T | 2013 |
Acute oxcarbazepine-induced hepatotoxicity in a patient susceptible to developing drug-induced liver injury.
Topics: Acridines; Carbamazepine; Chemical and Drug Induced Liver Injury; Delivery, Obstetric; Female; Human | 2013 |
Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.
Topics: Carbamazepine; Dementia; Diazepam; Electroencephalography; Haloperidol; Hematology; Humans; Hydroxoc | 2013 |
Septo-optic dysplasia: fitting the pieces together.
Topics: Anticonvulsants; Carbamazepine; Child; Electroencephalography; Humans; Hypoglycemia; Hypopituitarism | 2013 |
[A paradoxical reaction on valproates in a female patient with juvenile absence epilepsy].
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2013 |
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Lamotrigine; Phenobarbital; Pregnancy; Pregnancy Com | 2013 |
Successful treatment of early myoclonic encephalopathy using lidocaine and carbamazepine.
Topics: Anesthetics, Local; Anticonvulsants; Brain; Carbamazepine; Electroencephalography; Epilepsy, Tonic-C | 2013 |
Design, synthesis and anticonvulsant activity evaluation of novel 4-(4-substitutedphenyl)-3-methyl-1H-1,2,4-triazol-5(4H)-ones.
Topics: Animals; Anticonvulsants; Carbamazepine; Convulsants; Drug Design; Drug Evaluation, Preclinical; Ele | 2014 |
Carbamazepine-induced DRESS syndrome in a child: rapid response to pulsed corticosteroids.
Topics: Adolescent; Anti-Inflammatory Agents; Anticonvulsants; Brain Injuries; Carbamazepine; Drug Hypersens | 2013 |
Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Topics: Adrenal Cortex Hormones; Allergens; Carbamazepine; Ceftriaxone; Child; Child, Preschool; Drug Erupti | 2013 |
Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Benzoxazines; Brain; Cannabinoid Receptor Agonists; Ca | 2013 |
Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Disease Models, Animal; Drug Combinatio | 2014 |
Novel anticonvulsive effects of progesterone in a mouse model of hippocampal electrical kindling.
Topics: Action Potentials; Animals; Anticonvulsants; Berberine Alkaloids; Carbamazepine; Convulsants; Diseas | 2014 |
Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital.
Topics: Adolescent; Adult; Anticonvulsants; Bangladesh; Carbamazepine; Child; Drug Combinations; Epilepsies, | 2013 |
Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus.
Topics: Administration, Rectal; Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Carbamazep | 2014 |
Carbamazepine treatment of generalized tonic-clonic seizures in idiopathic generalized epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy, Generalized; Female; Humans; Male; Middle Aged; Sei | 2014 |
Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
Topics: Acetamides; Adult; Aged; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Inte | 2014 |
Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Dr | 2014 |
The ictal bradycardia syndrome: persistence of seizures despite cardiac pacemaker implantation.
Topics: Anticonvulsants; Bradycardia; Carbamazepine; Cardiac Pacing, Artificial; Electrocardiography; Electr | 2014 |
Peri-ictal headache due to epileptiform activity in a disconnected hemisphere.
Topics: Anticonvulsants; Brain; Carbamazepine; Child, Preschool; Electroencephalography; Epilepsy; Female; F | 2014 |
Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients.
Topics: Alleles; Asian People; Carbamazepine; Epilepsy; Genotype; Humans; NAV1.1 Voltage-Gated Sodium Channe | 2014 |
Pause for thought? Syncope and sinus arrest as the presenting feature of temporal lobe epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy, Temporal Lobe; Humans; Male; Pacemaker, Artificial; | 2014 |
Gelastic epilepsy without hypothalamic hamartoma: three additional cases.
Topics: Adolescent; Anticonvulsants; Behavior; Carbamazepine; Child; Child, Preschool; Electroencephalograph | 2014 |
Serial EEG study in a girl with Landau-Kleffner syndrome associated with continuous spikes and waves during slow sleep.
Topics: Anticonvulsants; Brain; Carbamazepine; Electroencephalography; Female; Humans; Infant; Landau-Kleffn | 2014 |
Epilepsy in patients with gliomas: incidence and control of seizures.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Female; Glioma; Humans; Inci | 2015 |
Cerebral aspergillosis in a patient with leprosy and diabetes: a case report.
Topics: Amphotericin B; Anticonvulsants; Antifungal Agents; Aspergillus fumigatus; Biopsy; Carbamazepine; Ce | 2014 |
Validation of a multigenic model to predict seizure control in newly treated epilepsy.
Topics: Adult; Algorithms; Anticonvulsants; Artificial Intelligence; Australia; Biomarkers, Pharmacological; | 2014 |
HLA-B∗ 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Female; Gene Expression; HLA-B15 Antige | 2014 |
[Convulsions due to an interaction between anti-epileptic drugs and rifampicin].
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Cytochrome P-450 Enzyme System; Drug Interactions; Epile | 2014 |
Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Drug Resistance; Electrod | 2015 |
Phenytoin induced toxic epidermal necrolysis.
Topics: Anticonvulsants; Carbamazepine; Drug Hypersensitivity; Humans; Male; Middle Aged; Phenytoin; Seizure | 2014 |
Haematidrosis associated with epilepsy in a girl successfully treated with oxcarbazepine: case report.
Topics: Anticonvulsants; Carbamazepine; Child; Female; Hemorrhage; Humans; Oxcarbazepine; Seizures; Sweating | 2015 |
Modafinil and its metabolites enhance the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model.
Topics: Animals; Anticonvulsants; Avoidance Learning; Benzhydryl Compounds; Brain; Carbamazepine; Central Ne | 2015 |
Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort.
Topics: Adult; Anticonvulsants; Brain Injuries; Carbamazepine; Case-Control Studies; Chemoprevention; Cohort | 2016 |
New benzo[d]thiazol-2-yl-aminoacetamides as potential anticonvulsants: synthesis, activity and prediction of molecular properties.
Topics: Acetamides; Animals; Anticonvulsants; Benzothiazoles; Carbamazepine; Computer Simulation; Disease Mo | 2015 |
Nocturnal paroxysmal dystonia - case report.
Topics: Anticonvulsants; Carbamazepine; Electroencephalography; Female; Humans; Middle Aged; Nocturnal Parox | 2015 |
Effect of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of classical antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Drug Synergism; Electroshock; Male; Methoxsalen; Mice; Phen | 2015 |
Carbamazepine and oxcarbazepine in adult patients with Dravet syndrome: Friend or foe?
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsies, Myoclonic; Female; Humans; Inpatients; Male; Midd | 2015 |
Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Levetiracetam; Male; Mice | 2015 |
Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsies, Partial; Fem | 2015 |
Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cohort Studies; Female; Humans; Male | 2015 |
Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes.
Topics: Adolescent; Adult; Anticonvulsants; Bromides; Carbamazepine; Child; Child, Preschool; Epilepsies, My | 2016 |
Visual Diagnosis: Newborn With a Facial Vascular Birthmark.
Topics: Anticonvulsants; Carbamazepine; Humans; Infant, Newborn; Low-Level Light Therapy; Magnetic Resonance | 2015 |
Influence of MPEP (a selective mGluR5 antagonist) on the anticonvulsant action of novel antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, | 2016 |
Superficial siderosis of the central nervous system with seizures onset.
Topics: Ataxia; Carbamazepine; Carcinoma; Central Nervous System; Diagnosis, Differential; Female; Gait; Hum | 2015 |
Seizures with an atypical aetiology in an elderly patient: Eagle's syndrome--how does one treat it?
Topics: Analgesics, Non-Narcotic; Anticonvulsants; Carbamazepine; Diagnosis, Differential; Female; Glossopha | 2015 |
Early toxic epidermal necrolysis syndrome post-intra-cranial tumor resection.
Topics: Anticonvulsants; Asian People; Carbamazepine; Female; Humans; Immunoglobulins; Meningeal Neoplasms; | 2016 |
Mexiletine and its Interactions with Classical Antiepileptic Drugs: An Isobolographic Analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Drug Interactions; Electroshock; | 2016 |
Isobolographic Analysis of Interaction for Three-Drug Combination of Carbamazepine, Phenobarbital and Topiramate in the Mouse Maximal Electroshock-Induced Seizure Model.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Drug Therapy, Co | 2016 |
The effects of cimetidine chronic treatment on conventional antiepileptic drugs in mice.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Cimetidine; Drug Interactions; Electroshock; Male; M | 2016 |
Seizures triggered by pentylenetetrazol in marmosets made chronically epileptic with pilocarpine show greater refractoriness to treatment.
Topics: Animals; Anticonvulsants; Brain; Callithrix; Carbamazepine; Chronic Disease; Disease Models, Animal; | 2016 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
Catamenial Epilepsy: The Menstrual Cycle as a Clue to Predict Future Refractory Seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Menstrual Cycle; Seizures | 2017 |
Influence of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of various novel antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Acetamides; Animals; Anticonvulsants; Carbamazepine; Drug Synergism; Electroshock; Fructose; Lacosam | 2016 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Severe Carbamazepine Intoxication in Children: Analysis of a 40-Case Series.
Topics: Adolescent; Brain Injuries; Carbamazepine; Child; Child, Preschool; Coma; Female; Glasgow Coma Scale | 2016 |
Clinical Epidemiology and Treatment of Febrile and Afebrile Convulsions With Mild Gastroenteritis: A Multicenter Study.
Topics: Anticonvulsants; Carbamazepine; Diazepam; Female; Fever; Gastroenteritis; Humans; Infant; Linear Mod | 2017 |
Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Body Weight; Carbamazepine; Child; Child, Pr | 2017 |
Unusual association of SCN2A epileptic encephalopathy with severe cortical dysplasia detected by prenatal MRI.
Topics: Adult; Brain Diseases; Carbamazepine; Female; Humans; Infant, Newborn; Infant, Premature; Magnetic R | 2017 |
The effect of newer antiepileptic drugs in combination therapy.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Drug Therapy, Combination; Epi | 2017 |
A study on epileptic negative myoclonus in atypical benign partial epilepsy of childhood.
Topics: Adrenal Cortex Hormones; Anticonvulsants; Brain; Carbamazepine; Child; Child, Preschool; Clonazepam; | 2009 |
Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.
Topics: Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Brain; Carbamates; Carbamazepine; Di | 2009 |
Transient lesion in the splenium of the corpus callosum due to carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Corpus Callosum; Female; Humans; Magnetic Resonance Imaging; Psychop | 2008 |
Oxcarbazepine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Topics: Adolescent; Anticonvulsants; Carbamazepine; Drug Eruptions; Eosinophilia; Fever; Glucocorticoids; Hu | 2008 |
Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine.
Topics: 4-Aminopyridine; Acoustic Stimulation; Animals; Anticonvulsants; Auditory Threshold; Carbamazepine; | 2008 |
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
Topics: Animals; Anticonvulsants; Biological Transport; Carbamazepine; Chromatography, Liquid; Dose-Response | 2008 |
Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures.
Topics: Acute Disease; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bl | 2008 |
[Use of anticonvulsant pregabalin as an add-on therapy in patients with partial epilepsy with polymorphic seizures].
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsies, Partial; F | 2008 |
Rapamycin reduces seizure frequency in tuberous sclerosis complex.
Topics: Anticonvulsants; Carbamazepine; Cerebral Cortex; Child; Dose-Response Relationship, Drug; Drug Thera | 2009 |
Focal epileptic seizures mimicking sleep paralysis.
Topics: Anticonvulsants; Carbamazepine; Diagnosis, Differential; Electroencephalography; Epilepsies, Partial | 2009 |
Clinical characteristics of benign convulsions with rotavirus gastroenteritis.
Topics: Anticonvulsants; Body Weight; Carbamazepine; Child; Child, Preschool; Chlorides; Creatinine; Female; | 2009 |
Synthesis of 2-substituted-6-(4H-1,2,4-triazol-4-yl)benzo[d]oxazoles as potential anticonvulsant agents.
Topics: Animals; Anticonvulsants; Behavior, Animal; Benzoxazoles; Carbamazepine; Disease Models, Animal; Ele | 2009 |
Eruptive pyogenic granulomas developing after drug hypersensitivity reaction.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Drug Hypersensitivity; Granuloma, Pyogenic; Humans; Male | 2009 |
Seizure deterioration in women treated with oxcarbazepine during pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Humans; Oxcarbazepine; Pregnancy; Pregnancy Complicat | 2009 |
Effect of celecoxib on anticonvulsant activity of carbamazepine against maximal electroshock-induced convulsions in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relatio | 2008 |
Cerebral schistosomiasis--an unusual presentation of an intracranial mass lesion.
Topics: Adult; Animals; Anthelmintics; Anti-Inflammatory Agents; Anticonvulsants; Antitubercular Agents; Bra | 2009 |
Neuro-protective effects of carbamazepine on sleep patterns and head and body shakes in kainic acid-treated rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Calcium Channels, L-Type; Carbamazepine; Kainic Acid; Ma | 2009 |
Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.
Topics: 3-Mercaptopropionic Acid; Analysis of Variance; Animals; Anticonvulsants; ATP Binding Cassette Trans | 2009 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
EEG-fMRI coregistration in non-ketotic hyperglycemic occipital seizures.
Topics: Anticonvulsants; Carbamazepine; Electroencephalography; Female; Humans; Hyperglycemia; Hypoglycemic | 2009 |
N-(anilinomethyl)-p-isopropoxyphenylsuccinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model.
Topics: Aniline Compounds; Animals; Anticonvulsants; Brain; Carbamazepine; Dose-Response Relationship, Drug; | 2009 |
Serum biotinidase activity in children treated with valproic acid and carbamazepine.
Topics: Alanine Transaminase; Ammonia; Anticonvulsants; Aspartate Aminotransferases; Biotinidase; Carbamazep | 2010 |
Possible epileptic origin of symptoms in a case exemplifying the sleeper kind of 'limbic psychotic trigger reaction'.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Crime; Epilepsy; Female; Hallucinations | 2009 |
Effectiveness of the first antiepileptic drug in the treatment of pediatric epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Fructose; Humans; Retrospective S | 2009 |
The use of antiepileptic drugs in pediatric brain tumor patients.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Child; Drug Interactions; Fo | 2009 |
Antiepileptic drugs abolish ictal but not interictal epileptiform discharges in vitro.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anticonvulsants; Brain; Carbamazepine; Convulsants; Dis | 2010 |
Neurocysticercosis in the infant of a pregnant mother with a tapeworm.
Topics: Albendazole; Animals; Anthelmintics; Anti-Inflammatory Agents; Anticonvulsants; Carbamazepine; Dexam | 2009 |
Effect of ethacrynic acid on the anticonvulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Avoidance Learning; Brain; Brain Chemistry; Carbamaz | 2009 |
The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Electri | 2010 |
Effect of various antiepileptic drugs in a pentylenetetrazol-induced seizure model in mice.
Topics: Adenosine; Algorithms; Animals; Anti-Inflammatory Agents; Anticonvulsants; Barbiturates; Carbamazepi | 2009 |
Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Catalase; Cognition; Cognition D | 2010 |
Superficial siderosis of the central nervous system manifested with seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Central Nervous System; Cerebellar Ataxia; Cerebellum; Hearin | 2010 |
Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Disease Models, Animal; Dopamine Antago | 2010 |
Interaction of pregabalin with carbamazepine in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; ga | 2010 |
Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Drug Resistance; Epilepsies, Par | 2010 |
Seizure after intrathecal baclofen bolus in a multiple sclerosis patient treated with oxcarbazepine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Baclofen; Benzodiazepines; Carbamazepine; Female; GABA | 2011 |
Retrospective analysis of the effectiveness of first-line antiepileptic drugs for generalized onset and unclassified epileptic seizures in Chinese children.
Topics: Age of Onset; Anticonvulsants; Asian People; Carbamazepine; Child; Child, Preschool; Epilepsy; Femal | 2011 |
Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves.
Topics: Animals; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; | 2010 |
Benign infantile focal epilepsy with midline spikes and waves during sleep: a new epileptic syndrome or a variant of benign focal epilepsy?
Topics: Age of Onset; Anticonvulsants; Carbamazepine; Child, Preschool; Drug Therapy, Combination; Electroen | 2010 |
Effects of three N-(carboxyanilinomethyl) derivatives of p-isopropoxyphenylsuccinimide on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model.
Topics: Aniline Compounds; Animals; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Disease Models, | 2010 |
Synthesis and anticonvulsant activity of 7-alkoxy-triazolo-[3, 4-b]benzo[d]thiazoles.
Topics: Animals; Anticonvulsants; Benzothiazoles; Carbamazepine; Drug Evaluation, Preclinical; Electroshock; | 2010 |
Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Topics: Adult; Aged; Anticonvulsants; Bayes Theorem; Carbamazepine; Chronic Disease; Databases, Factual; Dem | 2011 |
Seizures due to water loading in a young epileptic woman preparing for full bladder ultrasound.
Topics: Adult; Anticonvulsants; Carbamazepine; Drinking; Epilepsy; Female; Humans; Hyponatremia; Seizures; U | 2011 |
Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Benzoxazines; Cannabinoid Receptor Agonists; Carbamaze | 2011 |
Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Catalase; Cognition Disorders; Disease Models, Animal; Drug | 2011 |
Risk factors for late-onset seizures related to cerebral contusions in adults with a moderate traumatic brain injury.
Topics: Adult; Aged; Aging; Anticonvulsants; Brain; Brain Injuries; Carbamazepine; Electroencephalography; F | 2011 |
[Multicenter observational study of the effect of oxcarbazepine on the general well-being of adults with partial epilepsy].
Topics: Adult; Affect; Aged; Anticonvulsants; Anxiety; Carbamazepine; Epilepsies, Partial; Female; Happiness | 2010 |
Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy.
Topics: Amino Acids; Animals; Carbamazepine; Convulsants; Drug Evaluation, Preclinical; Electroshock; Epilep | 2011 |
Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Electroencephalo | 2011 |
Impact of oxcarbazepine sulfate metabolite on incurred sample reanalysis and quantification of oxcarbazepine.
Topics: Anticonvulsants; Artifacts; Biotransformation; Calibration; Carbamazepine; Chromatography, High Pres | 2011 |
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Depression; Dose-Response Relationship, Drug; Electr | 2011 |
The influence of valproic acid and carbamazepine treatment on serum biotin and zinc levels and on biotinidase activity.
Topics: Adolescent; Anticonvulsants; Biotin; Biotinidase; Carbamazepine; Child; Female; Humans; Male; Seizur | 2011 |
Carbamazepine inhibits distinct chemoconvulsant-induced seizure-like activity in Dugesia tigrina.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Convulsants; Dose-Response Relationship, | 2011 |
Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dopamine; Hippocampus; Homovanillic | 2011 |
A case of combined forms of unilateral heterotopia.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Brain Diseases; Carbamazepine; Cereb | 2012 |
Successful Gamma Knife-based stereotactic radiosurgery treatment for medically intractable heterotopia-based seizure disorder.
Topics: Anticonvulsants; Brain Edema; Carbamazepine; Drug Resistance; Female; Humans; Magnetic Resonance Ima | 2011 |
Localisation value of ictal arterial spin-labelled sequences in partial seizures.
Topics: Adult; Anticonvulsants; Brain Injuries; Carbamazepine; Depressive Disorder; Diffusion Magnetic Reson | 2011 |
Fronto-polar epilepsy masquerading as juvenile myoclonic epilepsy.
Topics: Anticonvulsants; Brain; Carbamazepine; Diagnosis, Differential; Electroencephalography; Epilepsy, Fr | 2011 |
New onset left frontal lobe seizure presenting with ictal asystole.
Topics: Adult; Anticonvulsants; Bradycardia; Carbamazepine; Electrocardiography; Electroencephalography; Fro | 2011 |
The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Atorvastatin; Brain; Carbamazepine; Disease Models, Animal; Drug Interacti | 2012 |
A once-per-day, drug-in-food protocol for prolonged administration of antiepileptic drugs in animal models.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2012 |
Reversible carbamazapine encephalopathy with frontal intermittent rhythmic delta activity.
Topics: Aged; Anticonvulsants; Brain Diseases; Carbamazepine; Delta Rhythm; Electroencephalography; Female; | 2011 |
Carbamazepine-induced hypogammaglobulinemia.
Topics: Adult; Agammaglobulinemia; Anticonvulsants; Brain Neoplasms; Carbamazepine; Humans; Male; Oligodendr | 2012 |
Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Chromatography, High | 2011 |
Interaction of hydroalcoholic extract of Acorus calamus Linn. with sodium valproate and carbamazepine.
Topics: Acorus; Animals; Anticonvulsants; Carbamazepine; Convulsants; Dose-Response Relationship, Drug; Drug | 2012 |
Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population.
Topics: Adolescent; Adult; Asian People; Carbamazepine; Child; Cohort Studies; Female; Genetic Association S | 2012 |
Carbamazepine-induced thrombocytopenia.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Female; Humans; Platelet Count; Seizures; Thrombocytopen | 2012 |
Drug-induced pemphigus after six years of treatment with phenytoin and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Middle Aged; Multiple Sclerosis; Pemphigus; Phenytoi | 2012 |
Genetic polymorphisms and retention rate of antiepileptic drugs.
Topics: Asian People; Carbamazepine; Female; Humans; Male; Medication Adherence; NAV1.1 Voltage-Gated Sodium | 2012 |
Variability of carbamazepine and valproate concentrations in elderly nursing home residents.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Data Interpretation, Statistical; Databases | 2012 |
Seizure management at Auckland City Hospital Emergency Department between July and December 2009: time for a change?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Disease Management; Emer | 2012 |
Are proprioceptive-induced reflex seizures epileptically-enhanced stretch reflex manifestations?
Topics: Age of Onset; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, Reflex; Femal | 2012 |
Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine.
Topics: Animals; Anticonvulsants; Calorimetry, Differential Scanning; Carbamazepine; Chemistry, Pharmaceutic | 2012 |
Prevalence of seizures in children infected with human immunodeficiency virus.
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Female; HIV Infections; Humans; Male; Pheno | 2013 |
Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin.
Topics: Anticonvulsants; Carbamazepine; Drug Resistance; Electroencephalography; Humans; Infant; Male; Neuro | 2012 |
Protective effect of carbamazepine on kainic acid-induced neuronal cell death through activation of signal transducer and activator of transcription-3.
Topics: Animals; Apoptosis; CA3 Region, Hippocampal; Carbamazepine; Kainic Acid; Male; Mice; Mice, Inbred IC | 2013 |
Pharmacokinetic simulation of fatal carbamazepine intoxication in 23-month old child following phenytoin discontinuation.
Topics: Anticonvulsants; Autopsy; Biotransformation; Carbamazepine; Computer Simulation; Drug Administration | 2013 |
Seizure recurrence and remission after switching antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Cross-Over Studies; Humans; Male; Pheny | 2013 |
Randomised controlled monotherapy trials: which comparators to use?
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Humans; Seizures; Valproic Acid | 2012 |
Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs.
Topics: Animals; Anticonvulsants; Association Learning; Brain; Carbamazepine; Cognition Disorders; Epilepsy; | 2014 |
The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Electroence | 2012 |
Deconstructing the neural and ionic involvement of seizure-like events in the striatal network.
Topics: Action Potentials; Animals; Anticonvulsants; Benzofurans; Cannabinoid Receptor Antagonists; Carbamaz | 2013 |
Stevens Johnson syndrome--an adverse drug reaction occurred after uncomplicated removal of an intracerebral cavernous hemangioma.
Topics: Adolescent; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Eruptions; Epilepsies, Partial; Ep | 2013 |
H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures.
Topics: Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Epilepsy; Famotidine; Fema | 2002 |
Combination of carbamazepine and valproate in different dose proportions in maximal electroshock seizure model in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2002 |
Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; Bicuculline; Carbamazepine; Ceftizoxime; Dizocilpin | 2002 |
Misdiagnosis of epilepsy in patients prescribed anticonvulsant drugs for other reasons.
Topics: Adult; Anticonvulsants; Carbamazepine; Diagnostic Errors; Epilepsy; Humans; Male; Middle Aged; Seizu | 2003 |
Paroxysmal dyskinesia in phenytoin toxicity.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Chorea; Female; Humans; Phenytoin; Seizures | 2002 |
Atypical benign epilepsy of childhood with rolandic spikes: features of a subset requiring more than one medication for seizure control.
Topics: Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsy, Rolandic; Female; Humans; Male; Re | 2002 |
A child with supraventricular tachycardia and convulsions.
Topics: Anticonvulsants; Carbamazepine; Child; Electrocardiography; Electroencephalography; Female; Humans; | 2003 |
A patient with incomplete seizure control during initial monotherapy with carbamazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Resistance; Female; Humans; Seizures | 2003 |
Modafinil for treatment of cognitive side effects of antiepileptic drugs in a patient with seizures and stroke.
Topics: Anticonvulsants; Benzhydryl Compounds; Carbamazepine; Cognition Disorders; Humans; Infarction, Middl | 2003 |
A review of neurological disorders presenting at a paediatric neurology clinic and response to anticonvulsant therapy in Gambian children.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Developmental Disabilities; Fem | 2003 |
Seizures associated with quetiapine treatment.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Carbamazepine; Dibenzothiazepines; Dose-Response Rela | 2003 |
REPORT ON THE ANTI-EPILEPTIC ACTION OF TEGRETOL.
Topics: Acetazolamide; Adolescent; Anticonvulsants; Biomedical Research; Carbamazepine; Child; Chlordiazepox | 1964 |
A CASE OF INTOXICATION WITH TEGRETOL.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy; Electroencephalography; Epilepsy; Epilepsy, Temporal L | 1964 |
Carbamazepine-induced pseudo mycosis fungoides.
Topics: Carbamazepine; Humans; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Seizures; Time Fac | 2003 |
Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics--a comparative study.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2003 |
Seizure exacerbation associated with oxcarbazepine in idiopathic focal epilepsy of childhood.
Topics: Action Potentials; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsies, Partia | 2003 |
Anticonvulsant efficiency, behavioral performance and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3).
Topics: alpha-Linolenic Acid; Analysis of Variance; Animals; Anticonvulsants; Carbamazepine; Disease Models, | 2004 |
Anticonvulsant hypersensitivity reaction in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Drug Hypersensitivity; Female; Humans; Meningeal Neoplasms; Meningio | 2003 |
Ictal SPECT in a case of pure musicogenic epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Resistance; Electroencephalography; Epilepsy, Reflex; Fe | 2003 |
Adjunctive oxcarbazepine in comorbid anxiety and affective disorder with hyponatremic seizure: case analysis and literature review.
Topics: Adult; Anticonvulsants; Anxiety; Carbamazepine; Comorbidity; Drug Therapy, Combination; Follow-Up St | 2003 |
Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes.
Topics: Adolescent; Age of Onset; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, R | 2004 |
Appropriateness of serum level determinations of antiepileptic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Monitoring; Female; | 2003 |
L-histidine is a beneficial adjuvant for antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Drug Synergism; Electroshock; Histidine; Mice; Phenytoin; S | 2004 |
Hypersensitivity to topiramate sprinkle capsules does not preclude the use of topiramate tablets.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Benzodiazepines; Capsules; Carbamazepine; Clobaza | 2004 |
Frontal lobe seizures and uveitis associated with acute human parvovirus B19 infection.
Topics: Acute Disease; Anti-Inflammatory Agents; Anticonvulsants; Brain; Carbamazepine; Child, Preschool; El | 2004 |
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug | 2004 |
Carbamazepine and myasthenia gravis.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Female; Humans; Myasthenia Gravis; Seizures | 2004 |
Spinal congenital dermal sinus associated with upper thoracic meningocele. Case Report.
Topics: Abnormalities, Multiple; Adult; Carbamazepine; Electroencephalography; Headache; Humans; Hypesthesia | 2003 |
Elevated pitch perception owing to carbamazepine-activating effect on the peripheral auditory system: auditory brainstem response study.
Topics: Anticonvulsants; Carbamazepine; Child; Evoked Potentials, Auditory, Brain Stem; Humans; Male; Pitch | 2004 |
Unusual manifestation of subacute sclerosing panencephalitis: case with intracranial high-pressure symptoms.
Topics: Anticonvulsants; Brain; Carbamazepine; Child, Preschool; Diplopia; Female; Fructose; Humans; Intracr | 2004 |
Interactions between riluzole and conventional antiepileptic drugs -- a comparison of results obtained in the subthreshold method and isobolographic analysis.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; Ma | 2004 |
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous Syst | 2005 |
Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes.
Topics: Anticonvulsants; Carbamazepine; Computer Simulation; Epilepsy; Genetic Heterogeneity; Humans; Meta-A | 2005 |
Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Drug Interactions | 2005 |
[Carbamazepine-induced pneumonitis definitively diagnosed by accidental readministration].
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Humans; Male; Pneumonia; Seizures | 2005 |
A case of type IV hypersensitivity to topiramate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Drug Eruptions; Female; Fructose; Humans; Middle Aged; Patch Tests; | 2005 |
Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transp | 2005 |
Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model--an isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Brain; Carbamazepine; Cyclohexanecarboxylic Acids; Disease Models, | 2005 |
Influence of aminoglutethimide and spironolactone on the efficacy of carbamazepine and diphenylhydantoin against amygdala-kindled seizures in rats.
Topics: Aminoglutethimide; Amygdala; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Dru | 2005 |
Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model.
Topics: Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Disease Models, Animal | 2005 |
Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Female; Fructose; Humans; Levetiracetam; | 2005 |
Histidine enhances carbamazepine action against seizures and improves spatial memory deficits induced by chronic transauricular kindling in rats.
Topics: Animals; Anticonvulsants; Brain; Brain Stem; Carbamazepine; Drug Synergism; Hippocampus; Histamine; | 2005 |
Case records of the Massachusetts General Hospital. Case 34-2005. A 10-year-old girl with a bullous skin eruption and acute respiratory failure.
Topics: Carbamazepine; Child; Diagnosis, Differential; Female; Humans; Lung; Radiography; Respiratory Distre | 2005 |
[Low-dose therapy with carbamazepine for convulsions associated with mild gastroenteritis].
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Dose-Response Relationship, Drug; Drug Administrat | 2005 |
The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cost-Benefit Analysis; D | 2005 |
Multidose activated charcoal in the treatment of carbamazepine overdose with seizures: a case report.
Topics: Adult; Anticonvulsants; Carbamazepine; Charcoal; Drug Overdose; Humans; Intubation, Gastrointestinal | 2005 |
2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Brain; Carbamazepine; Dose-Response Relationship, Dr | 2006 |
Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Disease Models, Animal; Dose-Respo | 2006 |
Benign convulsion with mild gastroenteritis and benign familial infantile seizure.
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Female; Gastroenteritis; Humans; Male; Rota | 2006 |
Intracranial sewing needle in a man with seizure: a case of child abuse?
Topics: Adult; Anticonvulsants; Carbamazepine; Child Abuse; Foreign Bodies; Humans; Infant; Male; Needles; R | 2007 |
EEG and seizure exacerbation induced by carbamazepine in Panayiotopoulos syndrome.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Electroencephalography; Epilepsies, Partial; Human | 2006 |
Diagnostics for confounding in PK/PD models for oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Dose-Response Relationship, Drug; Humans; Models, Biol | 2007 |
A 19-year-old male with generalized seizures, unconsciousness and a deviation of gaze.
Topics: Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Brain Diseases; Brain Edema; Brain Neoplasm | 2006 |
Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
Topics: Adult; Aged; Aging; Anticonvulsants; Bayes Theorem; Carbamazepine; Databases, Factual; Epilepsy; Fem | 2006 |
Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine.
Topics: Anticonvulsants; Carbamazepine; Glioma; Humans; Neurosurgical Procedures; Oxcarbazepine; Postoperati | 2007 |
Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Dioxolanes; Dose-Response Relationship, Drug; Drug S | 2006 |
Should we routinely perform blood tests in children with uncontrolled seizures?
Topics: Anticonvulsants; Carbamazepine; Child; Hematologic Tests; Humans; Male; Seizures | 2006 |
Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation.
Topics: Analgesics, Non-Narcotic; Animals; Anticonvulsants; Antitubercular Agents; Calcium Channels, L-Type; | 2007 |
Taylor-type focal cortical dysplasia: is the epilepsy always resistant to medical treatment?
Topics: Adolescent; Anticonvulsants; Attention; Brain; Carbamazepine; Cerebral Cortex; Cognition; Epilepsies | 2006 |
Evaluation of in vitro-in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose.
Topics: Animals; Anticonvulsants; Carbamazepine; Cellulose; Chemistry, Pharmaceutical; Drug Evaluation, Prec | 2006 |
Oxcarbazepine-induced headache.
Topics: Aged; Anticonvulsants; Carbamazepine; Female; Headache; Humans; Oxcarbazepine; Seizures | 2007 |
Blue rubber bleb nevus syndrome.
Topics: Anticonvulsants; Carbamazepine; Central Nervous System Vascular Malformations; Cerebral Veins; Diagn | 2007 |
Effect of pentobarbital on pH and electrolyte levels after induced seizure in rats.
Topics: Animals; Anticonvulsants; Calcium; Carbamazepine; Disease Models, Animal; Drug Interactions; Electro | 2007 |
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Female; Fetus | 2007 |
Effects of certain antiepileptics on behavioral and electromyographic seizure patterns induced by maximal electroshock in mice.
Topics: Administration, Oral; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Dose-Response Relat | 2007 |
Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Drug Interactions; Drug Synergis | 2007 |
Interactions between two enantiomers of losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model--an isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Drug Interactions; Electroshock; | 2007 |
Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock.
Topics: Acetamides; Algorithms; Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Disease | 2007 |
[Miliary cerebral Histoplasma capsulatum in an HIV-negative patient].
Topics: Anticonvulsants; Antifungal Agents; Brain; Carbamazepine; Drug Interactions; Hepatomegaly; Histoplas | 2007 |
Cholecalciferol enhances the anticonvulsant effect of conventional antiepileptic drugs in the mouse model of maximal electroshock.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Cholecalciferol; Disease Models, Animal | 2007 |
Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model.
Topics: Analysis of Variance; Animals; Anticonvulsants; Antidepressive Agents, Second-Generation; Brain; Car | 2007 |
Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale.
Topics: Anticonvulsants; Carbamazepine; Causality; Child; Child, Preschool; Drug Hypersensitivity; Female; H | 2007 |
Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols.
Topics: Administration, Oral; Animals; Anticonvulsants; Carbamazepine; Cross-Over Studies; Disease Models, A | 2007 |
Transposition of the great arteries in a newborn whose mother was treated with carbamazepine during pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Diagnosis, Differential; Female; Humans; Infant, Newborn; Mal | 2007 |
Seizure-freedom with combination therapy in localization-related epilepsy.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Drug Therapy, Combination; Female; Frontal Lobe; Fruct | 2008 |
Case report: severe neurological manifestation of Dobrava hantavirus infection.
Topics: Adult; Anticonvulsants; Carbamazepine; Encephalitis; Hantavirus Infections; Humans; Male; Paresis; S | 2007 |
Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2008 |
Temporal pattern of oxcarbazepine and phenytoin withdrawal seizures during epilepsy monitoring.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Electroencephalography; Epi | 2008 |
Trouble at dinner: an unusual case of eating-induced seizures.
Topics: Aged; Anticonvulsants; Aspirin; Brain Stem Neoplasms; Carbamazepine; Drug Administration Schedule; D | 2008 |
Hyponatraemia during low-dose carbamazepine therapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Humans; Hyponatremia; Risk Factors; Seizures | 2007 |
Seizures induced by the sight of moving water.
Topics: Adult; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsy, Reflex; Female; Humans; Mag | 2008 |
Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy.
Topics: Adenoma, Liver Cell; Adolescent; Anticonvulsants; Biopsy; Carbamazepine; Female; Humans; Liver Neopl | 2008 |
Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male; Middle Aged; Oxca | 2008 |
Mechanisms of action of antiepileptic drugs.
Topics: Acetazolamide; Animals; Anti-Anxiety Agents; Anticonvulsants; Barbiturates; Benzodiazepines; Carbama | 1982 |
Recent advances in anticonvulsant management of childhood seizure disorders.
Topics: Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Child, Preschool; Clonazepam; Human | 1984 |
Interactions of the anticonvulsant carbamazepine with adenosine receptors. 2. Pharmacological studies.
Topics: Animals; Carbamazepine; Guinea Pigs; Ileum; Male; Mice; Mice, Inbred Strains; Nicotine; Purines; Rec | 1983 |
Anticonvulsant potency of common antiepileptic drugs in the gerbil.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Ethosuximide; Female; Gerbillinae; Male; Phenobar | 1983 |
Nonsedative regimens in the treatment of epilepsy.
Topics: Carbamazepine; Epilepsy; Ethosuximide; Humans; Phenytoin; Seizures; Valproic Acid | 1983 |
Pharmacologic therapy of seizures in the elderly.
Topics: Aged; Anticonvulsants; Carbamazepine; Humans; Phenobarbital; Phenytoin; Primidone; Seizures; Status | 1984 |
Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice.
Topics: Animals; Brain; Carbamazepine; Drug Synergism; Female; Mice; Mice, Inbred ICR; Nervous System; Proad | 1984 |
High-dose monotherapy in treatment of intractable seizures.
Topics: Adult; Carbamazepine; Epilepsy; Humans; Middle Aged; Phenytoin; Seizures | 1984 |
Effects of carbamazepine and its epoxide metabolite on amygdala-kindled seizures in rats.
Topics: Amygdala; Animals; Carbamazepine; Kindling, Neurologic; Male; Rats; Rats, Inbred Strains; Seizures | 1984 |
Tics and vocalizations in children treated with carbamazepine.
Topics: Carbamazepine; Child; Female; Humans; Male; Seizures; Tic Disorders; Tourette Syndrome | 1984 |
The effectiveness of prophylactic anticonvulsants following neurosurgery.
Topics: Anticonvulsants; Carbamazepine; Humans; Neurosurgery; Phenytoin; Postoperative Complications; Prospe | 1983 |
A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults.
Topics: Adult; Aged; Anticonvulsants; Behavior; Carbamazepine; Clinical Trials as Topic; Double-Blind Method | 1983 |
Carbamazepine in prophylaxis of febrile seizures in phenobarbital failures.
Topics: Carbamazepine; Child, Preschool; Fever; Humans; Infant; Phenobarbital; Seizures | 1983 |
Acute carbamazepine intoxication: clinical spectrum and management.
Topics: Acute Disease; Adult; Arrhythmias, Cardiac; Ataxia; Carbamazepine; Catharsis; Charcoal; Coma; Gastri | 1984 |
Leucopenia as an adverse reaction to carbamazepine therapy.
Topics: Adult; Agranulocytosis; Carbamazepine; Dose-Response Relationship, Drug; Female; Humans; Leukocyte C | 1984 |
Should alcohol withdrawal seizures be treated with anti-epileptic drugs?
Topics: Adult; Aged; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Carbamazepine; Chlormethiazol | 1984 |
Pharmacologic advances in seizure control.
Topics: Anticonvulsants; Carbamazepine; Child; Clonazepam; Humans; Kinetics; Phenytoin; Seizures; Status Epi | 1981 |
Drug treatment of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Electroencephalography; Epilepsy; Ethosuximide; Female; | 1981 |
Effects of some antiepileptic drugs in pentetrazol-induced convulsions in mice lesioned with kainic acid.
Topics: Acetazolamide; Animals; Anticonvulsants; Carbamazepine; Diazepam; Dose-Response Relationship, Drug; | 1981 |
Quantitative evaluation of anticonvulsant effects on penicillin-induced spike foci in cats.
Topics: Animals; Anticonvulsants; Carbamazepine; Cats; Electroencephalography; Ethosuximide; Penicillins; Ph | 1981 |
Protection from oxygen-induced seizures by clonazepam and propylene glycol.
Topics: Animals; Benzodiazepinones; Carbamazepine; Cats; Clonazepam; Hyperbaric Oxygenation; Polyethylene Gl | 1981 |
Differentiating between organic and functional seizures: a common diagnostic problem.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Diagnosis, Differential; Dose-Response Relationsh | 1981 |
Interactions between folates and carbamazepine or valproate in the rat.
Topics: Animals; Brain; Carbamazepine; Drug Interactions; Flurothyl; Folic Acid; Leucovorin; Male; Rats; Rat | 1982 |
Effects of carbamazepine, clonazepam, and phenytoin on seizure threshold in amygdala and cortex.
Topics: Amygdala; Animals; Benzodiazepinones; Carbamazepine; Cerebral Cortex; Clonazepam; Differential Thres | 1983 |
Effects of carbamazepine and diphenylhydantoin on metrazol seizures during ontogenesis in rats.
Topics: Aging; Animals; Carbamazepine; Male; Pentylenetetrazole; Phenytoin; Rats; Rats, Inbred Strains; Seiz | 1983 |
Reduction in early alcohol abstinence fits by administration of carbamazepine syrup instead of tablets.
Topics: Adult; Aged; Carbamazepine; Ethanol; Female; Humans; Male; Middle Aged; Seizures; Substance Withdraw | 1983 |
Hyponatraemia during carbamazepine therapy in children.
Topics: Adolescent; Carbamazepine; Child; Child, Preschool; Female; Humans; Hyponatremia; Male; Osmolar Conc | 1983 |
The effect of an experimental epileptiform syndrome on memory in rats.
Topics: Animals; Carbamazepine; Evoked Potentials; Hippocampus; Memory; Mental Recall; Rats; Seizures; Tetan | 1981 |
Carbamazepine. Pharmacology and clinical uses.
Topics: Adult; Alcohol Withdrawal Delirium; Arrhythmias, Cardiac; Behavior; Carbamazepine; Child; Diabetes I | 1981 |
Carbamazepine-isoniazid interaction.
Topics: Adolescent; Carbamazepine; Drug Interactions; Female; Humans; Isoniazid; Seizures | 1982 |
Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Electroshock; Hippocampus; Injections, Intraventr | 1982 |
Generalized penicillin epilepsy in the cat and the brain uptake of carbamazepine.
Topics: Animals; Brain; Carbamazepine; Cats; Female; Kinetics; Male; Penicillin G; Seizures | 1982 |
Anticonvulsant drugs and cognitive functions.
Topics: Adult; Anticonvulsants; Carbamazepine; Cognition Disorders; Drug Therapy, Combination; Electroenceph | 1982 |
Experience with carbamazepine (Mazetol) an analysis of 156 cases.
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Male; Middle Ag | 1982 |
Carbamazepine in seizure management in acute intermittent porphyria.
Topics: 5-Aminolevulinate Synthetase; Carbamazepine; Humans; Porphobilinogen; Porphyrias; Seizures | 1981 |
Carbamazepine in seizure management in acute intermittent porphyria.
Topics: Acute Disease; Carbamazepine; Humans; Porphyrias; Seizures | 1981 |
Temporal lobe seizure presenting as "laryngospasm".
Topics: Adolescent; Carbamazepine; Electroencephalography; Female; Humans; Laryngismus; Seizures; Temporal L | 1981 |
Tonic seizures in a patient with multiple sclerosis.
Topics: Carbamazepine; Clonazepam; Female; Humans; Middle Aged; Multiple Sclerosis; Phenytoin; Seizures | 1980 |
Carbamazepine-induced leukocytosis.
Topics: Adult; Carbamazepine; Female; Humans; Leukocytosis; Neutrophils; Phenobarbital; Phenytoin; Seizures | 1980 |
[A study of effects on antiepileptic drugs upon the hippocampal afterdischarge (author's transl)].
Topics: Animals; Anticonvulsants; Carbamazepine; Cats; Electric Stimulation; Female; Hippocampus; Male; Phen | 1980 |
Carbamezepine poisoning, a surprisingly severe case.
Topics: Adult; Carbamazepine; Drug Tolerance; Hemolysis; Humans; Hyperbilirubinemia; Male; Respiratory Insuf | 1980 |
Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Bicuculline; Carbamazepine; Drug Evaluation, Preclinical | 1995 |
[Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome].
Topics: Adolescent; Anticonvulsants; Brain Diseases; Carbamazepine; Child; Child, Preschool; Epilepsy; Femal | 1995 |
Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures.
Topics: Action Potentials; Animals; Anticonvulsants; Carbamazepine; Cells, Cultured; Male; Mice; Oxcarbazepi | 1994 |
Aspirin and anticonvulsant interaction.
Topics: Animals; Aspirin; Carbamazepine; Disease Models, Animal; Drug Synergism; Electroshock; Female; Male; | 1995 |
Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine.
Topics: Affinity Labels; Amygdala; Animals; Autoradiography; Azides; Benzodiazepines; Bridged Bicyclo Compou | 1994 |
Effects of the peptide BCH-325 upon the efficacy of common antiepileptic drugs.
Topics: Amino Acid Sequence; Animals; Anticonvulsants; Carbamazepine; Diazepam; Drug Interactions; Endorphin | 1994 |
[Exacerbation of seizures by carbamazepine in four children with symptomatic localization related epilepsy].
Topics: Carbamazepine; Child; Child, Preschool; Electroencephalography; Epilepsies, Partial; Female; Humans; | 1995 |
Severe hyponatremia caused by cement ingestion during carbamazepine therapy.
Topics: Carbamazepine; Construction Materials; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Mid | 1995 |
Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Carbama | 1993 |
Contingent tolerance to carbamazepine: alterations in TRH mRNA and TRH receptor binding in limbic structures.
Topics: Animals; Carbamazepine; Functional Laterality; Gene Expression; Kindling, Neurologic; Limbic System; | 1994 |
Generic substitution.
Topics: Carbamazepine; Child; Drugs, Generic; Florida; Hospitalization; Humans; Male; Medical History Taking | 1994 |
Carbamazepine measurement in samples from the emergency room.
Topics: Adolescent; Adult; Aged; Carbamazepine; Child; Child, Preschool; Chromatography, High Pressure Liqui | 1994 |
Adenosine receptors are not involved in theophylline-induced seizures.
Topics: Adenosine; Animals; Carbamazepine; Dipyridamole; Dose-Response Relationship, Drug; Injections, Intra | 1994 |
Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: comparison with the structural analogs dizocilpine and carbamazepine.
Topics: Animals; Anticonvulsants; Carbamazepine; Cocaine; Dizocilpine Maleate; Dose-Response Relationship, D | 1994 |
Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
Topics: Animals; Anticonvulsants; Carbamazepine; Drug Evaluation, Preclinical; Electroshock; Hippocampus; In | 1994 |
Efficacy of carbamazepine compared with other agents: a clinical practice survey.
Topics: Attitude of Health Personnel; Bipolar Disorder; Carbamazepine; Drug Utilization; Electroconvulsive T | 1994 |
Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.
Topics: Animals; Anticonvulsants; Brain Ischemia; Carbamazepine; Cerebral Arteries; Electrophysiology; Elect | 1994 |
Acute encephalopathy with vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aminocaproates; Anticonvulsants; Carbamazepine; Com | 1993 |
Involvement of adenosine in postictal events in rats given electroshock.
Topics: Adenosine; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Electroshock; Female; Hindlimb | 1994 |
Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat.
Topics: Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Drug Evaluation, Preclinical; Female; Oxaz | 1994 |
Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide.
Topics: Adult; Age of Onset; Carbamazepine; Female; Humans; Male; Middle Aged; Phenytoin; Seizures; Status E | 1994 |
Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures.
Topics: Amygdala; Animals; Carbamazepine; Drug Tolerance; Kindling, Neurologic; Male; Rats; Rats, Sprague-Da | 1993 |
Carbamazepine toxicity resulting from generic substitution.
Topics: Carbamazepine; Child; Drugs, Generic; Humans; Male; Osmolar Concentration; Seizures | 1993 |
Possible interaction between phenobarbital, carbamazepine and itraconazole.
Topics: Adult; Aspergillosis; Brain Diseases; Carbamazepine; Drug Interactions; Enzyme Induction; Humans; It | 1993 |
Reflex seizures as initial manifestations of systemic lupus erythematosus in childhood.
Topics: Acoustic Stimulation; Carbamazepine; Child; Evoked Potentials, Auditory; Evoked Potentials, Visual; | 1993 |
Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread.
Topics: Adenosine; Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Culture Techniques; Dopamine; | 1993 |
[A case of carbamazepine-induced lupus with myositis].
Topics: Adult; Carbamazepine; Female; Humans; Lupus Erythematosus, Systemic; Myositis; Seizures | 1993 |
Identification of treatment-resistant depressives who respond favorably to carbamazepine.
Topics: Adult; Carbamazepine; Depressive Disorder; Dichotic Listening Tests; Epilepsies, Partial; Humans; Ma | 1993 |
Unusual seizures with a benign course in a case of acute lymphoblastic leukemia of childhood.
Topics: Carbamazepine; Child, Preschool; Electroencephalography; Humans; Male; Precursor Cell Lymphoblastic | 1993 |
[Lafora disease. Report of a new case diagnosed by biopsy from the axillary skin].
Topics: Axilla; Biopsy; Carbamazepine; Child; Eccrine Glands; Epilepsies, Myoclonic; Epilepsy, Tonic-Clonic; | 1993 |
Carbamazepine therapy in neuropsychiatric patients.
Topics: Adult; Age Factors; Carbamazepine; Drug Therapy, Combination; Humans; Mental Disorders; Seizures; Ti | 1993 |
Focal paroxysmal EEG changes during atypical panic attacks.
Topics: Adult; Brain; Brain Diseases; Carbamazepine; Clonazepam; Electroencephalography; Female; Humans; Mag | 1993 |
Genetic differences in the time course for the development and persistence of the anticonvulsant effects of carbamazepine against cocaine seizures.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Cocaine; Diet; Male; Mice; Mice, Inbred BALB C; Mice | 1993 |
Protective effect of flunarizine and nifedipine alone and in combination with anticonvulsant drugs against PTZ-induced seizures in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactions; Ethosu | 1993 |
Reflex seizures in Down syndrome.
Topics: Acoustic Stimulation; Adult; Carbamazepine; Cerebral Cortex; Down Syndrome; Electroencephalography; | 1993 |
[Purpura revealing convulsive crisis].
Topics: Adult; Carbamazepine; Humans; Male; Purpura; Seizures | 1993 |
Lymphopenic effect of carbamazepine in a patient with chronic lymphocytic leukemia.
Topics: Aged; Anticonvulsants; Carbamazepine; Female; Granulocytes; Humans; Leukemia, Lymphocytic, Chronic, | 1995 |
Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved.
Topics: Anticonvulsants; Blood Chemical Analysis; Carbamazepine; Carrier Proteins; Humans; Phenytoin; Seizur | 1996 |
Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice.
Topics: Analgesics, Opioid; Animals; Anticonvulsants; Carbamazepine; Convulsants; Diazepam; Disease Models, | 1996 |
Failure of carbamazepine to prevent behavioural and histopathological sequels of experimentally induced status epilepticus.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Electric Stimulation; Male; Rats; Rats, W | 1996 |
Influence of D-cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Carbamazepine; Cycloserine; Disease | 1996 |
Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis.
Topics: Adult; Anticonvulsants; Carbamazepine; Humans; Kidney Failure, Chronic; Male; Peritoneal Dialysis, C | 1996 |
Audiogenic seizures following global ischemia induced by chest compression in Long-Evans rats.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Behavior, Animal; Biomechanical Phenomena; Blood Glu | 1996 |
Carbamazepine-lithium drug interaction.
Topics: Bipolar Disorder; Carbamazepine; Drug Interactions; Female; Humans; Lithium; Middle Aged; Seizures | 1996 |
Chronic caffeine and the anticonvulsant potency of antiepileptic drugs against maximal electroshock.
Topics: Animals; Anticonvulsants; Caffeine; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactio | 1996 |
Intracerebroventricular pertussis toxin enhances sensitivity to chemical convulsants and decreases the protective efficacy of carbamazepine in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Convulsants; Diazepam; Drug Synergism; GTP-Binding Proteins | 1996 |
Population pharmacokinetics of felbamate in children.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Drug Interactions; Drug Monitoring; Felbamate; Hu | 1997 |
Hippocampal and cerebellar extracellular amino acids during pilocarpine-induced seizures in freely moving rats.
Topics: Amino Acids; Animals; Aspartic Acid; Carbamazepine; Cerebellum; gamma-Aminobutyric Acid; Glutamic Ac | 1997 |
A patient with mania and photoconvulsive epilepsy.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Brain; Carbamazepine; Drug Therapy, Combination; Elec | 1996 |
Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1997 |
Psychomotor seizures presenting with hypnagogic visual hallucinations.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Craniocerebral Trauma; Epilepsy, Tempora | 1996 |
Combined valproate or carbamazepine and electroconvulsive therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 1997 |
Reversible MRI lesions after seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Cerebral Cortex; Epilepsy; Female; Frontal Lobe; Humans; Magn | 1997 |
Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+.
Topics: Animals; Anticonvulsants; Calcium; Carbamazepine; Dose-Response Relationship, Drug; Electroshock; Ex | 1997 |
Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease.
Topics: Anemia, Sickle Cell; Anticonvulsants; Antisickling Agents; Blood Transfusion; Carbamazepine; Child; | 1997 |
Carbamazepine induced sino-atrial block in a young adult.
Topics: Adult; Anticonvulsants; Carbamazepine; Cardiac Pacing, Artificial; Dose-Response Relationship, Drug; | 1996 |
Alopecia with carbamazepine in two patients with focal seizures.
Topics: Adult; Alopecia; Anticonvulsants; Carbamazepine; Female; Humans; Seizures | 1997 |
A rash of oversights.
Topics: Adolescent; Age Factors; Anticonvulsants; Carbamazepine; Drug Eruptions; Drug Interactions; Drug Lab | 1997 |
Effect of chronic ethanol treatment in vivo on excitability in mouse cortical neurones in vitro.
Topics: Alcoholism; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Convulsants; Excitatory Postsy | 1997 |
Acute effects of various GABA receptor agonists and glutamate antagonists on focal hippocampal seizures in freely moving rats elicited by low-frequency stimulation.
Topics: Animals; Anticonvulsants; Ataxia; Carbamazepine; Diazepam; Dizocilpine Maleate; Excitatory Amino Aci | 1998 |
Acute comitant esotropia in a boy with head trauma and convulsions receiving carbamazepine.
Topics: Acute Disease; Anticonvulsants; Carbamazepine; Child; Diplopia; Dose-Response Relationship, Drug; Es | 1998 |
BW1003C87, phenytoin and carbamazepine elevate seizure threshold in the rat amygdala-kindling model of epilepsy.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Dose-Response R | 1997 |
Carbamazepine induced pseudolymphoma syndrome.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Humans; Male; Pseudolymphoma; Seizures; Syndrome | 1997 |
Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats.
Topics: Animals; Anticonvulsants; Benzamides; Carbamazepine; Electroshock; Male; Mice; Rats; Seizures | 1998 |
Carbamazepine interference with an immune assay for tricyclic antidepressants in plasma.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents, Tricyclic; Carbamazepine; Child, Preschool; Chro | 1998 |
The influence of L-NG-nitroarginine methyl ester, an inhibitor of nitric oxide synthase, upon the anticonvulsive activity of conventional antiepileptic drugs against maximal electroshock in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Drug Antagonism; Electroshock; Enzyme I | 1998 |
Anticonvulsant drug effects in the direct cortical ramp-stimulation model in rats: comparison with conventional seizure models.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 1998 |
Frontal versus transcorneal stimulation to induce maximal electroshock seizures or kindling in mice and rats.
Topics: Animals; Anticonvulsants; Carbamazepine; Cornea; Differential Threshold; Electroshock; Female; Front | 1998 |
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Cornea; Disease Models, Animal; Dizocilpine Malea | 1998 |
Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Electroencephal | 1998 |
Additive anticonvulsant effect of flunarizine and sodium valproate on electroshock and chemoshock induced seizures in mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Drug Synergism; | 1998 |
Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use.
Topics: Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carb | 1998 |
Paroxysmal kinesigenic choreoathetosis in Singapore and its relationship to epilepsy.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Athetosis; Carbamazepine; Child; Chorea; Comorbidi | 1998 |
Effect of clobenpropit, a centrally acting histamine H3-receptor antagonist, on electroshock- and pentylenetetrazol-induced seizures in mice.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Differential Threshold; Electroshock; His | 1998 |
Exacerbation of epileptic seizures by carbamazepine: report of 10 cases.
Topics: Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cognition Disorders; Dose-Resp | 1998 |
Carbamazepine levels in head hair of patients under long-term treatment: a method to evaluate the history of drug use.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Child; Child, Preschool; | 1999 |
Carbamazepine-associated severe bile duct injury.
Topics: Anticonvulsants; Carbamazepine; Cholangitis; Female; Humans; Liver; Middle Aged; Seizures | 1999 |
Suspected carbamazepine-induced hepatotoxicity.
Topics: Adverse Drug Reaction Reporting Systems; Anticonvulsants; Carbamazepine; Chemical and Drug Induced L | 1999 |
Induction of seizures by the potent K+ channel-blocking scorpion venom peptide toxins tityustoxin-K(alpha) and pandinustoxin-K(alpha).
Topics: 4-Aminopyridine; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Dizo | 1999 |
A man with a mysterious hypogammaglobulinaemia and skin rash.
Topics: Adult; Agammaglobulinemia; Anticonvulsants; Carbamazepine; Diabetes Mellitus, Type 1; Drug Eruptions | 1999 |
Effect of adenosinergic modulation on the anticonvulsant effect of phenobarbitone and carbamazepine.
Topics: Adenosine; Animals; Anticonvulsants; Carbamazepine; Convulsants; Drug Combinations; Male; Pentylenet | 1999 |
[Acute self-induced poisoning with carbamazepine].
Topics: Acute Disease; Adult; Carbamazepine; Carbon; Coma; Female; Gastric Lavage; Humans; Hypotension; Male | 1999 |
Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Amlodipine; Animals; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Drug Interactions; Dr | 1999 |
Radial microbrain form of micrencephaly: possible association with carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Infant, Newborn; Male; Microcephaly; Pregnancy; Preg | 1999 |
Insights into the tetanus toxin model of early-onset epilepsy from long-term video monitoring during anticonvulsant therapy.
Topics: Age of Onset; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Epilepsy; Hippocampus; Inje | 1999 |
The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures.
Topics: Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Evaluation, Preclini | 2000 |
Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Cholesterol, LDL; Dose-Response Relationship, Drug | 2000 |
Effects of the calcium antagonists verapamil and nitrendipine on carbamazepine withdrawal.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Convulsants; Male; Nitrendipine; | 1999 |
Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Dose-Response R | 2000 |
Carbamazepine--indinavir interaction causes antiretroviral therapy failure.
Topics: Anti-HIV Agents; Anticonvulsants; Carbamazepine; Cytochrome P-450 Enzyme Inhibitors; Drug Interactio | 2000 |
Brain distribution and efficacy of carbamazepine in kainic acid induced seizure in rats.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, | 2000 |
High-efficiency dialysis for carbamazepine overdose.
Topics: Anticonvulsants; Carbamazepine; Coma; Drug Overdose; Humans; Infant; Renal Dialysis; Seizures; Treat | 2000 |
Is a "color effect" demonstrated for hair analysis of carbamazepine?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Carbamazepine; Child; Child, Prescho | 2000 |
Acute 4-aminopyridine seizures increase the regional cerebral blood flow in the thalamus and neocortex, but not in the entire allocortex of the mouse brain.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Autoradiography; Carbamazepine; Cerebrovascular Circulati | 2000 |
Ictal increased writing preceded by dysphasic seizures.
Topics: Aphasia; Carbamazepine; Child; Disease Progression; Electroencephalography; Epilepsy, Temporal Lobe; | 2000 |
Effects of oxcarbazepine on the behavioral response and neuroanatomical alterations following administration of kainic acid.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Excitatory Amino Acid Agonists; Hippocamp | 2000 |
Antiepileptic drug-induced visual hallucinations in a child.
Topics: Anticonvulsants; Carbamazepine; Child; Hallucinations; Humans; Male; Seizures | 2000 |
Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Benzoxazines; Carb | 2000 |
Ritonavir-induced carbamazepine toxicity.
Topics: Adult; Anticonvulsants; Ataxia; Carbamazepine; Drug Interactions; HIV Infections; HIV Protease Inhib | 2001 |
Seizures in multiple sclerosis.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Anticonvulsants; Atrophy; Brain; Carbamazepine; | 2001 |
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Excitatory Amino Acid Antagonists; Kindling, Neur | 2001 |
Association of drug levels & pharmacokinetics of carbamazepine with seizure control.
Topics: Adult; Anticonvulsants; Area Under Curve; Carbamazepine; Female; Half-Life; Humans; Male; Seizures | 2000 |
Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of acute carbamazepine.
Topics: Action Potentials; Animals; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Disease Models, | 2001 |
Posttraumatic isolated infarction in the territory of Heubner's and lenticulostriate arteries: case report.
Topics: Anticonvulsants; Carbamazepine; Child; Craniocerebral Trauma; Electroencephalography; Humans; Infarc | 2001 |
Effect of oxcarbazepine on kainic acid-induced seizure.
Topics: Animals; Anticonvulsants; Carbamazepine; Electrodes, Implanted; Electroencephalography; Electrophysi | 2001 |
2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anticonvulsant activity of carbamazepine and clonazepam in mice.
Topics: 2-Chloroadenosine; Animals; Anticonvulsants; Carbamazepine; Clonazepam; Drug Synergism; Drug Therapy | 2002 |
Unmasking of absence seizures by carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Electroencephalography; Female; Follow-Up Studies; | 2002 |
Influence on ictal seizure semiology of rapid withdrawal of carbamazepine and valproate in monotherapy.
Topics: Adult; Anticonvulsants; Automatism; Carbamazepine; Female; Humans; Male; Middle Aged; Movement Disor | 2002 |
Oxcarbazepine and hepatic porphyria.
Topics: Anticonvulsants; Carbamazepine; Humans; Oxcarbazepine; Porphyrias, Hepatic; Seizures | 2002 |
Niguldipine impairs the protective activity of carbamazepine and phenobarbital in amygdala-kindled seizures in rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |
[Differential diagnosis of frontal lobe epilepsy and psychogenic paroxysm].
Topics: Anticonvulsants; Carbamazepine; Child; Diagnosis, Differential; Epilepsy, Frontal Lobe; Humans; Male | 2002 |
Carbamazepine in childhood seizures.
Topics: Barbiturates; Carbamazepine; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Humans; Phenytoin; Sei | 1978 |
Carbamazepine revisited in a monkey model.
Topics: Animals; Biological Availability; Carbamazepine; Disease Models, Animal; Electroencephalography; Hap | 1979 |
Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Dogs; Dose-Response Relationship, Drug; Haplorhini; | 1979 |
Evidence against serotonin involvement in the tonic component of electrically induced convulsions and in carbamazepine anticonvulsant activity.
Topics: Animals; Anticonvulsants; Brain Chemistry; Carbamazepine; Electroshock; Female; Raphe Nuclei; Rats; | 1979 |
A form of chorea that responds to dantrolene sodium.
Topics: Adult; Carbamazepine; Dantrolene; Female; Humans; Huntington Disease; Seizures | 1979 |
Effect of convulsions and anticonvulsive drugs on cerebrospinal fluid cyclic AMP in rabbits.
Topics: Animals; Aspartate Aminotransferases; Carbamazepine; Cyclic AMP; Depression, Chemical; Female; Male; | 1976 |
Carbamazepine: mechanisms of action.
Topics: Animals; Anura; Axons; Carbamazepine; Cats; Cerebellar Cortex; Depression, Chemical; Dose-Response R | 1975 |
Prophylactic effects of phenytoin, phenobarbital, and carbamazepine examined in kindling cat preparations.
Topics: Animals; Carbamazepine; Cats; Disease Models, Animal; Drug Evaluation, Preclinical; Electric Stimula | 1976 |
Photosensitive epilepsy in Papio papio as a model for drug studies.
Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Drug Evaluation, Preclinical; gamma-Aminob | 1978 |
Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain.
Topics: Adenosine; Animals; Anticonvulsants; Brain; Carbamazepine; Cerebellum; Cerebral Cortex; Clonazepam; | 1979 |
[Psychotropic drugs in the clinical picture of epilepsy (review of the literature)].
Topics: Amitriptyline; Animals; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Carbamazepine; C | 1975 |
A primate model for testing anticonvulsant drugs.
Topics: Allyl Compounds; Animals; Anticonvulsants; Carbamazepine; Chromatography, Gas; Diazepam; Disease Mod | 1975 |
A comparative study of the efficacy of newer antiepiletpic drugs on experimentally-induced febrile convulsions.
Topics: Animals; Anticonvulsants; Body Temperature; Carbamazepine; Clonazepam; Male; Mice; Phenobarbital; Se | 1977 |
The drug of choice for major seizures?
Topics: Carbamazepine; Decision Making; Humans; Phenytoin; Seizures; Valproic Acid | 1979 |
[The serum concentration of anticonvulsants -- pharmacokinetic findings and practical therapeutic applications (author's transl)].
Topics: Antacids; Anticonvulsants; Biological Availability; Carbamazepine; Chromatography, Gas; Clonazepam; | 1979 |
Effect of anticonvulsants on cortical focal seizure in cats.
Topics: Acetazolamide; Animals; Anticonvulsants; Carbamazepine; Cats; Diazepam; Electrocardiography; Epileps | 1977 |
Anticonvulsant therapy. Approaches to some common clinical problems.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Epilepsy; Eth | 1979 |
Carbamazepine-induced dystonia.
Topics: Carbamazepine; Dystonia; Humans; Seizures | 1979 |
Dystonia associated with carbamazepine administration: experience in brain-damaged children.
Topics: Carbamazepine; Child, Preschool; Dystonia; Humans; Infant; Male; Seizures | 1979 |
Carbamazepine dose-frequency requirement in children.
Topics: Adolescent; Carbamazepine; Child; Drug Administration Schedule; Female; Half-Life; Humans; Male; Sal | 1979 |
[Non-epileptic fits in multiple sclerosis].
Topics: Ataxia; Carbamazepine; Dysarthria; Humans; Multiple Sclerosis; Pain; Paresthesia; Seizures; Time Fac | 1979 |
[Paroxysmal motor and sensory-motor manifestations in multiple sclerosis].
Topics: Adult; Carbamazepine; Contracture; Extremities; Female; Follow-Up Studies; Humans; Male; Multiple Sc | 1979 |
Carbamazepine: prevention of alcohol withdrawal seizures.
Topics: Alcoholism; Animals; Carbamazepine; Humans; Rats; Seizures; Substance Withdrawal Syndrome | 1979 |
Carbamazepine for childhood seizures.
Topics: Age Factors; Carbamazepine; Child; Humans; Kinetics; Leukopenia; Seizures | 1978 |
Seizure susceptibility and anticonvulsant activity of carbamazepine, diphenylhydantoin and phenobarbital in rats with selective depletions of brain monoamines.
Topics: Animals; Anticonvulsants; Biogenic Amines; Brain; Carbamazepine; Electroshock; Female; Hydroxydopami | 1978 |
Carbamazepine as a substitute treatment of single and compound seizures.
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Drug Evaluation; Electroencephalography; | 1978 |
Carbamazepine as a single drug in the treatment of epilepsy. A prospective study of serum levels and seizure control.
Topics: Adolescent; Adult; Aged; Carbamazepine; Child; Dose-Response Relationship, Drug; Drug Evaluation; Ep | 1978 |
Perspectives in complex partial seizures.
Topics: Carbamazepine; Diagnosis, Differential; Epilepsies, Partial; Epilepsy; Epilepsy, Temporal Lobe; Hist | 1975 |
Acute anticonvulsant effects of diphenylhydantoin, phenobarbital, and carbamazepine: a combined electroclinical and serum level study in amygdaloid kindled cats and baboons.
Topics: Amygdala; Animals; Carbamazepine; Cats; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 1976 |
Decreased anticonvulsant activity of carbamazepine in 6-hydroxydopamine-treated rats.
Topics: Animals; Anticonvulsants; Brain Chemistry; Carbamazepine; Dopamine; Electroshock; Female; Hydroxydop | 1977 |
Anticonvulsant drug antagonism of delta9tetrahydrocannabinol-induced seizures in rabbits.
Topics: Animals; Anticonvulsants; Cannabidiol; Cannabinol; Carbamazepine; Diazepam; Dose-Response Relationsh | 1977 |
Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects.
Topics: Aging; Animals; Carbamazepine; Electroshock; Female; Kinetics; Male; Maternal-Fetal Exchange; Pentob | 1976 |
Serum carbamazepine concentration and clinical control.
Topics: Adult; Carbamazepine; Epilepsy; Female; Humans; Male; Pregnancy; Seizures; Substance-Related Disorde | 1975 |
Paradoxical intoxication--a complication of anticonvulsant administration.
Topics: Carbamazepine; Drug Therapy, Combination; Humans; Hydantoins; Mephenytoin; Phenytoin; Seizures | 1975 |
[Correlation between the anticonvulsant and tranquilizing effects of carbamazepine and methindione in experimental temporal epilepsy].
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Emotions; Hippocampus; Indans; I | 1976 |
From the Alcohol, Drug Abuse, and Mental Health Administration.
Topics: Animals; Carbamazepine; Cocaine; Humans; Memory; Mice; Mice, Inbred C57BL; Neurons; Seizures; Substa | 1992 |
Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline.
Topics: Aminophylline; Animals; Anticonvulsants; Carbamazepine; Electroshock; Male; Mice; Phenytoin; Seizure | 1992 |
Phenobarbital exacerbation of self-injurious behavior.
Topics: Acute Disease; Adult; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hu | 1992 |
[A case of skin reactions to carbamazepine].
Topics: Blister; Carbamazepine; Child, Preschool; Combined Modality Therapy; Drug Eruptions; Humans; Male; S | 1992 |
Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug.
Topics: Carbamazepine; Child; Drug Hypersensitivity; Enzyme-Linked Immunosorbent Assay; Hospitalization; Hum | 1992 |
Cerebral cavernous angioma: a potentially benign condition? Successful treatment in 16 cases.
Topics: Adolescent; Adult; Angiography; Brain Neoplasms; Carbamazepine; Cerebral Hemorrhage; Child; Epilepsy | 1992 |
Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations.
Topics: Adolescent; Adult; Biological Availability; Carbamazepine; Circadian Rhythm; Delayed-Action Preparat | 1992 |
Age dependency of the susceptibility of rats to aminooxyacetic acid seizures.
Topics: Aging; Aminooxyacetic Acid; Animals; Anticonvulsants; Body Temperature; Brain; Carbamazepine; Clonaz | 1992 |
Serum sodium and carbamazepine overdose.
Topics: Carbamazepine; Child, Preschool; Drug Overdose; Humans; Hyponatremia; Male; Seizures; Sodium | 1992 |
Tolerance to the anticonvulsant effects of carbamazepine, diazepam, and sodium valproate in kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Brain; Carbamazepine; Diazepam; Drug Tolerance; Electrodes, Impl | 1992 |
Tolerance to the anticonvulsant effects of phenobarbital, trimethadione, and clonazepam in kindled rats: cross tolerance to carbamazepine.
Topics: Amygdala; Animals; Anticonvulsants; Brain; Carbamazepine; Clonazepam; Drug Tolerance; Electrodes, Im | 1992 |
Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizur
Topics: Animals; Anticonvulsants; Carbamazepine; Dizocilpine Maleate; Ethanol; Male; Mice; Mice, Inbred C57B | 1992 |
Carbamazepine encephalopathy.
Topics: Aged; Brain Diseases; Carbamazepine; Female; Humans; Seizures | 1992 |
Elevated carbamazepine levels associated with diltiazem use.
Topics: Aged; Carbamazepine; Diltiazem; Humans; Hypertension; Male; Seizures | 1992 |
Antiepileptic drugs delay the onset of seizures induced by aminophylline in conscious rats.
Topics: Aminophylline; Anesthesia; Animals; Anticonvulsants; Carbamazepine; Consciousness; Diazepam; Electro | 1992 |
Loss of seizure control associated with generic substitution of carbamazepine.
Topics: Adolescent; Adult; Carbamazepine; Drugs, Generic; Female; Humans; Male; Pregnancy; Pregnancy Complic | 1992 |
Pharmacogenetic assessment of the effects of carbamazepine on cocaine-kindled and cocaine-induced seizures.
Topics: Animals; Anticonvulsants; Carbamazepine; Cocaine; Genotype; Kindling, Neurologic; Male; Mice; Mice, | 1992 |
Contingent tolerance to carbamazepine: a peripheral-type benzodiazepine mechanism.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Drug Tolerance; Isoquinolines; Kindling, Neurolog | 1991 |
Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by D-serine and antagonized by 7-chlorokynurenic acid.
Topics: Animals; Anticonvulsants; Carbamazepine; Drug Synergism; Electroshock; Glycine; Kynurenic Acid; Male | 1991 |
Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine.
Topics: Alprazolam; Animals; Anxiety; Carbamazepine; Cerebral Cortex; Disease Models, Animal; Drug Administr | 1991 |
[Carbamazepine-induced diarrhea and eosinophilic inflammation of the colon].
Topics: Carbamazepine; Cerebral Infarction; Colitis; Diarrhea; Eosinophilia; Humans; Male; Middle Aged; Seiz | 1990 |
The investigation of antiepileptic action of qingyangshen (QYS)--effect of QYS on the concentrations of neuropeptides in rat brain.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Drugs, Chinese Herbal; Male; Neuropeptides; Pentylen | 1991 |
More problems with drug names.
Topics: Carbamazepine; Humans; Male; Medication Errors; Middle Aged; Pharmaceutical Preparations; Seizures; | 1992 |
Contingent tolerance to carbamazepine is associated with lowering of amygdala-kindled seizure thresholds.
Topics: Amygdala; Animals; Carbamazepine; Drug Tolerance; Kindling, Neurologic; Male; Rats; Seizures | 1991 |
Suppression of carbamazepine-induced rash with prednisone.
Topics: Adult; Carbamazepine; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Prednisone; Seizure | 1991 |
Patch test diagnosis of carbamazepine sensitivity?
Topics: Aged; Carbamazepine; Dermatitis; Drug Eruptions; Humans; Male; Patch Tests; Seizures | 1991 |
Effect of carbamazepine on cyclosporin blood level.
Topics: Carbamazepine; Cyclosporins; Drug Interactions; Humans; Kidney Transplantation; Male; Meningitis; Mi | 1991 |
Carbamazepine-induced Diabetes mellitus.
Topics: Adult; Carbamazepine; Diabetes Mellitus; Female; Humans; Seizures | 1991 |
Tegretol excipient-induced allergy.
Topics: Azo Compounds; Carbamazepine; Drug Hypersensitivity; Female; Humans; Middle Aged; Seizures | 1991 |
Clinical implications of seizures in neurosarcoidosis.
Topics: Adolescent; Adult; Brain Diseases; Carbamazepine; Female; Humans; Male; Middle Aged; Nervous System | 1991 |
Myoclonic epilepsy--pitfalls in diagnosis and management.
Topics: Adolescent; Adult; Carbamazepine; Diagnosis, Differential; Epilepsies, Myoclonic; Female; Humans; Ma | 1991 |
Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D- aspartate antagonist (+-)-5-aminocarbonyl-10,11-dihydro-5H- dibenzo[a,d]cyclohepten-5,10-imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine.
Topics: Administration, Oral; Animals; Anticonvulsants; Carbamazepine; Dizocilpine Maleate; Dose-Response Re | 1991 |
Impaired water homeostasis following mixed carbamazepine and phenobarbital overdose.
Topics: Adult; Body Water; Carbamazepine; Female; Homeostasis; Humans; Osmolar Concentration; Phenobarbital; | 1991 |
Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children.
Topics: Analysis of Variance; Carbamazepine; Carnitine; Child; Drug Combinations; Fatty Acids; Fatty Acids, | 1991 |
Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Carbamazepine; Diltiazem; Drug Interactions; Female | 1991 |
[Aplastic anemia in carbamazepine therapy].
Topics: Aged; Anemia, Aplastic; Carbamazepine; Epilepsy; Humans; Male; Pancytopenia; Seizures; Sick Sinus Sy | 1991 |
The effect of carbamazepine and ethosuximide on hyperoxic seizures.
Topics: Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Electroencephalography; E | 1991 |
Effect of MK-801 and its interaction with adenosinergic agents and carbamazepine against hypoxic stress-induced convulsions and death in mice.
Topics: 2-Chloroadenosine; Adenosine; Animals; Carbamazepine; Dipyridamole; Dizocilpine Maleate; Drug Intera | 1990 |
Depression, anxiety, and temporal lobe epilepsy. Laterality of focus and symptoms.
Topics: Adult; Analysis of Variance; Anxiety; Carbamazepine; Depression; Epilepsy, Temporal Lobe; Female; Fu | 1990 |
In vivo determination of valproate binding constants during sole and multi-drug therapy.
Topics: Binding, Competitive; Carbamazepine; Drug Therapy, Combination; Food; Humans; Phenytoin; Seizures; V | 1990 |
Metabolic profiling of valproic acid in patients using negative-ion chemical ionization gas chromatography-mass spectrometry.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Carbamazepine; Child; Ch | 1990 |
Antiepileptic medications.
Topics: Anticonvulsants; Barbiturates; Carbamazepine; Dental Care for Disabled; Epilepsy; Humans; Hydantoins | 1990 |
Carbamazepine induced systemic lupus erythematosus. Another warning.
Topics: Adolescent; Carbamazepine; Female; Humans; Lupus Erythematosus, Systemic; Seizures | 1990 |
Carbamazepine overdose: a prospective study of serum levels and toxicity.
Topics: Adolescent; Adult; Age Factors; Carbamazepine; Child; Child, Preschool; Coma; Drug Overdose; Humans; | 1990 |
The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. I. The influence of administration vehicles.
Topics: Absorption; Animals; Anticonvulsants; Biological Availability; Carbamazepine; Differential Threshold | 1990 |
The effect of interstimulation interval on the assessment of anticonvulsant drug potency in fully kindled rats.
Topics: Animals; Anticonvulsants; Ataxia; Carbamazepine; Kindling, Neurologic; Male; Phenobarbital; Rats; Ra | 1990 |
Protein binding of antiepileptic drugs during pregnancy, labor, and puerperium.
Topics: Adult; Anticonvulsants; Carbamazepine; Fatty Acids, Nonesterified; Female; Fetal Blood; Humans; Labo | 1990 |
Effects of anticonvulsants on hippocampus-generating seizures.
Topics: Animals; Anticonvulsants; Carbamazepine; Cats; Dose-Response Relationship, Drug; Electric Stimulatio | 1990 |
Potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats.
Topics: Animals; Anticonvulsants; Brain Chemistry; Carbamazepine; Chromatography, High Pressure Liquid; Diaz | 1990 |
Rapid loading of critically ill patients with carbamazepine suspension.
Topics: Adolescent; Carbamazepine; Child; Critical Care; Female; Humans; Infant; Intestinal Absorption; Male | 1990 |
Corpus callosum agenesis and uncinate seizures.
Topics: Agenesis of Corpus Callosum; Carbamazepine; Child; Female; Humans; Seizures | 1990 |
[Seizures induced by movement].
Topics: Adolescent; Adult; Carbamazepine; Electroencephalography; Female; Humans; Magnetic Resonance Imaging | 1990 |
Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine-induced hyperactivity.
Topics: Animals; Carbamazepine; Cocaine; Hyperkinesis; Kindling, Neurologic; Male; Motor Activity; Probabili | 1990 |
Anticonvulsant drug mechanisms of action.
Topics: Action Potentials; Animals; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Clonazepa | 1985 |
The effect of repeated seizures on anticonvulsant drug response in the kindling model.
Topics: Animals; Brain; Carbamazepine; Kindling, Neurologic; Male; Membrane Potentials; Phenobarbital; Pheny | 1987 |
Carnitine deficiency associated with anticonvulsant therapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Carnitine; Cerebral Palsy; Drug Therapy, Co | 1989 |
An atypical hypersensitivity reaction.
Topics: Adolescent; Carbamazepine; Drug Eruptions; Glomerulonephritis; Humans; Liver; Liver Function Tests; | 1989 |
Effects of carbamazepine and phenobarbital on kainic acid-induced model of psychomotor seizures during ontogenesis in the rat.
Topics: Aging; Animals; Carbamazepine; Dose-Response Relationship, Drug; Kainic Acid; Male; Phenobarbital; R | 1989 |
A retrospective study of mentally retarded patients with behavioral disorders who were treated with carbamazapine.
Topics: Carbamazepine; Electroencephalography; Humans; Intellectual Disability; Mental Disorders; Retrospect | 1989 |
Carbamazepine-induced systemic lupus erythematosus.
Topics: Adolescent; Carbamazepine; Humans; Lupus Erythematosus, Systemic; Male; Seizures | 1989 |
Effect of aminophylline upon the protective activity of common antiepileptic drugs and their plasma levels in mice.
Topics: Aminophylline; Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Male; Mice | 1989 |
Possible carbamazepine-induced reversible onychomadesis.
Topics: Adult; Carbamazepine; Fingers; Humans; Male; Nail Diseases; Seizures; Toes | 1989 |
Effects of intranigral application of clinically-effective anticonvulsants on electroshock-induced seizures.
Topics: Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Electroshock; Hindlimb; I | 1989 |
Nocturnal complex partial seizures precipitated by REM sleep. A case report.
Topics: Adolescent; Carbamazepine; Circadian Rhythm; Electroencephalography; Humans; Male; Seizures; Sleep, | 1989 |
Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Drug Tolerance; Humans; | 1989 |
Effects of carbamazepine and valproic acid on brain immunoreactive somatostatin and gamma-aminobutyric acid in amygdaloid-kindled rats.
Topics: Amygdala; Animals; Brain Chemistry; Carbamazepine; gamma-Aminobutyric Acid; Kindling, Neurologic; Ma | 1986 |
Generic versus branded carbamazepine.
Topics: Adult; Carbamazepine; Female; Humans; Male; Middle Aged; Seizures; Therapeutic Equivalency | 1987 |
Efficacy and generic drugs.
Topics: Carbamazepine; Drug Prescriptions; Humans; Seizures; Therapeutic Equivalency | 1987 |
Time course of carbamazepine autoinduction. The VA Cooperative Study No.118 Group.
Topics: Adult; Carbamazepine; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Seizures; Time Fa | 1989 |
[Effect of diazepam, carbamazepine, sodium valproate and their combinations with vitamin preparations on epileptic activity].
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Drug Therapy, Combination; Male; Niacinamide; Pen | 1985 |
Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Chlorpromazine; Diazepam; Disease Models, | 1986 |
[The correlation between concentrations of anticonvulsive drugs in the brain and various parameters of maximal electroshock seizures in mice].
Topics: Animals; Anticonvulsants; Brain Chemistry; Carbamazepine; Drug Evaluation, Preclinical; Electroshock | 1986 |
Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture.
Topics: Action Potentials; Animals; Carbamazepine; Cells, Cultured; Cerebral Cortex; Dose-Response Relations | 1986 |
Clinical recognition of Rett syndrome.
Topics: Adolescent; Autistic Disorder; Carbamazepine; Child; Child, Preschool; Diagnosis, Differential; Fema | 1986 |
Inhibition of quisqualate-induced seizures by glutamic acid diethyl ester and anti-epileptic drugs.
Topics: Aminooxyacetic Acid; Animals; Anticonvulsants; Carbamazepine; Diazepam; Female; Glutamates; Mice; Ox | 1986 |
Rectal anticonvulsants in pediatric practice.
Topics: Administration, Rectal; Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child, Preschoo | 1988 |
Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital.
Topics: Animals; Brain; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Electroshock; Female; M | 1988 |
Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes.
Topics: Adolescent; Adult; Aggression; Ataxia; Carbamazepine; Chorea; Coma; Female; Hallucinations; Humans; | 1988 |
Anticonvulsant activity of carbamazepine and N6-L-phenylisopropyladenosine in rabbits. Relationship to adenosine receptors in central nervous system.
Topics: Adenosine; Animals; Anticonvulsants; Caffeine; Carbamazepine; Central Nervous System; Drug Interacti | 1988 |
Verapamil-induced carbamazepine neurotoxicity. A report of two cases.
Topics: Adult; Ataxia; Carbamazepine; Drug Interactions; Female; Humans; Middle Aged; Seizures; Verapamil | 1988 |
Short-term treatment of atypical spells with carbamazepine.
Topics: Acute Disease; Adult; Carbamazepine; Electroencephalography; Humans; Male; Seizures | 1988 |
Audiogenic seizures in Wistar rats before and after repeated auditory stimuli: clinical, pharmacological, and electroencephalographic studies.
Topics: Acoustic Stimulation; Animals; Behavior, Animal; Carbamazepine; Dose-Response Relationship, Drug; El | 1988 |
Hypnogenic paroxysmal dystonia with panic attacks responsive to drug therapy.
Topics: Adult; Anxiety Disorders; Carbamazepine; Dystonia; Fear; Female; Humans; Panic; Seizures; Syndrome | 1987 |
Carbamazepine as therapy for psychiatric sequelae of herpes simplex encephalitis.
Topics: Carbamazepine; Electroencephalography; Encephalitis; Herpes Simplex; Humans; Male; Middle Aged; Psyc | 1987 |
Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development.
Topics: Amygdala; Animals; Carbamazepine; Kindling, Neurologic; Male; Rats; Rats, Inbred Strains; Seizures | 1987 |
Oculogyric crisis: a distinct toxic effect of carbamazepine.
Topics: Adult; Carbamazepine; Dystonia; Female; Fixation, Ocular; Humans; Seizures | 1986 |
Is carbamazepine an alternative maintenance therapy for neonatal seizures?
Topics: Carbamazepine; Humans; Infant, Newborn; Kinetics; Seizures; Suspensions | 1987 |
Complex partial status epilepticus presenting as fever of unknown origin.
Topics: Carbamazepine; Epilepsy, Temporal Lobe; Female; Fever of Unknown Origin; Follow-Up Studies; Humans; | 1987 |
Kindling of audiogenic seizures in the rat.
Topics: Acoustic Stimulation; Animals; Carbamazepine; Electroencephalography; Ethosuximide; Female; Kindling | 1987 |
Paroxysmal tonic seizures in demyelinating disease.
Topics: Adult; Carbamazepine; Demyelinating Diseases; Female; Humans; Middle Aged; Multiple Sclerosis; Seizu | 1986 |
Truncal seizures: an unusual presentation of cerebral cysticercosis.
Topics: Adult; Carbamazepine; Cysticercosis; Female; Humans; Movement Disorders; Praziquantel; Prednisone; S | 1986 |
Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.
Topics: Adolescent; Adult; Carbamazepine; Depression; Female; Humans; Nystagmus, Pathologic; Seizures; Visio | 1987 |
Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse.
Topics: Animals; Anticonvulsants; Carbamazepine; Electroshock; Female; Kinetics; Mice; Phenobarbital; Phenyt | 1985 |
Anticonvulsant drugs and the genetically epilepsy-prone rat.
Topics: Acoustic Stimulation; Amitriptyline; Animals; Anticonvulsants; Carbamazepine; Desipramine; Disease M | 1985 |
Exacerbation of seizures in children by carbamazepine.
Topics: Carbamazepine; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; Humans; M | 1985 |
Free level monitoring of carbamazepine and valproic acid: clinical significance.
Topics: Adolescent; Adult; Aged; Carbamazepine; Child; Dose-Response Relationship, Drug; Female; Humans; Imm | 1985 |
Seizure control following administration of anticonvulsant drugs in the quaking mouse.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Ethosuximide; Mice; Mice, Inbred C57BL; Mice, Qua | 1985 |
Seizure disorders and pregnancy.
Topics: Carbamazepine; Female; Humans; Phenytoin; Pregnancy; Pregnancy Complications; Seizures | 1986 |
Spinal cord seizures in transverse myelopathy: report of two cases.
Topics: Acute Disease; Adult; Carbamazepine; Female; Follow-Up Studies; Humans; Middle Aged; Muscle Spastici | 1986 |
Drug-induced erythema multiforme: a possible immunologic pathogenesis.
Topics: Adult; Carbamazepine; Erythema Multiforme; Female; Humans; Lymphocyte Activation; Phenytoin; Seizure | 1985 |
Efficacy of carbamazepine for febrile seizures.
Topics: Carbamazepine; Child, Preschool; Humans; Infant; Seizures; Seizures, Febrile | 1985 |
Epilepsy in a community--management and social impact.
Topics: Adolescent; Adult; Aged; Ambulatory Care Facilities; Carbamazepine; Craniocerebral Trauma; Epilepsy; | 1985 |
Adenosine antagonists. Lack of effect on the inhibition of kindled seizures in rats by carbamazepine.
Topics: Adenosine; Animals; Caffeine; Carbamazepine; Kindling, Neurologic; Male; Rats; Rats, Inbred Strains; | 1985 |
A case report of phenytoin encephalopathy. Correlation between serum levels, seizure increase and E.E.G. spike and wave activity.
Topics: Brain Diseases; Carbamazepine; Child, Preschool; Convulsants; Drug Interactions; Electroencephalogra | 1985 |
A possible case of carbamazepine-induced pancreatitis.
Topics: Aged; Carbamazepine; Female; Humans; Pancreatitis; Seizures | 1985 |
[Paroxysmal dysarthria and ataxia. A pathognomonic seizure syndrome in multiple sclerosis (author's transl)].
Topics: Adult; Ataxia; Axons; Carbamazepine; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Neurolog | 1974 |
Anticonvulsant drugs. I. Patho-physiological and pharmacological aspects.
Topics: Acetates; Acetazolamide; Anticonvulsants; Carbamazepine; Diazepam; Dibenzazepines; Electroencephalog | 1972 |
Osteomalacia due to phenytoin sodium. A case report with review of literature.
Topics: Adult; Bone and Bones; Calcium; Carbamazepine; Clavicle; Deficiency Diseases; Female; Folic Acid; Hu | 1973 |
Neuropharmacology of SQ 10,996, a compound with several therapeutic indications.
Topics: Amides; Animals; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Carbamazepine; C | 1973 |
[Preventive anticonvulsive treatment in recent brain injuries and brain diseases].
Topics: Adolescent; Adult; Anticonvulsants; Brain Diseases; Brain Injuries; Carbamazepine; Electroencephalog | 1972 |
Anticonvulsive-sedative treatment of delirium alcoholicum.
Topics: Adult; Carbamazepine; Chlordiazepoxide; Chlormethiazole; Diazepam; Dibenzazepines; Drug Synergism; F | 1971 |
[Results of treatment of dysthymic attacks with carbamazepine].
Topics: Adolescent; Adult; Carbamazepine; Drug Tolerance; Electroencephalography; Epilepsy, Temporal Lobe; E | 1971 |
[Use of "Tegretol" in cerebral disrhythmies].
Topics: Adolescent; Adult; Carbamazepine; Dibenzazepines; Female; Humans; Intellectual Disability; Male; Sei | 1968 |
Some properties of a coma producing material obtained from mammalian brain.
Topics: Amylases; Animals; Blood Pressure; Brain Chemistry; Carbamazepine; Cats; Cerebral Cortex; Chromatogr | 1970 |
[Pharmacology of carbamazepine].
Topics: Animals; Carbamazepine; Cats; Dibenzazepines; Female; Male; Mice; Pregnancy; Pregnancy, Animal; Rabb | 1967 |
[Tegretol in the treatment of severe infantile convulsions].
Topics: Carbamazepine; Child; Child, Preschool; Dibenzazepines; Female; Humans; Infant; Infant, Newborn; Inf | 1967 |
[Experience with Tegretol in polygraphic sleep EEG].
Topics: Adolescent; Adult; Anticonvulsants; Barbiturates; Carbamazepine; Child; Electroencephalography; Epil | 1968 |